MICRORNA EXPRESSION IN STROKE PATHOGENESIS by LIU FUJIA
  







LIU FU JIA 




A THESIS SUBMITTED 
FOR THE DEGREE OF DOCTOR OF PHILOSOPHY 
DEPARTMENT OF PHARMACOLOGY 






I would like to express my gratitude to my main supervisor Professor Peter 
Wong Tsun Hon who has supported me throughout my Ph.D study with his 
advice, constructive comments and warm encouragement. I have greatly 
benefited from his motivation, kindness and guidance, for which I am 
extremely appreciated. 
My sincere thanks also go to my co-supervisor Professor Kandiah Jeyaseelan 
for the continuous support of my Ph.D study with his patience, encouragement, 
insightful comments and suggestions. His immerse knowledge, advice and 
guidance help me in all the time of my research. His patience, kindness as well 
as persistent effort have been invaluable on my academic research as well as 
personal character. Without his guidance and support, I could not transform 
from a medical doctor to a researcher, for which I am extremely grateful.  
I am also very grateful to Dr. Arunmozhiarasi Armugam for guiding and 
encouraging me throughout my studies, especially her indispensable 
contribution on performing microarrays for the purpose of this study. Under 
her guidance, I have learnt a lot and successfully overcame many problems.  
Her encouragement and advice drove me towards the completion of my Ph.D 
program. 
 I would like to thank all members of the laboratory, especially Kai Ying for 
teaching me ischemic stroke animal models. I also thank all the other labmates, 
Suguna Sepramaniam, Karolina Dwi Setyowati, Chai Siaw Ching, Tan Jun 
Rong, Prameet Kaur and Silambarasan Maskomani for their help, assistance, 
encouragement and support throughout my studies. 
ii 
 
Last but not least, this thesis is dedicated to my family: my parents, my brother, 
my husband and daughter. Without their sincere love, care and support, I 
would not have finished my Ph.D study. I am particularly grateful for my 
parents for having supported me spiritually throughout my life. I am also very 
appreciative and thankful for my husband and six-year-old daughter for their 




















Table of Contents 
Summary        xv 
List of tables         xviii 
List of figures        xx 
List of publications       xxv 
List of conference papers      xxvi 
Abbreviations        xxvii 
1.  Introduction 
1.1  Stroke        1                                         
1.1.1  Stroke subtypes      3 
1.1.2  Risk factors of stroke      3 
1.2  Stroke pathogenesis      5 
1.2.1  Hypoxia       7 
1.2.2  Bioenergetic deficiency     10 
1.2.3  Excitotoxicity       11 
1.2.4  Oxidative stress      12 
1.2.5  Inflammation       13 
1.2.6  Cell death       17 
1.2.6.1  Necrosis       18 
1.2.6.2  Apoptosis       19 
1.2.6.3  Necroptosis       22 
1.2.7  Effects of stroke      22 
1.3  Diagnosis of ischemic stroke     23 
1.4  Treatment and management of stroke   26 
1.4.1  Re-canalization of the occluded artery   26 
iv 
 
1.4.2  Other medications clinically used for acute ischemic 28 
stroke 
1.4.3  Other studies on alternative therapy for stroke  29 
1.4.3.1  Neuroprotectants      29 
1.4.3.2  Neuronal repair      31 
1.5  Animal models in cerebral ischemia    33 
1.5.1  Ischemic stroke models in rat     35 
1.5.2  Embolic stroke model      37 
1.6  microRNAs  (miRNAs)     39 
1.6.1  Biogenesis of miRNAs and mode of action   40 
1.6.2  miRNA database and validation method   42 
1.6.3  miRNAs and diseases      43      
1.6.4  miRNAs in therapy      45 
1.7  Objectives of the study     46 
2  MATERIALS & METHODS 
2.1  Materials       49                                                        
2.1.1  Animal procedure and anaesthesia    49 
2.1.1.1  Animals       49 
2.1.1.2  Anaesthesia       49 
2.1.1.3  2,3,5-triphenyltetrazolium chloride 2% w/v (TTC)  49 
2.1.2  Reagents for RNA extraction     50 
2.1.2.1  RNA extraction from cells/tissue    50 
2.1.2.1.1 Ethanol       50 
2.1.2.1.2 DEPC treated water      50 
2.1.2.1.3 Deionised formamide      50 
v 
 
2.1.2.2  RNA extraction from whole blood    50 
2.1.2.2.1 Wash 1 : Ethanol (70%) : Denaturation Solution (30%) 51 
2.1.2.2.2 Wash 2 : Ethanol (80%) : NaCl (50mM)   51 
2.1.3  Reagent for RNA agarose gel electrophoresis  51 
2.1.3.1  MOPS running buffer (10x)     51 
2.1.3.2  RNA sample buffer (per sample)    51 
2.1.3.3  RNA loading buffer      52 
2.1.3.4  RNA agarose gel (1%)     52 
2.1.4  Reagents for RNA polyacrylamide gel electrophoresis 52 
(PAGE) 
2.1.4.1  15% Denaturing polyacrylamide gel    52 
2.1.4.2  RNA sample buffer (per sample)    53 
2.1.5  Reagents for reverse transcription (RT)   53 
2.1.5.1  RT mixture for mRNA     53 
2.1.5.2  RT mixture for miRNA     54 
2.1.6  Reagents for quantitative real-time polymerase chain 54 
reaction (qPCR) 
2.1.6.1  TaqMan assay for 18s (for mRNAs)    54 
2.1.6.2  SYBR green assay for mRNA    54 
2.1.6.3  TaqMan assay for 18s (for miRNAs)    55                 
2.1.6.4  TaqMan assay for miRNA     55 
2.1.7  Reagents for protein extraction    55 
2.1.7.1  Protein wash buffer      55 
2.1.7.2  Protein pellet solubilisation buffer    56 
2.1.8  Reagents for Tris-Tricine SDS-PAGE   56 
vi 
 
2.1.8.1  Gel stock buffer      56 
2.1.8.2  Cathode Buffer (upper electrode buffer)   56 
2.1.8.3  Anode buffer (lower electrode buffer)   56 
2.1.8.4  2 x SDS PAGE loading buffer    57 
2.1.8.5  Tris-tricine SDS-PAGE gel     57 
2.1.9  Reagents for Western Blotting    58 
2.1.9.1  Transfer buffer      58 
2.1.9.2  Phosphate buffered saline (PBS)    58 
2.1.9.3  PBST buffer       58 
2.1.9.4  Blocking solution      58 
2.1.10  Cell lines and culture reagents    59 
2.1.10.1 Primary neuron culture reagents    59 
2.1.10.1.1 Poly-D-lysine       59 
2.1.10.1.2 1M HEPES       59 
2.1.10.1.3 97% HBSS       59 
2.1.10.1.4 0.05% trypsin (+) EDTA (prepare fresh)   60 
2.1.10.1.5 NB/B27 Media      60 
2.1.10.1.6 1mg/ml trypsin inhibitor (prepare fresh)   60 
2.1.10.2 Secondary cell lines and culture reagents   60 
2.1.10.2.1 Saline        61 
2.1.10.2.2 Trypsin       61 
2.1.10.2.3 Sterile glycerol      61 
2.1.10.2.4 Basal DMEM (1L)      61 
2.1.10.2.5 Complete DMEM (1L)     61 
2.1.10.2.6 Freezing Medium (100ml)     61 
vii 
 
2.1.10.2.7 Opti-mem       62 
2.1.11  Reagents for Immuno Cyto-Chemistry   62 
2.1.11.1 PBS buffer with fetal bovine serum (FBS)   62 
2.1.11.2 Fluorescein coupled secondary antibody   62 
2.1.11.3 Nuclear stain       62 
2.1.11.4 Mounting medium      63 
2.1.12  Cell viability assay      63 
2.1.12.1 MTT solution       63 
2.1.12.2 Cell Viability and apoptosis assay using   63 
Hoechst/Ethidium Homodimer III Nuclear Staining 
2.1.13  Cytotoxicity assay      63 
2.1.13.1 Lactate dehydrogenase assay     63 
2.1.14  Reagents for DNA gel     63 
2.1.14.1 10 x Tris-Borate-EDTA (TBE) buffer   64 
2.1.14.2 Ethidium bromide      64 
2.1.14.3 DNA gel (1%)       64 
2.1.15  Reagents for cloning      64 
2.1.15.1 Reverse transcription (RT)     65 
2.1.15.2 Polymerase chain reaction (PCR)    65 
2.1.15.3 Ligation       65 
2.1.15.3.1 Ligation of TA cloning vector    65 
2.1.15.3.2 Ligation of pMIR vector     66 
2.1.15.4 pMIR-REPORT
TM  
vectors     66 
2.1.15.5 Component cells      66 
2.1.15.6 Ampicillin       66 
viii 
 
2.1.15.7 Lysogeny broth (LB)      67 
2.1.15.8 LB agar plates       67 
2.1.15.9 Plasmid isolation reagents     67 
2.1.15.9.1 Resuspension buffer      67 
2.1.15.9.2 Lysis Buffer       68 
2.1.15.9.3 Precipitation buffer      68 
2.1.15.10 RNase        68 
2.1.16  Reagents for restriction enzyme digestion   68 
2.1.17  Reagents for sequencing     68 
2.1.17.1 Cycle sequencing reaction     69                                             
2.1.17.2 Purification of extension products    69 
2.1.18  Reagents for miRNA array     69 
2.1.18.1 miRNA dephosphorylation (per sample)   69 
2.1.18.2 miRNA labelling (per sample)    69 
2.1.18.3 Wash buffers       70 
2.1.18.3.1 Wash buffer A      70 
2.1.18.3.2 Wash buffer B       70 
2.1.18.3.3 Wash buffer C       70 
2.1.19  Reagents for mRNA array     70 
2.1.19.1 Reverse transcription master mixture    70 
2.1.19.2 Second strand master mixture     71 
2.1.19.3 In vitro transcription mixture      71 
2.2  Methods       71 
2.2.1  Animal model       71 
ix 
 
2.2.1.1  Surgical manipulation and neurological measurements 71
  in animal models 
2.2.1.1.1 Transient focal middle cerebral artery occlusion  71 
(embolic method) 
2.2.1.1.2 Preparation for homologous clot    74 
2.2.1.1.3 Preparation of modified PE-50 catheter   74 
2.2.1.1.4 Preparation for injection of the clot    74 
2.2.1.1.5 Laser-Doppler flowmetry     75 
2.2.1.1.6 Neurological measurement for animal models  76 
2.2.1.1.7 Histological analysis of brain infarct volume   77 
2.2.1.2  Intracerebroventricular injection (ICV) of miRNAs  78 
2.2.2  Pathway analyses for miRNAs and mRNAs   78 
2.2.3  RNA extraction      79 
2.2.3.1  Isolation of the total cellular RNA from brain  79 
tissue/cells 
2.2.3.2  Isolation of total RNA from whole blood   80 
2.2.4  Checking RNA integrity     81 
2.2.4.1  RNA gel electrophoresis     81 
2.2.4.2  Denaturing polyacrylamide gel electrophoresis  82 
2.2.5  Reverse transcription (RT)     83 
2.2.5.1  RT of mRNA       83 
2.2.5.2  RT of miRNA       83 
2.2.6  Quantitative real-time PCR (qPCR)    83 
2.2.6.1  qPCR (mRNA)      83 
2.2.6.2  Stem-loop qPCR      84 
x 
 
2.2.7  Extraction of total protein from cells/brain tissue  85 
2.2.8  Determination of protein concentration   85 
2.2.9  Tris-Tricine SDS-PAGE     86 
2.2.10  Western Blot       86 
2.2.11  Cell culture       87 
2.2.11.1  Primary cortical neuronal cultures    87 
2.2.11.2 HeLa cells culture      88                                                                  
2.2.12  Transfection       88 
2.2.12.1 miRNA transfection      88 
2.2.12.2 miRNA and reporter plasmid transfection   89 
2.2.13  Luciferase assay      90 
2.2.14  MTT Assay       91 
2.2.15.1 Morphologic Assessment of Apoptosis and Cell  91  
Viability Using Hoechst/Ethidium Homodimer  
III Nuclear Staining and Fluorescence Microscopy 
2.2.15.2 LDH Assay       92 
2.2.16  Immuno Cyto-Chemistry (ICC)    93 
2.2.17  Oxygen glucose deprivation (OGD)    94  
2.2.18  First strand cDNA synthesis for cloning   94 
2.2.19  Polymerase chain reaction (PCR)    95 
2.2.20  DNA gel extraction      95 
2.2.21  Ligation and transformation     96 
2.2.22  Plasmid extraction      97 
2.2.23  Restriction enzyme digestion     97 
2.2.24  Sequencing       98  
xi 
 
2.2.24.1 Cycle sequencing reaction     98 
2.2.24.2 Purification of extension products and sequencing  98  
2.2.25  miRNA array       99 
2.2.25.1 Sample labelling      99 
2.2.25.2 Sample preparation for hybridization    100 
2.2.25.3 Setting up of hybridization chamber    100 
2.2.25.4 Loading of sample for miRNA array    100 
2.2.25.5 Washing miRNA array slides     101 
2.2.25.6 Scanning of miRNA array chips and data analysis  102 
2.2.26  mRNA array       102 
2.2.26.1 cRNA amplification and purification    102 
2.2.26.2 mRNA hybridization      104 
2.2.26.3 Scanning of mRNA array chips and data analysis  104 
2.2.27  Statistic analysis      105 
3  microRNA profiling in embolic middle cerebral  
artery occlusion 
3.1  Introduction       106                 
3.2  Laser Doppler flowmetry and neurological   109  
assessment 
3.3  Infarct volumes      109 
3.4  miRNA profiling in acute (0 - 24hr) and recovery  112  
 (48 - 168hr) phases of eMCAo       
3.5  mRNA profiling upon recovery (12 - 168hr) phases  118  
of  eMCAo 




3.6.1  Pathway analysis for all the individual time   122  
points displaying stroke progression 
3.6.2  Pathway analysis for the acute and recovery phases  125 
3.6.3  Pathway indicating neuronal rescue after cerebral  127  
ischemia 
3.7  Real-time quantitation of miRNAs and mRNAs  128 
3.8   miR-206 as a predictive marker of infarct volume  132 
3.9   Expression of miR-206 in primary neuronal culture  133   
3.10   Anti miR-206 reduces infarct volume in eMCAo models 138 
4  miRNAs regulating the transcription factor hypoxia  
inducible factor-1α 
4.1  Introduction       156             
4.2  Measurements of infarct volume, HIF-1α mRNA as  159  
well as protein in the eMCAo model     
4.3  Bioinformatics prediction of miRNAs targeting Hif-1α 160 
4.4  Cloning of Hif-1a cDNA     163  
4.5  Luciferase reporter assays     168 
4.6  miR-335 regulates Hif-1α in primary neuron subjected 172  
to oxygen glucose deprivation    (OGD) 
4.7  Pre miR-335 reduces infarct volume by reducing Hif-1α 175  
and its downstream genes  
4.8  Realtime quantitation of miRNAs and genes in brain 177  
samples treated by pre miR-335 
5   miRNA profiling in blood samples of stroke patients 
xiii 
 
5.1  Introduction       179  
5.2  Clinical characteristics of patients under study  182 
5.3  miRNA profiling in the whole blood of stroke patients 184  
and controls  
5.4  miRNA expression in large artery stroke   186  
5.5  miRNA expression in small vessel stroke   196  
5.6  miRNAs that differentiate large artery and small vessel 201  
subtypes in acute phase of ischemic stroke 
5.7  miRNAs that differentiate large artery and small vessel 204  
subtypes during recovery phases of ischemic stroke 
5.8  miRNA expression at different time points in all stroke 208  
samples and stroke subtypes  
5.9 miRNAs commonly expressed in ischemic stroke  212  
models and human stroke patients  
6  Discussion  
6.1  Spontaneous recovery in ischemic stroke   217 
6.2  miRNA profiling study upon acute and recovery phases of 217  
eMCAo  
6.3  miRNAs in neuronal repair after ischemic stroke  220 
6.4  Fibrosis in cerebral ischemia recovery   223 
6.5  HIF-1α as a potential target in cerebral ischemia  224  
6.5.1  miR-335 directly targets Hif-1α    224 
6.5.2  miR-335 regulates Hif-1α in cerebral ischemia  225 
6.5.3   miR-17 is not protective in ischemic stroke model  229 
6.6  Circulating miRNAs as novel biomarkers in diseases 230 
xiv 
 
6.7  miRNA profiling in the blood of human stroke patients 233 
6.8  The possibility of translation from bench to bed side 239 
6.9 How to dissect the contributions of the various  241  
miRNAs in the pathogenesis of ischemic stroke,  
given the large number of miRNAs implicated 
6.10   The limitation of this study     242   
6.11  Conclusions and future prospects of the study  242 





















Ischemic stroke is a cerebrovascular event caused by an occlusion in cerebral 
arteries and resulting in clinical symptoms of neurological impairment. It is 
one of the leading causes of death and adult disability worldwide and causes 
heavy economic burdens in both developing and developed countries. Due to 
inadequate disease preventing systems in place and ever increasing aging 
population in many countries, it is predicted that the high prevalence of stroke 
for at least the next two decades is inevitable. Current common diagnosis of 
ischemic stroke relies on physician‘s clinical examination supplemented with 
neuroimaging techniques. There are no blood biomarkers that could be used in 
an acute setting to diagnose stroke, differentiate stroke subtypes, or predict 
prognosis of stroke. In addition, recombinant tissue plasminogen activator (rt-
PA) is the only FDA approved thrombolytic drug available for ischemic stroke 
treatment. However, the narrow therapeutic window of rt-PA (within 4.5 hours 
of onset of stroke) and its associated side effects limit its use to about 8 
percent of the stroke cases. Alternative stroke treatments using various 
potential neuroprotective agents have also been unsuccessful. Nevertheless, 
recent studies on microRNAs have shed some light on the possibilities of 
understanding the molecular mechanisms of stroke pathogenesis as well as to 
develop novel diagnostics, prognostics and therapeutics for stroke 
management. 
 
In this study, ischemic stroke model was created by occluding middle cerebral 
artery using an embolus and microRNA profiling was investigated to 
understand their role in cerebral ischemia. A total of 346 microRNAs has been 
xvi 
 
found to be differentially expressed upon cerebral ischemia and among them 
three specific groups of miRNAs have been observed to demonstrate different 
patterns of expression. miR-21, -142-3p, -142-5p, and -146a displayed 
significant upregulation during stroke recovery (48hr to 168hr) compared with 
those during acute phases (0hr to 24hr). On the other hand, an opposite trend 
was observed in the expression of miR-196a/b/c, -224 and -324-3p. 
Interestingly, miR-206, -290, -291a-5p and -30c-1*, positively correlated with 
the infarct sizes, with an initial increase up to 24hr followed by a gradual 
decrease from 48hr to 168hr. Functional analysis of microRNAs by using 
bioinformatics indicated that Hedgehog, Notch, Wnt and TGF-β signaling 
pathways could play significant roles in stroke recovery.  
 
Dysregulation in microRNAs upon cerebral ischemia affected the expression 
of respective genes and the interaction between specific miRNAs and their 
targets could bring about beneficial effects in cerebral ischemia. In this study, 
miR-335 was identified to directly target hypoxia inducible factor - 1α (HIF-
1α) and could modulate Hif-1α gene expression in both in vitro and in vivo 
conditions. Administration of miR-335 mimic brought about a reduction in 
infarct volume as well as a decrease in expression of Hif-1α in animal models 
of cerebral ischemia. By regulating Hif-1α expression, miR-335 also indirectly 
affected the expression of the downstream genes that were crucial in the 
maintenance of cell viability and blood brain barrier. 
   
microRNA expression were further investigated in the blood of human stroke 
patients. A total of 790 microRNAs was differentially expressed in the human 
xvii 
 
stroke samples. It was found that microRNAs could differentiate stroke 
samples from healthy controls in both acute and recovery phases. In addition, 
microRNAs specific for stroke subtypes were identified and these microRNAs 
could be used to differentiate large artery and small vessel stroke subtypes 
upon cerebral ischemia. The major functions of these microRNAs may involve 
immune response, proliferation and apoptosis, angiogenesis, hematopoietic 
regulation, inflammation, neuronal development and cell cycle. Commonly 
expressed microRNAs were identified in ischemic stroke models and human 
stroke patients. A total of seventeen microRNAs (miR-196a-5p, -196b-5p, -
26b-3p, -297, -484, -17-3p, -181d, -19a-3p, -19b-3p, -196a-3p, -223-3p, -25-
3p, -27b-3p, -374b-5p and -423-3p, -30c-1-3p and -877-5p) selected from 
ischemic stroke models was found to demonstrate similar expression in the 
blood of human stroke patients. Fifteen microRNAs (miR-129-1-3p, -138-1-3p, 
-196b-5p, -27a-3p, -27a-5p, -29a-5p, -297, -299-5p, -340-3p, -429, -542-5p, -
7-1-3p, -9-5p, -92b-3p and -99a-5p) selected from human stroke samples were 
found to be expressed in corresponding time points of ischemic stroke models. 
These microRNAs may be useful as potential biomarkers and therapeutic 
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1    Introduction 
1.1 Stroke  
Stroke is a neurological inadequacy caused by cerebral vasculature occlusion 
or rupture. It is one of the leading causes of death and long-term adult 
disability worldwide [1]. Stroke can occur at any age but nearly three-quarter 
of stroke patients are above the age of 65 in western countries. The life-time 
risk (LTR) of stroke in middle-aged adults (55-75 years old) is 1 in 6. Women 
are known to be at higher risk (1 in 5) due to their longer life expectancy [2]. 
According to an international study, National Health Care systems spent 0.27% 
of their gross domestic product on medical expenses, of which stroke care 
accounts for approximately 3% of the total health care expenditure [3].   
In Singapore, cerebral vascular diseases including stroke is the fourth cause of 
death after cancer, ischemic heart diseases and pneumonia [4]. Stroke is 
among the top ten causes of hospitalization and comprised 9–12% of all deaths. 
Stroke prevalence and incidence are 3.65% and 1.8/1000 respectively [5] and 
these rates are increasing with age, particularly in the male population. 
Venketasubramanian et al [6] reported that Singapore has the highest stroke 
prevalence among individuals > 65 years old when compared to many 









Figure 1.1 Prevalence of stroke per 1, 000, 000 population in selected countries.    









1.1.1 Stroke subtypes 
Stroke can be classified into five main types [7]: ischemic stroke, hemorrhagic 
stroke (intracerebral hemorrhage, ICH), subarachnoid hemorrhage, cerebral 
venous thrombosis and spinal cord stroke. These five subtypes of stroke can 
be further categorized according to different causes as depicted in Figure 1.2. 
Among them, ischemic and hemorrhagic stroke account for 80% and 15% of 
stroke cases respectively and the remaining 5% are due to unknown etiology 
[9, 10]. Hence, this study focuses on ischemic stroke that accounts for 
majority of the stroke cases.     
Ischemic stroke can result from atherothrombosis, cardioembolism, systemic 
hypoperfusion and other unknown causes. Atherothrombosis is the most 
common type of ischemic stroke and cardioembolism remains the second 
common type of ischemic stroke [11]. Compared to ischemic stroke, 
hemorrhagic stroke has lower incidence, but much higher mortality rate of 35% 
to 52% within 30 days [1]. Chronic hypertension (HTN) is the most important 
risk factor for ICH and is responsible for almost 60% of cases [12, 13]. The 
second most common cause of ICH, cerebral amyloid angiopathy (CAA), 
accounts for almost 20% of cases in patients older than 70 years of age [14]. 
The other reasons include bleeding diathesis, vascular malformation, caused 
by tumor, trauma, infection, toxin and unknown causes.   
 
1.1.2 Risk factors of stroke 
Stroke risk factors can be due to hereditary, lifestyle and other diseases. 
American stroke association classifies these risk factors into three categories: 












Figure 1.2 Subtypes of stroke as recommended by Amarenco et al. Stroke can be 
classified under 5 types. These five classifications can be further [7] sub-classified 








 (http://www.strokeassociation.org/) (Table 1.1). Among The changeable risk 
factors, high blood pressure is the most important controllable risk factor for 
stroke. Globally, 51% of strokes are attributable to high systolic blood 
pressure [15]. Stroke can be prevented by controlling or treating these 
changeable risk factors.  
Since changing the lifestyle of an individual and obtaining proper medication 
can control most of the changeable risk factors, up to about 80% of stroke 
cases can be prevented. Nevertheless, due to inadequate disease preventing 
systems in place, the ever increasing aging population and prevalence of 
related risk factors (like diabetes, obesity, and hypertension) worldwide, the 
high rate of stroke related death and disability is inevitable for at least the next 
two decades [16].  
 
1.2 Stroke Pathogenesis      
The sudden occlusion of a blood vessel results in an almost immediate loss of 
supply of oxygen and glucose to the cerebral tissues. Cerebral ischemia 
triggers various pathological pathways in the ischemic cascade involving 
cerebral hypoxia, bioenergetic failure, excitotoxicity, oxidative stress, 
inflammation and ultimately neuronal injury and death within minutes or 
hours of the onset. The main pathophysiological mechanisms leading to 








Table 1.1 Risk factors of stroke recommended by American stroke association 
(http://www.strokeassociation.org/).  




Heredity (family history)  
Race  
Sex (gender)  
Prior stroke , transient 
ischemic Attach  (TIA), 
heart attack  
High blood pressure  
Cigarette smoking  
Diabetes mellitus  
Carotid or other artery disease  
Peripheral artery disease  
Atrial fibrillation  
Other heart disease (heart failure, 
dilated cardiomyopathy,  
congenital heart defects)  
Sickle cell disease (also called 
sickle cell anemia)  
High blood cholesterol  
Poor diet  





Alcohol abuse  











Hypoxia is defined as a condition in which the oxygen level goes below 2% 
and this may eventually lead to severe hypoxia (anoxia) as the oxygen 
concentration reaches 0.02% or less. The sudden occlusion of the cerebral 
artery immediately brings about the deficiency of oxygen supply for a specific 
area (focal) cerebral tissue. Hence, hypoxia is an acute event of cerebral 
ischemia. The adaptation to a sustained reduction in oxygen availability 
(hypoxia) triggers alterations in gene expression, leading to reduction of 
oxygen consumption and increased oxygen delivery, which would counteract 
the detrimental effects of hypoxia [17, 18]. 
Hypoxia-inducible factor 1 (HIF-1), a master transcriptional regulator of 
hypoxia, detects the low oxygen concentration and triggers the hypoxia-
adaptation process through regulating the downstream genes [17]. HIF-1 has 
been suggested to be an essential player upon ischemic stroke due to its effects 
on the downstream genes that promote glucose metabolism, angiogenesis, 
erythropoiesis, cell survival and apoptosis [19, 20]. HIF-1 is a basic helix-
loop-helix (HLH) heterodimer protein, composed of α and β subunits. 
Although the α subunit is constitutively synthesized, it is rapidly degraded and 
almost absent in normoxic cells, β subunit is also constitutively expressed in 
cells but it does not respond to changes in oxygen (O2) tension [21]. In the 
presence of oxygen, HIF-1α undergoes enzymatic hydroxylation by prolyl 
hydroxylases (PHDs) [23] (Figure 1.4).  Hydroxylated HIF-1α is then 








Figure 1.3: The main pathophysiological mechanisms leading to cell death in 
acute ischemic stroke. HIF-1, hypoxia inducible factor 1; VEGF, vascular 

















Figure 1.4 HIF-1α regulated in normoxia and hypoxia conditions. In normoxia, 
oxygen activates HIF-1α prolyl-hydroxylation (PHD) to facilitate binding to the von 
Hippel Lindau protein (VHL). VHL binds to the hydroxylated HIF-1, which as part of 
an E3 ubiquitin ligase complex, targets it for proteasomal degradation. Hypoxic 
condition inhibits PHD and stabilizes HIF-1α. HIF-1α binding to its heterodimeric 
partner HIF-1β remains mainly in the nucleus and activates genes that are involved in 









pVHL acts as an E3 ubiquitin ligase and rapidly degrades HIF-1α by the 
proteasome [25]. A decrease in oxygen concentration results in an exponential 
increase in HIF-1α levels [26]. During hypoxia, the non-hydroxylated HIF-1α 
escapes interaction with pVHL and is therefore stabilized. By binding to its 
heterodimeric partner HIF-1β, it remains mainly in the nucleus and activates 
genes that are involved in the adaptation to hypoxic/ischemic stress.  
Upon cerebral artery occlusion, hypoxia and ischemia activate HIF-1α, which 
then transactivates its downstream genes to adapt to this emergency condition. 
Studies indicated that HIF-1α could be a double-edged sword in cerebral 
ischemia capable of regulating of its downstream genes. HIF-1α may exert 
protection to neuronal function via its downstream genes leading to 
angiogenesis, proliferation, neurogenesis [27]. At the same time, it may also 
have neuronal detrimental effects by aggravating apoptosis [28, 29], blood 
brain barrier dysfunction and cerebral edema [30]. It was proposed that the 
dual function of HIF-1α could be affected by different experimental settings 
and cell types [31].  
 
1.2.2 Bioenergetic deficiency 
Brain tissue has a relatively high consumption of oxygen and glucose, and 
depends almost exclusively on oxidative phosphorylation for energy 
production [32]. Upon deprivation of oxygen and glucose to a particular 
region, a failure in adenosine triphosphate (ATP) production takes place in the 
brain cells. This quickly leads to the dysfunction of energy-dependent ion 
transport pumps and depolarization of neurons and glial cells. Consequently, 
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presynaptic voltage-dependent calcium ion (Ca
2+
) channels become activated 
and excitatory amino acid glutamate is released into the extracellular space. 
The presynaptic reuptake of glutamate is impeded due to the loss of astrocytic 
functions [33, 34]. The increased glutamate accumulation in the extracellular 
space leads to excitotoxicity. 
 
1.2.3 Excitotoxicity 
Excitotoxicity refers to the damage caused by an abnormal release of 
excitatory neurotransmitters, especially glutamate [35, 36]. Glutamate is the 
major excitatory neurotransmitter in the mammalian brain and a key mediator 
for intracellular communication, plasticity, growth and differentiation. Under 
normal physiological conditions, the extracellular concentration of glutamate 
is maintained in micromolar range and is responsible for initiation of 
postsynaptic signalling. Glutamate functions through its ionotropic receptors, 
such as N-methyl-D-aspartate (NMDA), 2-amino-3-(3-hydroxy-5-
methylisoxazol-4-yl), propionate acid (AMPA), the various subtypes of 
kainate [37] and metabotropic receptors [38]. The activation of ionotropic 







) ions, while metabotropic receptors mediate mobilization of 
Ca
2+
 from internal stores.  





 ions through these receptors following cerebral ischemia. This causes 
neuronal depolarization and triggers greater influx of Ca
2+
 ions and subsequent 
glutamate release. This spontaneous depolarization wave could propagate to 
the penumbra region from the core and cause extended damage. Additionally, 
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passive entry of water into the cells results in cytotoxic edema. The elevation 
of intracellular Ca
2+
 can activate proteases that degrade cytoskeletal proteins 
[39] and extracellular matrix proteins. Other proteases activated by Ca
2+ 
signaling involving phospholipase A2 (PLA2), calpain, endonucleases, 
adenosine triphosphatase, cyclooxygenase (COX) as well as nitric oxide 
synthase (nNOS) consequently bring about extensive cellular necrosis or 
apoptosis [40, 41]. Furthermore, excitotoxicity can activate the expression of 
genes that initiate post-ischemic inflammation that contributes to ischemic 
injury. 
 
1.2.4 Oxidative stress 
The brain is believed to be particularly vulnerable to oxidative stress as it 
accounts for only 2% of total body weight but 20% of the body‘s oxygen 
consumption [42]. It contains high concentration of polyunsaturated fatty acids 
(PUFA) that are susceptible to lipid peroxidation as well. Furthermore, the 
brain is relatively high in redox transition metal ions, yet has relatively low 
antioxidant capacity when compared to other organs. Of all the brain cells, 
neurons are particularly vulnerable to oxidative insults as they contain low 
levels of reduced glutathione [43]. 
Under normal physiological conditions, reactive oxygen species (ROS) are 
generated at low levels and play important roles in signalling and metabolic 
pathways [44]. However, excessive oxidants may irreversibly oxidize 
macromolecules such as DNA, lipids and proteins and cause severe cellular 
injury. Intracellular sources of ROS include xanthine oxidase, mitochondrial 
electron transport chain, arachidonic acid (AA), and NADPH oxidases (NOX). 
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Endogenous antioxidants such as superoxide dismutases (SOD), glutathione 
peroxidase, glutathione and catalase play important roles in controlling ROS 
[45]. Other antioxidants including glutathione, ascorbic acid and vitamin E are 
also involved in the detoxification of oxidants [46]. Increased level of ROS is 
a major cause of tissue injury after cerebral ischemia. With ischemic stroke 
onset, there is an overproduction of ROS, inactivation of antioxidant enzymes 
and consumption of antioxidants, which eventually fail to protect the neurons 
from oxidative damage [47]. ROS may cause tissue damage after stroke either 
directly through participation in destruction of cellular proteins, lipids and 
DNA or indirectly by disrupting normal cellular signalling and gene regulation 
[48]. Figure 1.5 depicts the main oxidative responses upon ischemic stroke. 
 
1.2.5 Inflammation  
Inflammation is another vital pathological event in ischemic stroke and its 
major processes are shown in Figure 1.6. Ischemia/reperfusion (I/R) is 
regarded as the main cause of post-ischemic inflammation. Although 
reperfusion of ischemic brain tissue is critical for restoring normal function, it 
can paradoxically result in secondary damage, called I/R injury. The increase 
in oxygen free radicals triggers the expression of a number of pro-
inflammatory genes by inducing the synthesis of transcription factors such as 
NF-κB, HIF-1α, interferon regulator factor 1 and STAT3. As a result, cytokine 
levels rise in the cerebral tissue which in turn induce the expression of 
adhesion molecules including intercellular adhesion molecule 1 (ICAM-1), P-
selectin and E-selectin on the endothelial cell surfaces. These will facilitate the 








Figure 1.5 Illustration of oxidative stress response that follows acute focal 
cerebral ischemia. O2-., superoxide anion; ROS, reactive oxygen species; H2O2, 
hydrogen peroxide; .OH, hydroxyl radicals; ONOO-, peroxynitrite; GSHPx, 
glutathione peroxidase; NOX, NADPH oxidase; PI3K, Phosphatidylinositol 3-kinases; 
MAPK, mitogen-activated protein kinase; BAD, Bcl-2-associated death promoter 
protein; ERK, extracellular signal-regulated kinase; JNK, c-Jun N-terminal kinases; 
ATF2, activating transcription factor 2; NF-κB, nuclear factor-kappaB; COX-2, 










Figure 1.6 Acute (focal) cerebral ischemia and inflammation. I/R, 
ischemia/reperfusion; PLA2, phospholipases A2; nNOS, neuronal nitric oxide 
synthase; NO, nitric oxide; AA, arachidonic acid; MMP-9, matrix metallopeptidase 9, 






pathophysiology regarding I/R injury is still unclear. Oxidative stress 
mediators such as reactive oxygen species (ROS) released by inflammatory 
cells around the I/R injured areas are suggested to play a critical role [49]. The  
Cytokines, chemokines and cellular adhesion molecules (CAMs) are the 
important participators of post-ischemic inflammation. Cytokines are a group 
of small glycoproteins and originally described as mediators for regulating the 
innate and adaptive immune systems. The most intensively studied 
inflammatory cytokines in acute ischemic stroke are tumor necrosis factor-α 
(TNF-α), interleukins (IL) such as IL-1β, IL-6, IL-20, IL-10 and TGF-β [51]. 
While IL-1β and TNF-α, appear to exacerbate cerebral injury, TGF-β and IL-
10 are considered to be neuroprotective [52, 53].  
Chemokines are important for cellular communication and inflammatory cell 
recruitment. Expression of chemokines such as monocyte chemoattractant 
protein-1 (MCP-1) and macrophage inflammatory protein-1α (MIP-1α) 
following focal ischemia are thought to have a deleterious effect by increasing 
leukocyte infiltration [54]. In addition to chemotactic properties, chemokines 
have been found to directly affect blood brain barrier (BBB) permeability [55].  
CAMs play a pivotal role in the infiltration of leukocytes into the brain 
parenchyma [56]. The three main groups of CAMs that mediate the interaction 
between leukocytes and the vascular endothelium are selectins, 
immunoglobulin superfamily and integrins. Selectins, especially E- and P-
selectins are upregulated to mediate leukocyte rolling and recruitment during 
the early stages of ischemia [57]. Some of the CAMs have been reported to be 
a biomarker in cerebral ischemia, such as intercellular adhesions molecule-1 
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(ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) [58]. Patients 
with acute ischemic stroke have higher soluble intercellular adhesion 
molecule-1 (sICAM-1) levels compared to control. Moreover, sICAM-1 levels 
were significantly higher in patients who died compared to those who survived 
[58]. High sICAM-1 levels upon admission are associated with early death in 
ischemic middle-aged stroke patients suggesting a pathogenic role in 
inflammation in the progression of ischemic stroke. Serum levels of soluble 
VCAM-1 were also found to be significantly higher in patients with 
thromboembolic stroke than in those of controls [59]. 
 
1.2.6 Cell death 
Three types of cell death, necrosis, apoptosis and necroptosis, have been 
reported to be involved in ischemic stroke pathogenesis. With exception to 
necroptosis which was recently found in ischemic stroke, apoptosis and 
necrosis are well known to be concomitantly activated upon ischemic injury 
[60, 61]. These two processes have distinct mechanisms of cell death with 
very different characteristics. Necrosis is caused by overwhelming stress 
characterized by passive cell swelling, injury to cytoplasmic organelles 
including mitochondria, and rapid collapse of internal homeostasis which 
eventually leads to membrane lysis and release of cellular contents resulting in 
inflammation [62]. In contrast, apoptosis is featured as cell shrinkage, 
membrane blebbing, nucleus and chromatin condensation as well as DNA 
fragmentation [63, 64]. 
The severity of injury as well as the presence of reperfusion upon cerebral 
ischemia may determine the involvement of apoptosis or necrosis. Manabat  et 
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al [65] found that significant caspase activation is only present in the 
penumbra after reperfusion but not in the core and hence inhibition of caspase 
can protect against focal but not global ischemia [66]. 
 
1.2.6.1 Necrosis 
Several proteins have been found to be involved in necrotic cell death 
following ischemic brain injury. These include, Poly(ADP-ribose)-polymerase 
(PARP) and calpains. PARPs are a family of proteins that mediate the 
formation of poly(ADP-ribose) chain on selected proteins by using 
nicotinamide adenine dinucleotide (NAD+) as a co-factor. Poly-ADP-
ribosylation is known to play a role in DNA repair and maintenance of 
genomic stability [67]. PARP-1, a member of PARPs family, plays an 
important role in mediating DNA repair. Caspase-3 can cleave PARP to 
inhibit its DNA-repairing ability and this process serves a marker of apoptosis 
[68]. However, over-activation of PARP-1 has also been proposed to cause 
necrosis by excessive energy loss. PARP-1-/- mice demonstrated reduced 
infarct volume. The absence of changes in the apoptosis marker upon 
histological examination may imply that the loss of PARP-1 protects mostly 
against necrotic cell death.  PARP-1 has been shown to mediate mitochondrial 
damage and the release of apoptosis inducing factor (AIF) from the 
mitochondria to induce necrotic cell death [69, 70]. c-Jun N-terminal kinase 
(JNK), especially JNK1, was required for PARP-1-induced mitochondrial 




On the other hand, calpains are calcium-dependent neutral cysteine proteases 
and their function is regulated by Ca
2+
 concentration. During cerebral 
ischemia, calpains are activated by Ca
2+
 flux and contributes to neuronal cell 
death by cleaving multiple substrates including cytoskeletal and associated 
proteins, kinases and phosphatases, membrane receptors and transporters [72]. 
Excessive activation of calpain due to an increase in free Ca
2+
 leads to 
cytoskeletal protein breakdown, subsequent loss of structural integrity and 
disturbances of axonal transport, and finally to necrotic cell death [73]. 
 
1.2.6.2 Apoptosis 
Apoptosis is a programmed, energy-dependent cell death process which occurs 
for the disposal of redundant cells. Different from necrosis, membrane lysis 
and release of cellular contents seldom occur in apoptotic cells. Therefore, 
apoptosis is a kind of self-salvage response of cells to injury and it aims to 
minimize damage and disruption to neighbouring cells.  
In ischemic stroke, apoptosis has been identified in both neuronal cells [74] 
and non-neuronal cells such as glia, astrocytes, endothelial cells and 
infiltrating leukocytes and is the major cell death mechanism [75]. There are 
two general pathways for activation of apoptosis: the intrinsic and extrinsic 
pathways and both pathways are involved in the activation of apoptosis in 
stroke (Figure 1.7).  
In intrinsic apoptosis, rapid depletion of energy after cerebral ischemia leads 
to a loss of membrane potential and depolarization of nerves. Voltage-
dependent Ca
2+
 channels are then activated, and excitatory amino acids (EAA) 






Figure 1.7 Apoptotic pathways after ischemic stroke FasL, Fas ligand; FasR, Fas 
receptor; FADD, Fas-Associated protein with Death Domain; DISC, Death-Inducing 
Signaling Complex; BID, BH3 interacting domain death agonist; tBID, truncated BID; 
BAX, Bcl-2-associated X protein; BAD, Bcl-2-associated death promoter; MPTP, 
mitochondrial permeability transition pore; Cytc, cytochrome c; Apaf, apoptotic 










subsequently occurs and is thought to initiate a series of 
cytoplasmic and nuclear events, including the triggering of the intrinsic 
apoptotic pathway [76]. Accumulation of intracellular Ca
2+
 upon ischemic 
stroke activates calpain and caspase-8 resulting in the cleaving of Bcl-2 
interacting domain (BID) to its truncated active form tBID [77]. BID is a 
cytosolic member of the Bcl-2 family of pro-apoptotic proteins and has been 
shown to be a critical mediator of ischemic cell death within neurons [78]. At 
the mitochondrial membrane tBid forms heterodimers by interacting with 
apoptotic proteins such as Bad and Bax and open the mitochondrial transition 
pores (MTP) to promote mitochondrial cytochrome c release [79]. Both 
phosphatidylinositol-3-kinase (PI3-K)/Akt-mediated survival signalling and 
JNK-mediated death signalling are involved in Bad activation [80]. The 
released cytochrome c binds to the apoptotic protease activating factor 1 
(Apaf-1) in the presence of ATP/dATP and lead to the formation of a Apaf-1 
and cytochrome c complex. This complex recruits procaspase-9 in a 1:1 ratio 
to form the apoptosome [74]. This interaction activates caspase-9 which in 
turn activates caspase-3 and leads to DNA damage [81]. On the other hand, 
apoptosis of the extrinsic pathway is mediated by death receptors. Cell surface 
death receptors belong to the tumor necrosis factor receptor (TNFR) 
superfamily which includes TNFR-1, Fas, and p75
NTR
 [82]. All receptors 
contain the death domain (DD) in their intracellular regions to recruit 
downstream apoptotic proteins [83]. In the extrinsic pathway, the interaction 
of Fas ligand (FasL) and Fas has been widely studied. Upon binding to the 
FasL, Fas receptor forms microaggregates at the cell surface and recruits Fas-
associated death domain (FADD) to be its cytosolic tail [84], which binds to 
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procaspase-8 to form a death-inducing signaling complex (DISC). The signal 
complex transactivates procaspase-8 to generate caspase-8 [75], which is then 
released into the cytoplasm to initiate downstream cleavage of caspase-3 
followed by execution phase of apoptosis (Figure 1.7).  
 
1.2.6.3 Necroptosis  
Necroptosis is defined as a kind of cell death mediated by death receptor 
activation under apoptosis deficient conditions with necrotic cell death 
morphology [85]. Compared to the other two types of apoptosis, necroptosis is 
still largely unknown.It has been reported that stimulation of death receptors 
leads to the activation of receptor interaction protein (RIP) kinase, which leads 
to programmed necroptosis [86, 87]. FADD-RPI 1 and 3 have been found to 
be effective in mediating activation of necroptosis and formation of the 
necrosome [88, 89]. Necroptosis has been shown to contribute to delayed 
ischemic brain injury [86]. Necrostatin-1 (Nec-1), a specific inhibitor of RIP1 
[87] was found to inhibit necroptosis and protected neurons from ischemic 
injury [90, 91].   
 
1.2.7 Effects of stroke  
The sudden occlusion of the cerebral artery triggers an ischemic cascade 
involving complicated pathological processes and brings about devastating 
loss of neuron and other brain cells. As a result, a stroke lesion composing of a 
core and the penumbra surrounding the core is formed [92]. The core 
comprises of necrotic cell death and is formed rapidly after injury and may 
represent the irreversibly damaged tissues whereas the penumbra is defined as 
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a functionally impaired but structurally intact tissue between the lethally 
damaged core and the normal brain. The penumbra has been the therapeutic 
target for stroke therapy as it has been recognized as an area at risk and can be 
salvaged with appropriate intervention. The damaged brain tissue causes the 
varied clinical symptoms in stroke patients according to the different injured 
region and provides evidence for diagnosis.   
 
1.3 Diagnosis of ischemic stroke  
The brain is an extremely complex organ, which controls the whole body in 
terms of motion, sensation and activity. The focal cerebral artery occlusion 
stops the blood supply of related region and leads to tissue damage and 
functional deficiency. An accurate and fast diagnosis of cerebral ischemia is 
therefore crucial in order to provide an appropriate treatment as early as 
possible. In addition, precise identification of the location of stroke in the 
brain is equally valuable in facilitating treatment. The diagnosis of ischemic 
stroke usually requires the following information: 1) medical history; 2) 
symptoms; 3) physical and neurological examination; 4) laboratory (blood) 
tests; 5) blood flow results; 6) imaging data, [involving computed tomography 
(CT scan) or MRI (Magnetic resonance imaging)]; and 7) electrical activity 
tests. 
A detailed medical history of patients will aid in the diagnosis of ischemic 
stroke. This information is usually obtained through a clinical form which 
includes records on the the family medical history, patients' past diseases as 
well as medication history. Besides these, the clinician will also look out for 
stroke symptoms such as: sudden unexplained dizziness, trouble with walking, 
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loss of balance or unsteadiness; confusion, difficulty in speaking or 
understanding communications; unexplained weakness or numbness of the 
face, arms, or legs, or on one side of the body; loss of vision in one or both 
eyes; and sudden, unexplained severe headache [93].  
The patients also are subjected to physical examination of the whole body 
when hospitalized. In addition, specific neurological examination is crucial for 
patients with neurological diseases to determine the location of damage. In 
serious cases where there is neurological deficiency in brain stem, semicoma 
or coma, emergency care is required.   
Although stroke occurs in brain, it generally affects the functioning of the 
whole body. Hence it is important for stroke patients to do a general blood test 
in order to assess the function of vital organs such as heart, liver, kidney and 
lung. Furthermore, blood tests can also determine the presence of infection 
and haemostasis. Blood clotting tests can assess the coagulation status of 
patients and is therefore useful for monitoring patients treated with rt-PA. 
Although some blood biomarkers have recently been reported as potential 
biomarkers of stroke, none of them is yet used widely in clinical practice [94, 
95].  
Blood flow assessment evaluates the condition of patients' main artery by 
measuring the amount of blood flow through the blood vessel and it can assist 
in finding narrowing arteries. Ultrasound technology is the most frequently 
used for blood flow analysis. It has its limitation in detecting the large arteries 
like carotid and vertebral artery. Computered tomography angiograph (CTA), 
magnetic resonance angiography (MRA) and digital subtraction angiograph 
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(DSA) are useful in providing the intracranial artery image not only including 
the large arteries like middle cerebral artery, anterior and posterior cerebral 
artery but also involving the small and deep branches. Hence, they are useful 
to detect the narrowing in intracranial arteries and indicate surgical treatment. 
Compared to CTA and MRA, DSA is invasive and relatively risky. 
Nevertheless it can provide clearer images of arteries. However, these 
examinations cannot be carried out in acute stroke patients.  
Imaging tests mainly involving CT scan and MRI are the most important tests 
for acute stroke diagnosis. They will also assist in determining the stroke 
subtypes. Compared to MRI, CT is popularly used in the diagnosis of acute 
stroke because it can catch the image within minutes and also allow  
differentiation of ischemic from hemorrhagic stroke within 24hr. It is also 
much cheaper than MRI. MRI may be more efficient in the diagnosis of the 
infarct size and detection of small and deep infarct in sub-acute phase or 
chronic phase of stroke. It may also be useful to dynamically differentiate core 
and penumbra region by diffusion-weighted (DW) and perfusion-weighted 
(PW) MRI [96, 97].   
Electroencephalogram (EEG) and Evoked Response are two basic electrical 
tests to show the brain's electrical activity. EEG provides the general brain 
electrical condition while Evoked Response examines the response of the 
brain to different sensory information, such as hearing, vision or body 
sensation. Electric activity test is useful to evaluate the level of neurological 





1.4 Treatment and management of stroke 
Triggered by the cerebral vascular occlusion, the ischemic injury develops in a 
cascade manner and the amount of permanent damage depends on the degree 
and the duration of ischemia. Stroke therapeutic strategies are studied and 
designed based on the understanding of ischemic cascades. Clinically, re-
canalization of the occluded artery is the most important treatment of ischemic 
stroke, of which rt-PA was the only drug approved by Food and Drug 
Administration (FDA) in USA for acute ischemic stroke treatment. Other 
medications involve general treatment, anticoagulants, antiplatelet drugs as 
well as agents for edema reduction and hyperbaric oxygen.  
 
1.4.1 Re-canalization of the occluded artery 
Recanalization of occluded artery may improve clinical outcome through 
regional reperfusion and salvage of threatened tissues in acute ischemic stroke. 
The normal methods for recanalization involved thrombolytic agents such as 
urokinase (UK), streptokinase (SK), recombinant tissue type plasminogen 
activator (rt-PA) and mechanical device, such as Mechanical Embolus 
Removal in Cerebral Ischemia (MERCI). Currently, intravenous 
administration of rt-PA is the most beneficial and proven intervention for 
emergency stroke treatment according to stroke guidelines [93]. However, 
Doppler studies suggest that complete recanalization rate for middle cerebral 
artery occlusion (MCAo) after rt-PA treatment is only 30%, partial 
recanalization rate is 48%, and reocclusion rate is 27% [98]. In addition, the 
risk of haemorrhage and a restrictive 4.5 hr therapeutic window reduces the 
number of stroke patients eligible for rt-PA treatment to less than 8% [99]. 
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Recent studies indicate that besides the unquestionable benefit from its 
thrombolytic activity, tPA also has deleterious effects on the ischemic brain 
including cytotoxicity and increased permeability of the neurovascular unit 
(NVU) with the development of cerebral edema.  
A growing body of evidence indicates that rt-PA mediates a cerebral-
ischemia-induced increase in the permeability of the neurovascular unit (NVU) 
[100, 101]. rt-PA increases the permeability of the NVU via low-density-
lipoprotein-receptor related protein (LRP), a member of the low-density-
lipoprotein receptor gene family [102].  Immediately after the onset of the 
ischemic insult, the expression of LRP increases in perivascular astrocytes 
where its interaction with rt-PA induces the shedding of the ectodomain of 
LRP into the vascular basement membrane which leads to detachment of 
astrocytic end-feet processes into the basal lamina as well as an increase in the  
permeability of the NVU [103, 104]. Activated by the release of cytoplasmic 
domain of LRP, NF-kB also participates in this process causing an increase in 
iNOS and matrix metalloproteinase-9 (MMP-9) expression, which contributes 
to increased permeability of BBB.  
Potential benefits of endovascular interventions, such as emergency 
angioplasty and stenting, mechanical disruption of the clot, or extraction of the 
thrombus are suggested by the USA stroke treatment guideline. Among them, 
MERCI has been approved by FDA for ischemic stroke treatment in 2004. 
However, the clinical utility of these interventions remains unclear and the 





1.4.2 Other medications clinically used for acute ischemic stroke 
Besides the immediate stroke therapy described above, other treatments are 
also important for the management of ischemic stroke. It usually involves: 1) 
maintenance of body ionic and energy balance by injection of glucose, sodium 
chloride and potassium chloride solutions. 2) Prescribed medications 
according to the patients' medical history and laboratory examinations. This 
may involve drugs that control hypertension, high blood glucose, high 
cholesterol, inflammation and some stroke-related complications like stress 
ulcer, heart failure, septicaemia and pneumonia. A successful ischemic stroke 
treatment should include a comprehensive therapy for the stroke itself, 
accompanying clinical conditions as well as possible stroke complications. 
Antiplatelet and anticoagulants are also used to treat stroke patients clinically. 
Aspirin, as an antiplatelet drug, has been suggested for use within 24-48hr 
after stroke onset to reduce the risk of recurrent stroke in acute ischemic stroke 
patients [93]. It is the only antiplatelet drug recommended to treat acute 
ischemic stroke [93].  Although anticoagulants have been used to treat acute 
ischemic stroke for more than 50 years, their routine use has been questioned 
[93]. Anticoagulants used within 24hr of stroke onset are regarded as not only 
ineffective but carrying unacceptable risk of hemorrhagic side effects [93]. 
However, some low molecule anticoagulants are commercially available and 
locally used in a small dosage per day. Further evaluation on the use of these 
anticoagulants in acute ischemic stroke is necessary. 
Edema reduction agents have also been used in acute phase of ischemic stroke 
to alleviate edema. Mannitol (also referred to as mannite or manna sugar) is an 
osmotic agent as well as a free radical scavenger which may reduce the edema 
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upon stroke. Although mannitol has been used clinically to reduce brain 
swelling in some countries, there has been no large scale randomized 
controlled trials (RCT) to prove its beneficial effects in acute ischemic stroke 
[105].  
Supplementation with human serum albumin is a safe and effective treatment 
for patients whose circulating albumin is low. At the same time, albumin can 
absorb water to reduce cerebral edema. Neuroprotective effect of albumin has 
been supported by a clinical RCT study [106]. However, albumin has not been 
routinely used for stroke treatment clinically.  
Hyperbaric oxygen therapy (HBOT) is defined as breathing 100% oxygen  
under an atmospheric pressure higher than 1ata, usually using 2 or 3 
atmospheres absolute (ata) [107]. This may increase the amount of oxygen 
dissolved in blood and therefore the amount of oxygen taken by the cells. 
HBOT has been clinically used to treat ischemic stroke in some Eastern 
countries although there is no clinical evidence to prove its beneficial effects 
yet [108].  
 
1.4.3 Other studies on alternative therapy for stroke  
The lack of efficient and effective treatment for stroke has urged both 
scientists and clinicians to look for alternative therapies. Several studies have 
been carried out, of which some have shown promising results in the use of 
neuroprotectants and agents of neuronal repair [108, 109].   
 
1.4.3.1  Neuroprotectants 
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Neuroprotection for ischemic stroke refers to strategies applied singly or in 
combination to antagonize the injurious biochemical and molecular events that 
cause irreversible damage during ischemia [109]. Based on the current 
knowledge on ischemic stroke, neuroprotective therapy is often designed to 
interrupt the ischemic cascade. Since early 1990s, many clinical trials have 
been carried out for effective neuroprotection [109], some of them seem to be 
promising. 
Hypothermia could be one of the promising neuroprotective strategies for 
acute ischemic stroke which aims to slow down cerebral metabolism and 
protect neurons upon acute ischemia. It has been shown to improve 
neurological outcome in comatose survivors of cardiac arrest and patients with 
severe brain edema [110, 111]. A few clinical studies about mild hypothermia 
in acute ischemic stroke have been published which highlighted its feasibility 
as alternative therapy [112, 113]. The major problems with hypothermia 
treatment lie in determining the optimal temperature for stroke patients and the 
appropriate cooling process.  
Ionized magnesium has been demonstrated as an effective neuroprotectant in 
animal models of cerebral ischemia. Two independent clinical trials namely, 
Field Administration of Stroke Therapy-Magnesium (FAST-MAG) pilot trial 
[114] and the Intravenous Magnesium Efficacy in Stroke (IM-AGES) [115] 
found it as potentially useful in acute ischemic stroke. 
Cytidine 5‘-diphosphocholine (CDP-choline), also known as citicoline, is a 
key precursor in the synthesis of phosphatidylcholine, which is an essential 
cell membrane phospholipid. Citicoline has been increasingly recognized to be 
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a neuroprotectant in early and late stages of cerebral ischemia. Its 
neuroprotective mechanisms involve increasing phosphatidyl choline synthesis 
in the injured brain [116], repairing membranes [117], decreasing free radical 
formation, inhibiting free fatty acid release [118] as well as anti-apoptotic 
effect [119]. At the same time, citicoline is able to improve behavioural 
performance of learning and memory and reduce neurological deficits in 
ischemic animal models [120].  Clinical RCT studies demonstrated the 
beneficial effect of citicoline in cerebral ischemia as well [121-123]. Citicoline 
is currently approved in many countries to treat head trauma and other 
neurological disorders [124]. However, the optimised dose and duration of 
citicholine may need further evaluation using large cohort studies. 
 
1.4.3.2 Neuronal repair  
Neurons form the crucial cells that control our ability to think and move. 
Devastating loss of neurons upon stroke triggers a complex series of 
biochemical events that lead to total breakdown of cellular integrity and 
eventually cell death. In addition to brain injury responses, regenerative 
feedback such as vascular remodelling, angiogenesis, neurogenesis and 
synaptogenesis are also activated. The therapeutic strategies have been 
designed to help neuronal repair and improve neuronal recovery. Among them, 
hematopoietic growth factors (Granulocyte Colony Stimulating Factor, G-CSF) 
and stem cells have been tested in clinical trials and have yielded promising 
results. 
G-CSF is one of the hematopoietic growth factors that modulate the lineage 
specific differentiation of bone marrow stem cells which results in generation 
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of circulating blood cells and their mobilization to peripheral blood. G-CSF 
has been found to protect neurons [125], promote neurogenesis and 
angiogenesis in animal studies [126, 127]. The results of clinical phase I/II 
RCT study of G-CSF were promising as well. Patients treated by G-CSF 
demonstrated significantly greater neurological improvement than controls 
although infarct sizes remained the same. PET imaging revealed the G-CSF 
group had significantly greater glucose metabolic activity in the penumbral 
zone than did the controls [128-131].  Nonetheless, further larger clinical trials 
are needed to confirm its safety and efficacy. 
Stem cells have the capacity to self-renew and differentiate into different cell 
types, including neurons, astrocytes, and endothelial cells. Exogenous stem 
cells may potentially replace the lost cells or help to generate brain cells after 
cerebral ischemia and hence promote brain repair as well as restoration of 
function after a devastating stroke. The proposed [132] stem cells for stroke 
therapy are shown in Table 1.2. At present, only several small scale clinical 
trials have shown the feasibility of stem cells during treatment of stroke 
patients [133, 134]. Further large scale RCT studies are also needed to prove 










Table 1.2 Proposed stem cells therapies for stroke. Table was adapted from Hess et 
al [132]. 
Cell type  Safety  Ethical concerns  Scalability  
Mesenchyme stem cells 
(MSC)(autologous)  
Excellent (phase 1 
trial)  
None  Poor  
MSC (allogeneic)  Very good; host 
rejection possible  
None  Excellent  
Umbilical cord stem 
cells  
Very good  None  Very good  
Adult progenitor cells  Very good  None  Excellent  
Neural stem cells  Good but largely 
unknown  
Minor (depends 
on source)  
Moderate  
 
1.5 Animal models in cerebral ischemia  
Since Hill and colleagues [135] first described injections of homologous blood 
clots to induce ischemic stroke in a dog model, a wide variety of models for 
ischemic stroke have been proposed. Animal models have become a crucial 
approach for the study of stroke and its pathological process. Different animals 
have been used, including mice, rats, cats, rabbits, pigs, dogs, and non human 
primates (NHP).  
Theoretically, NHP is the closest to an ideal model of stroke since they are the 
species closest to human and therefore share several similarities with human in 
terms of motor and sensory integration and cerebral vasculature construction. 
However, the primate species is a big family and they vary widely in brain and 
vascular anatomy. Species that have been used for stroke models in the past 
studies are summarized in Table 1.3 [136]. Basically, two species are 
commonly used for stroke study; lissencephalic (smooth cortex) and 
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gyrencephalic (convoluted cortex with gyri and sulci). The smooth cortex of 
lissencephalic allows the precise functional mapping of motor, sensory and 
visual regions whereas gyrencephalic has an organized cortex closer to human 
which will be suitable for preclinical studies [137, 138]. Both the species are 
large and hence costs more for housing. For example, Papio anubis (baboon) 
is the most common species used for stroke model. However, a permanent 
stroke model can cause a huge edema in this species which requires an 
intensive care and results in a high mortality rate [139, 140]. Furthermore, 
NXY-059, a free radical scavenger, that has been tested in NHP stroke model, 
demonstrated beneficial effect for reducing the functional disability [140]. 
 
Table 1.3 Nonhuman primate species used in stroke research  
Species  Common name  Brain structure  
Callithrix jacchus*  Common marmoset  Lissencephalic  
Saimiri sciureus*  Squirrel monkey  Lissencephalic  
Aotus lemurinus  Owl monkey  Lissencephalic  
Galago senegalensis  Senegal bush baby  Lissencephalic  
Papio anubis*  Baboon  Gyrencephalic  
Macaca mulatta*  Rhesus macaque  Gyrencephalic  
Macaca fascicularis*  Cynomolgus macaque  Gyrencephalic  
Macaca fuscata  Japanese monkey  Gyrencephalic  
Cercopithecus aethiops  African green monkey  Gyrencephalic  
Cercopithecus pygerithus  Vervet monkey  Gyrencephalic  





However, NXY-059 was unsuccessful when tested clinically [141]. The only 
drug approved by FDA to treat ischemic stroke (rt-PA) was however 
translated to human from rabbit models of thromboembolic stroke [142, 143].  
 
1.5.1 Ischemic stroke models in rat 
Compared to large animals, small animal species used as stroke models have 
gained more interest. The majority of current stroke models are carried out in 
small animals such as the rats and mice. The possible reasons are its 
resemblance to humans in cerebrovascular anatomy (Figure 1.8) and 
physiology [145], its moderate size which allowed monitoring easily the 
physiologic parameters and examining the brain specimens [146], the relative 
homogeneity within strains, which make studies reproducible [147]. In 
addition, the rat has lower cost and higher ethical acceptability of use relative 
to larger animals.  
The two main classes of in vivo animal stroke models are global ischemia and 
focal ischemia. Global ischemic models are usually created by multiple vessel 
occlusion and hence is more relevant to clinical cardiac arrest and asphyxia in 
humans [148]. The three most commonly used animal models in global 
ischemia are: 1) Rat - four-vessel occlusion or two-vessel occlusion combined 
with hypotension; 2) Gerbil - two-vessel occlusion; 3) Mouse - two-vessel 
occlusion [148, 149].  
Focal ischemic stroke model involves both direct and indirect focal ischemic 





Figure 1.8 Comparison of vessels of human and rats. (A) Vessels in rats at the 
cervical area; (B) Vessels in human at the cervical area. (C) The cerebral blood 
vessels (Willis circle) in rat and human. CCA, common carotid artery; ECA, external 
carotid artery; ICA, internal carotid artery. ACA, anterior cerebral artery; MCA, 
middle cerebral artery; PCA, posterior cerebral artery;  SCA, superior cerebellar 
artery; BA, basal artery; VA, vertebral artery; P com, posterior communicating artery. 
Image was adapted from Wang [144].  
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artery (MCA) territory, which is the most common occlusion area in clinical 
patients [150]. Direct occlusion leads to MCA permanent occlusion and results 
in a region of severe ischemic damage (core) surrounded by a zone of less 
damaged tissue [151]. Due to the absence of recanalization, direct occlusion 
focal ischemic stroke model only mimics minor clinical stroke condition. On 
the contrary, indirect ischemic stroke model is widely used because it allows 
reperfusion and correlates with majority of clinical condition, such as transient 
ischemic attack, therapy-induced thrombolysis, spontaneous thrombolysis.   
The technique of direct MCAo models mainly involves local direct occlusion 
of the distal MCA by electrocauterization through a craniectomy [152, 153]. 
The indirect occlusion model blocks the proximal MCA from the internal 
carotid usually by intraluminal suture MCAo occlusion [154] and embolic 
cerebral ischemia [155, 156]. Figure 1.9 demonstrates the MCAo and the 
infarct area [157]. Currently, embolic stroke and intraluminal suture models 
are the two stroke models that are most relevant to human and hence they are 
widely used in stroke related studies.  
 
1.5.2 Embolic stroke model  
Kudo et al [155] and Kaneko et al [158] initially created embolic stroke model 
in rats by using a suspension of blood clot fragments to occlude the entire 
arterial tree. Zhang et al [156] and Busch et al [159] improved this technique 
by using a single 25mm blood clot to block the origin of ipsilateral MCA, 
which made the infarct limited to the MCA distribution area. Embolic 
ischemic stroke model has two categories: thromboembolic models and non-








Figure 1.9 Cerebral ischemia induced by indirect middle cerebral artery 
occlusion.  Arrow shows the insert place of suture or catheter with blood clot. The 
"area of stroke" indicates the infarct area when middle cerebral artery occlusion is 









since most of the stroke is caused by thromboembolus occlusion. 
Thromboembolic model is induced most commonly by the injection of 
autologous thrombi through internal carotid artery into middle cerebral artery. 
This gives an advantage that it can be used to test the effects of thrombolytic 
agents [160], such as rt-PA. Therefore, in this study, autologous embolus 
injection was used to induce ischemic stroke in rats to examine the gene 
expression profiles after ischemic stroke. This model was also used for 
exploring possible treatments for ischemic stroke. 
 
1.6 microRNAs (miRNAs)   
miRNAs are a novel class of endogenous, small, non-coding RNAs that 
control gene expression at transcriptional and translational levels. The first 
miRNA lin-4 was discovered in 1990 by Ambros et al [161] and found to 
control the developmental timing of Caenorhabditis elegans (C. elegans) by 
post-transcriptional regulation of the gene lin-14. Lin-4, a non coding RNA 
molecule was observed to bind to 3'UTR of lin-14 gene [161]. However, the 
importance of this 21-nucleotide long RNA molecule was not fully understood 
at that point of time. Rather it was believed to be an isolated event occurring in 
the C. elegans as the lin-4 sequence was not conserved in other species. It took 
another seven years before the second RNA molecule, let-7, which was highly 
conserved in many species, was shown to regulate the developmental timing in 
C. elegans [162]. Since then, more and more studies have emerged and these 
small nucleotides are now being recognised as a separate class of small RNA 




1.6.1 Biogenesis of miRNAs and mode of action 
miRNAs are found within both the intragenic (in introns or exons of protein-
coding regions) and intergenic sites in the genome [163, 164]. They can be 
presented either individually or in clusters [165, 166]. Figure 1.10 illustrates 
the biogenesis and function of miRNAs. They are transcribed from their own 
genes by RNA polymerase II (RNA Pol II) to generate single-stranded 
primary miRNA transcripts (pri-miRNA) in the nucleus [168]. Pri-miRNA 
transcripts can be more than 1kb long and are processed by a RNase III 
ribonuclease called Drosha into ~60 to 70 nucleotides long stem-loop 
structures known as the precursor miRNAs (pre-miRNAs) [169, 170]. The 
pre-miRNAs are exported out of the nucleus by the Ran-GTP (guanosine 
triphosphate) dependent Exportin-5 into the cytoplasm [171, 172]. Within the 
cytoplasm, further processing of the pre-miRNAs by RNAse III enzyme 
known as Dicer takes place and results in the formation of 18 to 22 nucleotides 
long miRNA duplexes [173, 174]. These duplexes are then incorporated into a 
ribonucleoprotein complex, referred to as RNA induced silencing complexes 
(RISC) [175].  
The RISC complex identifies miRNA targets for translational modulation via 
complementary base pairing. The RISC complex will cleave the mRNAs if the 
complementarity between the miRNA and the target mRNA is of perfect 
match. When the complementarity is imperfect, as often seen in mammals, the 
translation process will be inhibited [176]. However, in some cases imperfect 
match can also result in translational arrest and degradation of mRNA as in the 









Figure 1.10 miRNA biogenesis and function. The biosynthesis of miRNAs, as 
well as their activity in translational repression (RNA interference (RNAi)) 
and transcriptional modulation (RNAa or RNAi), is represented 
diagrammatically. Pre-miRNA, precursor miRNA; RISC, RNA-induced 









miRNA to bind to many mRNAs and regulate a large number of genes. Most 
miRNAs are thought to inhibit the translational process by binding to mRNAs 
at the 3'UTR. However, some reports suggest miRNAs have the ability not 
only to inhibit translation but also to modulate transcription (Figure 1.10) [178, 
179]. miRNAs binding to the promoter regions of a gene have been shown to 
either activate or inhibit transcription [178, 179].  
 
1.6.2 miRNA database and validation method  
Studies in the past ten years have uncovered that miRNAs are important 
regulators of mRNAs and have been involved in regulating almost all 
important biological as well as pathological processes [180]. To date, several 
miRNA databases have been developed to potentially determine the 
interaction between miRNAs and their potential targets.  
Some of the common databases are MiRanda (www.microRNA.org), 
TargetScan (www.targetscan.org), PicTar (pictar.mdc-berlin.de/), 
RegRNA.org  (regrna.mbc.nctu.edu.tw/html/prediction.html), Diana-microT 
(diana.cslab.ece.ntua.gr/microT/), MicroCosm (www.ebi.ac.uk/enright-
srv/microcosm/htdocs/targets/v5/), MAMI (mami.med.harvard.edu/), mirGen 
(www.diana.pcbi.upenn.edu/miRGen.html) and miRDB (mirdb.org/miRDB/). 
These databases work in similar manner but utilise different algorithms for the 
prediction. Basically, the 'seed' sequence for each miRNA is provided along 
with corresponding possible binding sites in different species. Depending on 
the criteria set, a list of miRNAs can then be shortlisted and validated with 
further experiments.    
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The most commonly used validation technique is luciferase assay. It requires 
cloning the 3' UTR of a mRNA into the luciferase reporter vector, which is 
then transfected into cells. miRNA mimic (pre-miR) and antagomir (anti-miR) 
are co-transfected with luciferase reporter plasmid containing the target 
recognition sites. This technique works in a way by which the binding of a 
miRNA to its specific mRNA target site will suppress or enhance the reporter 
protein production thereby affecting its activity which is then measured and 
compared to appropriate controls [181].  After confirming the interaction at 
mRNA level, it is necessary to bring the investigation further to protein level. 
This is because if the predicted mRNA is a true target of that specific miRNA, 
then the modulation of the given miRNA should correlate to the protein 
expression from the mRNA target. Such validation can be done easily by 
performing Western blot analysis using a specific antibody against that protein 
[182]. Alternatively, ELISA or immuno-cytochemistry can be used to study 
the differential protein expression. 
 
1.6.3 miRNAs and diseases  
It is well known that miRNAs play important roles in the developmental 
regulation of mammals. Thus it comes as no surprise that dysregulation of the 
miRNA expression is observed in patho-physiological conditions. This 
naturally opens up the avenue to study and possibly treat various disease 
conditions by modulating miRNA expression profiles. MiRNA profiling 
studies on various cancer samples showed that their expression patterns vary 
dramatically across the different tumour types [183]. The same study also 
noted that miRNA profiling data provided more accurate information in 
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classifying the various differentiated stages of the tumours when compared to 
mRNA data. Thus the potential of using miRNA profiling in cancer diagnosis 
becomes evident. A reduction in the overall expression of most miRNA in 
tumours has been reported [183]. In fact, Kumar et al [184] showed that global 
repression of miRNA maturation promotes cellular transformation and 
tumorigenesis. Knockdown of miRNA processing enzymes, Drosha and Dicer 
in a lung cell line caused a global reduction in the miRNA expression, thus 
mimicking a tumour state [184].  
Implications of miRNA deregulation do not stop at cancer alone. 
Cardiovascular disease [185], diabetes [186], neurological diseases such as 
Alzheimer's [187] and cerebral ischemia [188] are some of the many maladies 
they are associated with. In fact absence of certain miRNAs in the brain results 
in neuronal degeneration and death in mice models resulting in symptoms 
reminiscent of those seen in humans with neurodegenerative disorders [189]. 
In rat models of cerebral ischemia, it has been shown that 114 brain-specific 
miRNAs were differently expressed and several of these miRNAs were 
present in both the brain and blood [188]. The expression levels of miRNAs in 
the blood of stroke patients have also been found to be reproducible and 
indicative of the disease state [190]. Use of blood samples obtained from 
young ischemic stroke patients (18-49 years) has shown that, in addition to the 
disease progression, the stroke subtype can also be identified via the miRNA 
profiles [190]. Different brain injuries (ischemia stroke, intracerebral 
hemorrhage and kainate seizures) lead to different miRNA expression profiles 
both in the blood and brain, and do share some miRNAs [191]. Liu et al [191] 
reported that miR-542-3p was up-regulated and miR-155, -362-3p and -450a-
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5p were down-regulated in the brain after different injuries. Such differential 
expression could also be observed in blood for miRNAs such as miR-96, -152, 
-298, -333 and -505 (up-regulated) and miR-125a-5p, -130b, -142-3p, -330, -
243-5p and -685-347 (down-regulated). miR-298 was the only miRNA that 
was up-regulated in both brain and blood after different injuries (ischemic 
stroke and intracerebral hemorrhage). These plethora of information serve to 
establish the involvement of miRNAs in disease conditions and the possibility 
of regulating them for treatment.  
 
1.6.4 miRNAs in therapy 
miRNA-based therapeutics can be developed by two approaches: a) miRNA 
mimics (pre-miR) and b) antagomiR (anti-miR) [192, 193]. miRNA mimics 
therapy refers to delivery of miRNAs into cells or tissues and thereby increase 
the miRNA concentration and bring about inhibition of its target genes, which 
are detrimental in nature. miRNA mimics carry the same sequence as the 
endogenous miRNAs and are expected to target the same set of genes. Since 
most normal cells already express the miRNA, administration of miRNA 
mimics to normal tissue may bring about less adverse events. MiRNA 
antagomiRs bind to the endogenous miRNA strand with high affinity for 
inhibition. The new miRNA duplex is unable to be processed by RISC and 
hence fail to reach the target mRNAs. However, this antagomiR may non-
specifically bind to other mRNAs and hence may result in unexpected side 
effects.  
miRNA-122 is the first miRNA brought to clinical trial and its inhibitor 
miravirsen, a locked nucleic acid (LNA)-based antisense oligonucleotide, can 
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effectively inhibit miR-122 by delivery to liver. Currently, miravirsen has 
reached Phase IIA clinical trial (Santaris Pharma) for Hepatitis C virus (HCV) 
treatment. Several miRNA mimics have progressed into pre-clinical studies. 
let-7 mimic has been shown as a tumor inhibitor by targeting KRAS gene of 
human non-small cell lung cancer in mouse model. MRX34 (miR-34) is 
currently in phase I clinical trial for liver cancer treatment 
(http://clinicaltrials.gov). Candidates of antagomiR approach include 
antagomiR-208, -195 and -499, which are being developed in preclinical study 
for anti-hypertrophy.    
MiRNA therapy for ischemic stroke is still in preclinical stage. Several 
miRNAs tested in in vivo animal models have shown beneficial effects. For 
example, miR-320 was found to directly target Aqp1 and Aqp4 upon cerebral 
ischemia and administration of anti-miR-320 in ischemic stroke rats by ICV 
was found to significantly reduce the infarct volume [194]. Similar results 
were obtained from introducing anti miR-130a after MCAo [195].   
Based on these observations, an in-depth understanding of the molecular 
biology of stroke at the miRNA level will enable researchers to identify 
specific miRNAs for diagnosis, prognosis and even treatment of stroke in the 
near future.  
 
1.7 Objectives of the study  
Ischemic stroke is one of the devastating diseases. However, there are no 
effective treatments available at present due to the limitation of our 
understanding about the mechanisms underlying cerebral ischemia. Gene 
expression changes are triggered immediately after cerebral ischemia and play 
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a crucial role in the subsequent pathological process.  Hence it is important to 
first understand the gene expression changes upon ischemic stroke which may 
be useful to shed light on the mechanism of cerebral ischemia and to develop 
potentially useful therapeutic agents. 
1. The first objective of this study will therefore involve creation of animal 
model in stroke (especially embolic stroke models) with an occlusion at the 
middle cerebral artery (eMCAo). This eMCAo model will represent an 
analogous condition seen in most of ischemic stroke patients. miRNA 
profiling will then be carried out to understand the role of miRNAs in 
ischemic stroke. Since miRNA expression in recovery phase of cerebral 
ischemia remains unknown, miRNA profiling study in recovery phase of 
cerebral ischemia will be also included to understand the progression of 
ischemic stroke from early to late phase to provide a global picture of miRNA 
expression levels upon cerebral ischemia.  
2. A further aim will be to identify the potential mRNAs and miRNAs from 
the mRNA and miRNA profiling data. In this study the implications of 
modulating hypoxia-inducible factor 1-alpha gene (HIF-1α) in in vitro 
ischemic condition as well as in in vivo stroke models will be examined. It is 
envisaged that such a study may prove to be useful in developing a potential 
therapy in cerebral ischemia. 
3. The third aim of this study is to understand the molecular mechanisms 
underlying the pathology of cerebral ischemia in human stroke patients. This 
investigation will be carried out independently of the miRNA expression 
profiles in blood of various patients with different subtypes of stroke.   
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4. As the final aim of the study, attempts will be made to understand the 
biological function of commonly expressed miRNAs and relate them to the 
ischemic status of stroke patients. This will provide an opportunity to develop 






















2.1.1 Animal procedure and anaesthesia  
 
2.1.1.1 Animals 
Male Wistar rats (260-300g) were obtained from the Laboratory Animal 
Center (National University of Singapore, Singapore) and maintained on an ad 
libitum intake of standard laboratory chow and drinking water. All animals 
were handled according to the guidelines (Howard-Jones, 1995) given by the 
Council for International Organization of Medical Science (CIOMS) on 
animal experimentation (WHO, Geneva, Switzerland) and the National 




37% ketamine         75mg/kg  
Xylazine                 10mg/kg  
37% ketamine and xylazine were dissolved in sterile saline (0.9%) and used to 
anaesthetize the rats. 
 
2.1.1.3  2,3,5-triphenyltetrazolium chloride 2% w/v (TTC) 
TTC                              2g 
0.9% NaCl (sterile)    100ml 
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TTC was completely dissolved in 0.9% NaCl with a concentration of 2% (w/v) 
at room temperature and stored at 4℃ away from light. 
 
2.1.2 Reagents for RNA extraction 
 
2.1.2.1 RNA extraction from cells/tissue 
 
2.1.2.1.1Ethanol 
Ethanol (75%, v/v) was diluted in autoclaved water. 
 
2.1.2.1.2 DEPC treated water 
DEPC                                                 0.2ml 
Deionised water                                 100ml 
In a fume hood, DEPC was added to the water and mixed vigorously. The 
solution was autoclaved to inactive the DEPC and stored in room temperature. 
 
2.1.2.1.3 Deionised formamide 
Formamide (500ml) was stirred with 500mg Dowex XG8 resin for 1hr and the 
solution was filtered through Whatman No.1 paper. Deionised formamide was 
stored at room temperature away from light. 
 






2.1.2.2.1 Wash 1: Ethanol (70%): Denaturation Solution (30%) 
Ethanol (100%)  24.5ml 
Denaturation solution  10.5ml 
 
2.1.2.2.2 Wash 2: Ethanol (80%): NaCl (50mM) 
Ethanol (100%)  56ml 
NaCl (5M)   0.7ml 
Sterile deionized water 13.3ml 
 
2.1.3 Reagent for RNA agarose gel electrophoresis 
 
2.1.3.1 MOPS running buffer (10 x) 
MOPS (PH=7.0)   0.4M 
Sodium acetate   0.1M 
EDTA (PH=8.0)   10mM 
10x MOPS was prepared using DEPC treated water. 1 x MOPS was obtained 
from the 10x dilution of 10x MOPS with DEPC treated water and used for gel 
running. 
 
2.1.3.2 RNA sample buffer (per sample) 
Deionised formamide   10µl 
37% formaldehyde   3.5µl 





2.1.3.3 RNA loading buffer 
Glycerol    50% (v/v) 
Bromophenol blue   0.4% (w/v) 
EDTA (PH 8.0)   1mM 
 
2.1.3.4 RNA agarose gel (1%) 
Electrophoresis grade agarose 0.5g 
Deionised water   43.5ml 
37% formaldehyde   1.5ml 
10 x MOPS    5ml 
Ethidium Bromide (10mg/ml) 1µl   
Agarose powder was mixed with water and heated until the power was 
completely dissolved. It was cooled to about 60℃ before the addition of 37% 
formaldehyde, 10 x MOPS and ethidium bromide. 
 
2.1.4 Reagents for RNA polyacrylamide gel electrophoresis (PAGE) 
 
2.1.4.1 15% Denaturing polyacrylamide gel 
Urea     7.2g 
40% Acrylamide   5.63ml 
10 x TBE Buffer   1.5ml 
Deionised water   0.95ml 
TEMED    7.5 µl 
10% Ammonium persulfate (APS) 37.5 µl 
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Urea together with acrylamide and 10 x TBE buffer, were heated to 60℃ to 
dissolve urea completely. Once urea was dissolved, autoclaved water, TEMED 
and APS were added the mixture and gel was cast immediately. 
 
2.1.4.2 RNA sample buffer (per sample) 
10 x TBE Buffer    2 µl 
Deionised Formamide (section 2.1.2.1.3) 10 µl 
RNA Loading Buffer (section 2.1.3.3) 3 µl 
Ethidium bromide (10mg/ml)   1 µl  
 
2.1.5 Reagents for reverse transcription (RT) 
 
2.1.5.1 RT mixture for mRNA 
10 x TaqMan RT buffer   1µl 
25mM MgCl2     2.2 µl 
DeoxyNTPs  mixture    2 µl 
50 µM random hexamers   0.6 µl 
20U/ µl RNase inhibitor   0.2 µl 
50U/µl MultiScribe 
TM
Reverse transcriptase  0.25 µl 
Autoclaved water    1.75 µl 
RNA (100ng/μl)    2μl 
The individual components were obtained from the TaqMan RT Reagents kit 





2.1.5.2 RT mixture for miRNA 
10 x RT buffer    1.5μl 
100mM DeoxyNTPs mixture   0.15μl 
20U/ μl RNase inhibitor   0.19μl 
50u/ μl MultiScribeTMReverse Transcriptase 1μl 
Autoclaved Water    4.16μl 
Stemloop primer    3μl 
RNA (5ng/μl)     2μl 
TaqMan  miRNA RT kit (Applied Biosystems, Carlsbad, CA,USA) provided 
the individual components for the miRNA RT mixture. 
 
2.1.6 Reagents for quantitative real-time polymerase chain reaction 
(qPCR) 
2.1.6.1 TaqMan assay for 18s (for mRNAs) 
2 x TaqMan PCR master Mixture  10μl  
20 x Primer-Probe    1.25μl 
Autoclaved water    3.75μl 
RT product     5μl 
 
2.1.6.2 SYBR green assay for mRNA 
2 x SYBR Green PCR Master Mixture 10μl 
Forward Primer (10uM)   0.6μl 
Reverse Primer  (10uM)   0.6μl 
Autoclaved water    3.8μl 
RT product     5μl 
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The real-time PCR master mixture reagents and primer-probes were obtained 
from Applied Biosystems (Carlsbad, CA, USA). Gene specific forward and 





2.1.6.3 TaqMan assay for 18s (for miRNAs)  
2 x TaqMan PCR master Mixture  10μl  
20 x Primer-Probe    1.25μl 
Autoclaved      7.75μl 
RT product     1μl  
 
2.1.6.4 TaqMan assay for miRNA 
2 x TaqMan Universal PCR Master mixture 10 μl 
TaqMan miRNA probe   1 μl 
Autoclaved water    7.67 μl 
RT product      1.33μl 
The TaqMan Universal PCR Master Mixture reagent was obtained from the 
Applied Biosystems (Carlsbad, CA, USA). 
 
2.1.7 Reagents for protein extraction 
2.1.7.1 Protein wash buffer 
Guanidine-HCl in 95% ethanol  0.3M  
Guandine-HCL powder was purchased from Gibco, USA and dissolved in 95% 
ethanol. The buffer was used to wash protein pellets prior to dissolving them 
with the solubilisation buffer (section 2.1.7.2). 
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2.1.7.2 Protein pellet solubilisation buffer 
Urea      7M 
Thiourea     2M 
Chaps      2% (w/v) 
Dithiothreitol (DTT)    1% (v/v) 
Protease Inhibitor    1% (v/v) 
Nuclease Inhibitor    1% (v/v)   
The individual components of the buffer were obtained from Amersham 
Biosciences. 
 
2.1.8 Reagents for Tris-Tricine SDS-PAGE 
 
2.1.8.1 Gel stock buffer 
Tris-HCL, PH8.4    3M 
 
2.1.8.2 Cathode Buffer (upper electrode buffer) 
Tris base     0.1M 
Tricine      0.1M 
SDS, PH 8.25     1% 
 
2.1.8.3 Anode buffer (lower electrode buffer) 
Tris base     0.1M 
Tricine      0.1M 




2.1.8.4  2 x SDS PAGE loading buffer 
Tris-HCL, PH 6.8    100mM 
Glycerol     20% (v/v) 
SDS      4% (w/v) 
2-mercaptoethanol    2% 
Bromophenol blue    0.2% (w/v) 
 
2.1.8.5 Tris-tricine SDS-PAGE gel 
                                                              12% Resolving gel (ml)                      
40% Acrylamide    3.00                                            
Gel buffer     3.33                                            
(section 2.1.8.1) 
10 % SDS     0.10                                            
Glycerol     1.10                                              
Autoclaved water    2.40                                           
TEMED     0.01                                            
10% Ammonium persulfate (APS)  0.10              
                                                            5% Stacking gel (ml) 
40% Acrylamide    0.625 
Gel buffer     1.25 
(section 2.1.8.1) 
10 % SDS     0.05 
Autoclaved water    2.85 
TEMED     0.01 
10% Ammonium persulfate (APS)  0.10 
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TEMED and 10% APS were added to the gel mixture just prior to the casting 
of the gel. 
 
2.1.9 Reagents for Western Blotting 
 
2.1.9.1 Transfer buffer 
Tris base     48mM 
Glycine     39mM 
Methanol     15%(v/v) 
 
2.1.9.2 Phosphate buffered saline (PBS) 
NaCl      8g 
KCl      0.2g 
Na2HPO4.7H2O    2.68g 
KH2PO4     0.24g 
The solutes were dissolved in 1L of sterile deionized water and the pH was 
adjusted to 7.4. 
 
2.1.9.3 PBST buffer 
100µl of Tween-20 was added to 1L of PBS buffer. 
 
2.1.9.4 Blocking solution 





2.1.10 Cell lines and culture reagents 
 
2.1.10.1 Primary neuron culture reagents 
Primary cortical neuronal culture was prepared from pups of E15 Swiss albino 
pregnant mouse.  
 
2.1.10.1.1 Poly-D-lysine 
Poly-D-lysine was dissolved in autoclaved H2O to a concentration of 
0.1mg/ml, filtered with 0.22µm filter and stored in room temperature.  
 
2.1.10.1.2 1M HEPES 
HEPES     6.51g 
Autoclaved H2O    25ml 
The solution was adjusted pH to 7.4, filtered with 0.22µm filter and stored in 
room temperature. 
 
2.1.10.1.3 97% HBSS  
HBSS      97ml 
Sodium pyruvate (100mM)   1ml  
HEPES (1M)     1ml  
Penicillin-Streptomycin   1ml   











     1940μl 
Sodium pyruvate (100mM)   20µl  
HEPES (1M)     20µl   
Penicillin-Streptomycin   20µl  
Trypsin (0.5%)    200μl 
 
2.1.10.1.5 NB/B27 Media 
Neurobasal media (Gibco, USA)  49ml  
B27 (Invitrogen, USA)   1ml 
L-Glutamine (200mM)   125µl  
Penicillin-Streptomycin   0.5ml  
Equilibrate in incubator for 3hr before use. 
 
2.1.10.1.6 1mg/ml trypsin inhibitor (prepare fresh) 
Trypsin inhibitor (from soyabean Sigma, USA)  5mg  
HBSS       5ml  
The solution was filtered with 0.22µm filter. 
 
2.1.10.2 Secondary cell lines and culture reagents 
HeLa (CCL2) cells were obtained from the American Type Cell Culture 







NaCl (0.9%, w/v) was diluted in sterile deionized water and autoclaved. Once 
cooled it was stored at room temperature. 
 
2.1.10.2.2 Trypsin 
10 x Trypsin was diluted to 1 x with saline filtered with 0.22µm filter and 
stored at -20℃. 
 
2.1.10.2.3 Sterile glycerol 
Glycerol was autoclaved and used for stocking cells. 
 
2.1.10.2.4 Basal DMEM (1L) 
DMEM     17.4g 
L-glutamine     0.4g 
Sodium bicarbonate    1.74g 
Penicillin-Streptomycin (50U-50mg/ml) 1% 
 
2.1.10.2.5 Complete DMEM (1L) 
Basal DMEM     900ml 
Fetal Bovine Serum (FBS)   100ml 
 
2.1.10.2.6 Freezing Medium (100ml) 
Basal DMEM     30ml 
Fetal Bovine Serum (FBS)   70ml 
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Medium powder, together with L-glutamine and sodium bicarbonate were 
dissolved in deionized water. The pH was adjusted to 7.3 with 5M NaOH and 
sterile-filtered with a 0.22µm filter. FBS (if required) and penicillin-
streptomycin were added aseptically and the medium was stored in 4℃. 
Before using, the medium was warmed to 37℃ in a water bath. Cells were 
stored with freezing medium and 5% sterile glycerol and kept in -20℃. 
 
2.1.10.2.7 Opti-mem 
Opti-mem medium (Invitrogen, Carsbad, CA, USA.) was used for transfection 
studies. 
 
2.1.11 Reagents for Immuno Cyto-Chemistry 
 
2.1.11.1 PBS buffer with fetal bovine serum (FBS) 
5% FBS was prepared in 1 x PBS and stored at -20℃ in 1ml aliquots. 
 
2.1.11.2 Fluorescein coupled secondary antibody 
FITC (Fluorescein Isothiocyanate) Goat anti mouse IgG was used for immuno 
cyto-chemistry studies. (Bio-Rad, USA). 
 
2.1.11.3 Nuclear stain 






2.1.11.4 Mounting medium 
An aqueous mounting medium was used to mount the coverslips fixed with 
cells onto microscope slides (Dako, USA). 
 
2.1.12 Cell viability assay 
 
2.1.12.1 MTT solution 
3-(4,5-dimethylthiazole-2-yl)-2,5,-diphenyl tetrazolium bromide  (MTT) was 
dissolved in saline to prepare a stock concentration of 5.5mg/ml. it was filtered 
and stored at 4℃ in the dark. Working concentration was 0.5mg/ml. 
 
2.1.12.2 Cell Viability and apoptosis assay using Hoechst/Ethidium 
Homodimer III Nuclear Staining 
Hoechst 33342 and Ethidium Homodimer III (EtHD) dye were purchased 
from Biotium, USA. 
 
2.1.13 Cytotoxicity assay 
 
2.1.13.1 Lactate dehydrogenase assay 
Release of the cytoplasmic enzyme lactate dehydrogenase (LDH) into the 
culture medium was used as a measure of cytotoxicity. Presence of LDH was 
determined using a detection kit (Roche Molecular Biochemicals). 
 




2.1.14.1 10 x Tris-Borate-EDTA (TBE) buffer 
Tris Base     108g 
Boric Acid     55g 
0.5M EDTA (pH=8.0)   40ml 
Tris base and boric acid was dissolved in 960ml of deionized water before the 
addition of 40ml EDTA, pH 8.0. The 10 x TBE buffer was stored in room 
temperature. The solution was diluted to 1 x with deionized water and used as 
running buffer for DNA gel electrophoresis. 
 
2.1.14.2 Ethidium bromide 
Ethidium bromide was dissolved in deionized water at a concentration of 
10mg/ml and stored at room temperature away from light. The final working 
concentration was 0.1µg/ml. 
 
2.1.14.3 DNA gel (1%) 
Electrophoresis grade agarose  0.5g 
1 x TBE Buffer    50ml 
Ethidium bromide (10mg/ml)   1μl 
Powdered agarose was mixed with 1 x TBE buffer and heated to 100℃, to 
dissolve completely. It was then cooled to about 60℃ prior to the addition of 
ethidium bromide. 
 





2.1.15.1 Reverse transcription (RT) 
Random hexamer    1 µl 
5 x reaction buffer    4µl 
RibiLock
TM
RNase inhibitor   1 µl (20U/ µl) 
dNTP  mixture, 10mM each   2 µl 
ReverAid
TM 
Reverse transcriptase  1 µl (200U/ µl) 
Autoclaved water     top up to 20 µl  
The individual components for the RT mixture were obtained from the 
ReverAid
TM
 H Minus First Strand cDNA Synthesis Kit (Ferments, Lithuania). 
 
2.1.15.2 Polymerase chain reaction (PCR) 
Template DNA    2 µl 
10 x Taq buffer with MgCl2   2.5 µl 
dNTP Mixture     2.5 µl 
Forward primer (1OD stock)   2.5 µl 
Reverse primer (1OD stock)   2.5 µl 
Taq DNA Polymerase (2 units/ µl)  1 µl 




2.1.15.3.1 Ligation of TA cloning vector 
TOPO® vector    1 µl 
Salt Solution     1 µl 
Autoclaved water    top up to 6 µl 
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The individual components for TA ligation were obtained from TOPO® TA 
Cloning Kit for Sequencing (Invitrogen, USA). 
 
2.1.15.3.2 Ligation of pMIR vector 
2 x DNA Ligation buffer   5 µl 
T4 DNA Ligase (5U/ µl)   1 µl 
Autoclaved water    top up to 10 µl 
The individual components for ligation were obtained from Rapid DNA 







Luciferase miRNA Expression Report Vector (Ambion, 
USA). 
 
2.1.15.5 Component cells 
50 µl of chemically component TOP10 E.coli cells were used for each 
transformation procedure (Invitrogen, USA). 
 
2.1.15.6 Ampicillin  
Powered ampicillin (Sigma, USA) was dissolved in sterile water to make 
concentrated stocks of 100mg/ml. The stocks were aliquoted into small 






2.1.15.7 Lysogeny broth (LB) 
Tryptone     1% (w/v) 
NaCl      1% (w/v) 
Yeast Extract     0.5% (w/v)  
The pH of LB Broth was adjusted to 7.0 using 1M NaOH prior to autoclaving. 
The LB broth was stored at 4 ℃. 
 
2.1.15.8 LB agar plates 
Agar powder (Gibco, USA) at a final concentration of 1.3% (w/v) was mixed 
with the LB broth and autoclaved. The mixture was cooled to approximately 
60℃ and antibiotic ampicillin (section2.1.15.6) was added. 20ml of the molten 
agar was poured into each 90mm sterile petri dish and allowed to set at room 
temperature. The LB agar plates were sealed using parafilm and stored at 4℃ 
in an inverted position. All plates were pre-warmed at 37℃ for 1hr before use. 
 
2.1.15.9 Plasmid isolation reagents 
 
2.1.15.9.1 Resuspension buffer 
Glucose     50mM 
Tris-HCL (pH=8.0)     25mM 
EDTA (pH=8.0)    10mM 
The re-suspension buffer without glucose was sterilised by autoclaving and 
cooled at room temperature. Filter sterilised glucose was later added to the 




2.1.15.9.2 Lysis Buffer 
NaOH      0.2M 
SDS      1% (w/v) 
Freshly prepared lysis buffer was used for plasmid extraction. 
 
2.1.15.9.3 Precipitation buffer 
Potassium acetate    3M 
Glacial acetic acid    1.5% (w/v) 
Precipitation buffer was stored at 4℃. 
 
2.1.15.10 RNase 
Powered RNase dissolved in sterile nuclease free water at 10mg/ml. the 
solution was heated to 60℃ and stored at -20℃. 
 
2.1.16 Reagents for restriction enzyme digestion 
10 x restriction enzyme buffer  2μl 
H2O      top up to 20μl 
Restriction enzyme    1U  
The restriction enzymes used in this study were purchased from Roche (USA). 
For each reaction, the respective compatible buffers with 100% activity were 
used.  
 





2.1.17.1 Cycle sequencing reaction 
Terminator ready reaction mixture  4μl 
Sequencing buffer    4μl 
Primer (5OD)      1μl 
Nuclease free water    top up to 20μl 
 
2.1.17.2 Purification of extension products 
3M Sodium acetate (pH=4)   3μl 
95% Ethanol      62.5μl 
Autoclaved water    14.5μl 
 
2.1.18 Reagents for miRNA array 
 
2.1.18.1 miRNA dephosphorylation (per sample) 
Spike – in miRNA    2μl 
CIP buffer     0.5μl 
CIP enzyme     0.5μl 
 
2.1.18.2 miRNA labelling (per sample) 
Labelling buffer    3μl 
Hy
3
 Fluorescent label    1.5μl 
DMSO      2.0μl 





2.1.18.3 Wash buffers 
 
2.1.18.3.1 Wash buffer A 
20 x Salt buffer    60ml 
10% Detergent solution   12ml 
Sterile water      528ml 
Wash buffer A together with two containers was pre warmed overnight to 56℃ 
prior to use. 
 
2.1.18.3.2 Wash buffer B 
20 x salt buffer    20ml 
Sterile water     380ml 
 
2.1.18.3.3 Wash buffer C 
20 x Salt buffer    2ml 
Sterile water     198ml 
 
2.1.19 Reagents for mRNA array 
 
2.1.19.1 Reverse transcription master mixture 
T7 Oligo(dT) Primer    1μl 
10 x First Strand Buffer   2μl 
dNTP Mixture     4μl 
RNase Inhibitor    1μl 
ArrayScript      1μl 
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2.1.19.2 Second strand master mixture 
Nuclease-free water     63μl 
10 x Second Strand Buffer   10μl 
dNTP Mixture     4μl 
DNA Polymerase    2μl 
RNase H     1μl 
 
2.1.19.3 In vitro transcription mixture 
T7 10 x reaction buffer   2.5μl 
T7 Enzyme Mixture    2.5μl 




2.2.1 Animal model 
 
2.2.1.1 Surgical manipulation and neurological measurements in animal 
models 
2.2.1.1.1 Transient focal middle cerebral artery occlusion (embolic 
method) 
Adult Wistar rats were anesthetized intraperitoneally by using ketamine and 
xylazine at a dose of 200µl/100g weight (section 2.1.1.2). The animal was 
considered sufficiently anesthetized when there was a complete loss of pedal 
reflex. The rat was put on the Right Temp Homeothermic Warming System 
(Kent Scientific Corporation, Torrington, CT) to maintain body temperature at 
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37 ± 0.5°C. The region around the neck of rat was shaved and its fur was 
cleaned.  
The left Middle Cerebral Artery (MCA) was occluded using an ‗embolus‘ 
model of focal ischemia described by Zhang et al [156] (Figure 2.1A). In brief, 
a skin incision was made from the petrous bone to the scapula and the neck 
muscles were dissected to gain access to the common carotid artery (CCA). 
The CCA, the origin of internal carotid artery (ICA) and the external carotid 
artery (ECA) were then exposed (Figure 2.1B). The bifurcation of the CCA 
and the ECA was dissected carefully as close to its entrance to the skull as 
possible. The pterygopalatine artery (PPA) that is proximal to the skull was 
ligated using 5/0 Silk Black (B.Braun, Melsungen, Germany). The ECA was 
ligated as proximal as possible but still proximal to its branching (Figure 2.1C). 
Microvascular clips (World Precision Instruments, Inc. Sarasota, FL) were 
applied to the proximal side of CCA and ICA. The origin of the ECA was tied 
loosely with 5/0 Silk Black, and an incision was made in the ECA (Figure 
2.1C). A modified PE-50 tube (Polyethylene tubing, ID 0.58mm, OD 
0.965mm, Becton Dickinson, Haryana, India) is inserted proximally into the 
ECA and into the ICA, microclip is removed at the ICA to allow the modified 
PE-50 catheter to be gently advanced further into ICA about 15mm from the 












Figure 2.1 Diagrams of middle cerebral artery occlusion (embolic method MCAo) 
procedure.  (A) Schematic drawing of the catheter placed into the external carotid 
artery (ECA) and internal carotid artery (ICA) with its tip 2mm proximal to the origin 
of middle cerebral artery (MCA). (B) Dissection of the common carotid artery (CCA), 
external carotid artery (ECA) and internal carotid artery (ICA); (C) The CCA is 
temporarily ligated and the ECA is permanently ligated. ICA was temporarily clipped 
and incision was made on the stump of the ECA. The catheter was introduced to ICA 
by ECA until it was wedged intracranially, at a length 1.5mm from the bifurcation. 








away from the origin of the MCA). The clot was injected gently with 10µl of 
saline and the catheter was removed from the ECA after 5min. The suture at 
the proximal region of ECA is tightened and microclip is removed from the 
CCA. The incision was closed using 3/0 Silkam Black (B.Braun, 
Melsungen,Germany). The animal is kept for different time point for 
reperfusion before being euthanized.  
 
2.2.1.1.2 Preparation for homologous clot 
Homologous clots should be prepared one day before the embolic MCAo 
procedure. A rat was anaesthetized and femoral artery was cannulated after 
isolation. The blood was withdrawn from the arterial into 50cm of PE-50 tube 
(Polyethylene tubing, ID 0.58mm, OD 0.965mm, Becton Dickinson, Haryana, 
India). The clot was kept in the tube at room temperature for 2hr and then 
stored at 4  C for up to 24hr before use. 
 
2.2.1.1.3 Preparation of modified PE-50 catheter 
Modified PE-50 catheter was prepared for injecting the clot to MCA region. 
Firstly, PE-50 tube was cut into 40 to 50cm pieces. Both ends of the tube were 
held with forceps and the middle of the tube was heated up with a flame. The 
heated tube was pulled and tempered to make the tip of the catheter to an outer 
diameter of about 0.35 to 0.40mm. The catheter was then cut in the middle to 
produce two modified PE-50 catheters. 
 
2.2.1.1.4 Preparation for injection of the clot 
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The PE-50 tubing containing the clot was then cut to 4cm length and 
connected to a 5ml syringe with 23G needle and filled with saline. The clot 
was transferred into a petri dish filled with saline. Subsequently, the clot was 
aspirated into a 30cm PE-10 tube connected to a 5ml syringe with 30G needle. 
The clot was washed by moving back and forth (at least 5 times) in the PE-10 
tube. Thereafter, the PE-10 tube was connected to the modified PE-50 catheter 
to allow the transfer of the clot from PE-10 tube into the modified PE-50 
catheter. A 1ml syringe with 23G needle pre-filled with saline was connected 
to the modified PE-50 catheter with the blood clot which is ready for clot 
injection. 
 
2.2.1.1.5 Laser-Doppler flowmetry 
To evaluate the cerebral blood flow (CBF) reduction during MCA occlusion in 
embolic ischemia, cerebral cortical blood flow was monitored by Laser-
Doppler Flowmetry (LDF) (OxyFlo, Oxford Optronix, UK) during pre-
occlusion, immediately post occlusion. The CBF was then expressed as a 
percentage of the relative flow calculated from the pre ischemic baseline 
levels. On average, 80% of CBF reduction as compared to pre-ischemic 
baseline levels was observed upon occlusion. 
In order to measure the CBF, the head skull area fur of the rat was shaved and 
cleaned. An incision was made in the midline of the scalps. The temporal 
muscle was dissected from the bone. The skull of the animal was drilled (1mm 
in diameter) at 2mm posterior and 6mm lateral to the bregma using a high 
speed micro-drill (Fine-Science Tool, USA). Terumo® Surflo® Winged 
Infusion Set (Terumo Corporation, Tokyo, Japan) was cut into 5mm in length, 
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glued on the hole using Krazy Glue All Purpose (Elmer's Products, Inc, 
Columbus, OH, USA) and fixed firmly using ZAP Zip Kicker PT-29 CA 
Accelerator (Pacer Technology, CA, USA) to allow placement of a 5mm LDF 
probe (OxyFlo XP Probe, UK) for CBF measurement. The signals of CBF 
were digitized using a 4 channel Powerlab 4SP (ML760) and recordings were 
displayed with Chart 5 software (ADInstruments Pty Ltd, Australia). 
 
2.2.1.1.6 Neurological measurement for animal models 
The neurological status of each rat was assessed as described by Longa et al. 
[154] with some modification by Zhang et al [156]. The neurological 
examination was carried out for 5min. In brief, each rat was evaluated 
carefully at 3, 6, 12, 24, 48, 72, 120 and 168hr post MCAo procedure and a 
grading scale (level 0 to 4) was employed to evaluate the effects of occlusion 
(Table 2.1). The neurological examination was conducted sequentially. Firstly, 
rats left eye was observed and a sunken and small pupil of the eye and droopy 
upper eyelid indicated a Horner's syndrome. Subsequently, rats were held 
gently and carefully by the tail, suspended about a meter above the floor, and 
examined for any forelimb extension. Rats that exhibited any extent of 
consistent forelimb flexion were judged as failure to extend right forepaw. 
Then, at the same position, rats were recorded the direction of each swing they 
attempted. Attempts were ended when animals' head or forelimbs returned to 
vertical. Continue observation until 20 swings have been attempted and 
animals exhibiting consistent right side turn fell into level 3. Finally, the rats 
were permitted to move without any restriction and were examined for any 
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circling behaviour. Level 4 was given to rats which circled toward the paretic 
side consistently. 
 
Table 2.1 Neurological evaluation scale of eMCAo models.  
 
Neurological Score Observation 
0 No neurological deficit 
1 Left Horner‘s syndrome 
2 Failure to extend right forepaw 
3 Turning to right 
4 Circling to right 
 
2.2.1.1.7 Histological analysis of brain infarct volume 
At the end of different reperfusion time points (0 to 168hr), the rats were 
sacrificed and the whole brains were sectioned coronally into 2mm slices 
using an Alto SA-2160 brain-sectioning matrix (Roboz, Gaithersburg, MD, 
USA). The slices were incubated in 2% TTC staining (section 2.1.1.3) for 
30min and photographed [199]. A white unstained area in the brain 
represented the infarct region. The surrounding (surviving) area remained in 
purple/red. The infarct volume was quantified using Image J 
(http://rsbweb.nih.gov/ij/) and calculated according to an indirect method [200] 
and expressed in mm
3
, as below:  
IV = Σ(CH – INIH) x Thickness of slice / (conversion from pixel to mm2 ) 
where 
IV = Infarct Volume 
CH = Contralateral Hemisphere 
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INIH = Ipsilateral Non Infarct Hemisphere 
 
2.2.1.2 Intracerebroventricular injection (ICV) of miRNAs 
For intracerebroventricular (ICV) injections of miRNAs, anti or pre miRNAs 
(Ambion, Inc) were prepared at 50 pmoles final concentration (leave at room 





agent (Ambion, Inc) (left at room temperature for 10min) for 20min before 




 transfection agent 
(Ambion, Inc) were considered as negative control. Intracerebroventricular 
injection was performed as previously described by Senn et al [197]. 
Anaesthetised MCAo rats were placed in a stereotactic frame (David Kopf 
Instrument, Tujunga, USA). 10µl of the miRNA preparations (anti or pre 
miRNAs total amount 50 pmoles optimized and established in our lab and 
transfection agent) were injected into the left lateral ventricle at 3min intervals 
using a 100µl Hamilton micro syringe, with the coordinates of 0.8mm 
posterior to the bregma, 1.5mm lateral to the midline, and 4.5mm ventral to 
the outer surface of the skull under the guidance of a stereotaxic instrument. 
After the administration of above compounds, animals were kept for 10min 
before removing from the stereotactic frame. 
 
2.2.2 Pathway analyses for miRNAs and mRNAs  
The significantly expressed miRNAs (FDR p value < 0.05, fold change > 2 or 
< -2) were used for pathway analysis for both acute phase (0, 3, 6, 12, 24hr) 
and recovery phase (48, 72, 120 and 168hr). Partek software Genome Suite 6.6 
(Partek Inc, USA) and MicroCosm targets Version 5 database were used to 
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determine the predicted target genes (mRNAs) of miRNAs in the respective 
pathways. The pathway was selected according to enrichment score. The 
enrichment score is performed by chi-square to indicate the lead genes of a 
biological category. A combined mRNA:miRNA pathway analysis was 
performed for the recovery phase (48 to 168hr). For human blood samples 
analysis, partek software Genome Suite 6.6 (Partek Inc, USA) and TargetScan 
database were used to determine the predicted target genes (mRNAs) of 
miRNAs in the respective pathways. The significantly expressed miRNAs 





2.2.3.1 Isolation of the total cellular RNA from brain tissue/cells 
For rat brain tissue, 50 - 100mg of tissue was weighted out and placed in 1ml 
of TRIzol®reagent (Invitrogen, USA). The sample was homogenised until no 
visible pieces and a fine consistency achieved. This was then used for the 
following RNA extraction. For cell culture, medium from 24-well plates was 
aspirated after a treatment was completed. The wells were washed with 1% 
PBS and 1ml of TRizol® reagent was aliquoted into three wells of 24-well 
plate. The TRizol® reagent was pipetted up and down to lyse the cells before 
they were collected into a 1.5ml eppendorf tube. Total RNA was isolated from 
brain/cells according to manufacturer‘s instructions. Briefly, brain/cells trizol 
solutions were left 5min at room temperature. Total of 200μl of saturated 
chloroform was added to the tube, mixed vigorously and subsequently 
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centrifuged at 14,000rpm for 15min. The aqueous phase was carefully 
transferred to a new 1.5ml eppendorf tube. The remaining organic phase was 
subjected to protein extraction according to the manufacturer‘s protocol 
(section 2.2.7). DNase (3μl) was added to the aqueous phase and it was 
incubated at 37℃ for 20min. Thereafter, 500μl of isopropanol was added and 
mixed vigorously. The final solution was left at -80℃ overnight. Total RNA 
pelleted by centrifuging at 14,000 rpm at 4℃ for 10min. The pellet was 
washed by centrifuging it with 1ml of ice-cold 75% ethanol at 14,000rpm for 
5min at 4℃. The supernatant was discarded and the resultant pellet was air 
dried before it was solubilised in 20μl of autoclaved water. The RNA 
concentration was determined by ND-1000 Specrophotometer (Nanodrop™, 
Thermo Fisher Scientific, USA) at 260nm and integrity was determined by 
RNA gel electrophoresis. 
 
2.2.3.2 Isolation of total RNA from whole blood 
Total RNA (including small RNA) from blood was extracted using Ambion 
Ribopure blood extraction kit following manufacturer‘s protocol (Ambion, 
Texas, USA). Briefly, the sample was centrifuged at 14,500rpm for 5min. The 
supernatant was discarded and 1ml of lysis solution was added and vortexed 
vigorously to obtain a clear solution (If not, samples were separated into 2 
tubes and an extra 300 to 500µl of lysis solution were added and vortexed 
again). 10µl acetic acid was added and the sample was incubated on ice for 
5min. 400µl of Acid-Phenol: Chloroform was added. The mixture was 
vortexed for 30sec and centrifuged at 14,500rpm for 5min. The supernatant 
(~1.2ml) was transferred to fresh 15ml tube. 1ml of denaturation solution was 
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added and mixed thoroughly by vortexing. 2.7ml of 100% ethanol was added 
and vortexed until the mixture became clear. 700µl of this solution was 
filtered through filter cartridge followed by a short spin. This step was 
repeated until all solution went through the filter. The filter cartridge was 
washed once with 700µl of Wash 1 (section 2.1.2.2.1) and twice with 700µl of 
Wash 2 (section 2.1.2.2.2) and centrifuged at 14,500rpm for 5min. The filter 
was transferred into a new labelled collection tube. 100µl preheated (75 to 
80℃) elution solution was added and sample incubated at room temperature 
for 2min and centrifuged at 14,500rpm for 1min. Another 100µl preheated (75 
to 80℃) elution solution was added to the tube and sample was again 
incubated at room temperature for 1min and centrifuged at 14,500rpm for 
2min. 
The RNA concentration was determined by ND-1000 Specrophotometer 
(Nanodrop™, Thermo Fisher Scientific, USA) at 260nm and integrity was 
determined by RNA gel electrophoresis.  
 
2.2.4 Checking RNA integrity 
 
2.2.4.1 RNA gel electrophoresis 
Agarose gel electrophoresis was used to separate ribonucleic acid, which is 
necessary to determine the integrity of the RNA isolated. Molten RNA gel 
(section 2.1.3.4) was poured into horizontal gel-casting tray and an appropriate 
comb was inserted immediately to create wells for sample loading. After the 
gel become solidified, the comb was removed and the gel was submerged into 
the electrophoresis tank with 1 x MOPS running buffer. RNA samples (0.4-
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1.0ug) mixed with the sample buffer (section 2.1.3.2) and 2μl of RNA loading 
buffer (section 2.1.3.3) were incubated for 10min at 65℃ in a water bath prior 
to loading into the gel. Electrophoresis was carried out at 100V for about 
30min and the migration of the bands was visualized using a UV illuminator 
(Figure 2.2). 
 
Figure 2.2 RNA Agarose gel. RNA sample was run agarose gel and 28s and 
18s were demonstrated. 
 
2.2.4.2 Denaturing polyacrylamide gel electrophoresis (PAGE) 
The integrity of small RNAs was analysed by denaturing polyacrylamide gel 
electrophoresis. Molten RNA gel (section 2.1.4.1) was poured into a vertical 
gel-casting tray and an appropriate comb was inserted immediately to create 
wells for samples loading. After the gel solidified, the comb was removed and 
the gel was submerged into the electrophoresis tank containing 1 x TBE 
running buffer. The gel was pre-run for 30min at 100V. Meanwhile the RNA 
samples (5-10ug) mixed with sample buffer (section 2.1.4.2) were heated up to 
95℃ for 5min in a water bath. The samples were chilled immediately and 
centrifuged shortly prior to loading into the gel. Electrophoresis was carried 
out at 100V for about 1.5h and the migration of the bands was visualized using 






Figure 2.3 RNA Denaturing polyacrylamide gel. RNA sample was run in PAGE 
gel and 5.8s, 5s and tRNA bands were showed.  
2.2.5 Reverse transcription (RT) 
 
2.2.5.1 RT of mRNA 
Reverse transcription was done by using 200ng of total RNA (100ng/μl) with 
8μl of RT mixture (section 2.1.5.1) to generate 10μl of the first strand 
complementary DNA (cDNA). Synthesis of cDNA was carried out in a PCR 
machine (Perkin-Elmer, Germany) at 25℃ for 10min; 37℃ for 60min 
followed by 95℃ for 5min. 
 
2.2.5.2 RT of miRNA 
Reverse transcription was done by using 10ng of total RNA (5ng/μl) with 7μl 
of miRNA RT mixture (section 2.1.5.2) and 3μl of miRNA specific primers to 
generate 15μl of RT product. Synthesis was carried out using a PCR machine 
(Perkin-Elmer, German) at 16℃ for 30min; 42℃ for 30min followed by 85℃ 
for 5min. The miRNA specific primers were purchased as miRNA Assay kits 
(Applied Biosystems, USA). 
 
2.2.6 Quantitative real-time PCR (qPCR) 
 
2.2.6.1 qPCR (mRNA) 
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Real-time PCR was used to measure the changes in gene expression upon a 
particular treatment. TaqMan and SYBR green assay were used. TaqMan 
assay makes use of gene specific primers and fluorescent probes whereas 
SYBR green uses two (forward and reverse) gene specific primers and a DNA 
intercalating dye. Sequences for gene specific primers were designed using the 
PrimerExpress 2.0 software. The primers were designed to yield amplicons of 
about 200bp. Ribosomal RNA (18S) was used as an internal calibrator. 20μl of 
TaqMan (section 2.1.6.1) or SYBR green assay (section2.1.6.2) was mixed 
with 5μl of RT product (section 2.1.5.1) and loaded into 96 well optical plates. 
The plates were sealed with a clear plastic cover and the PCR reaction was 
carried out on ABI PRISM 7900 cycler with thermal cycling conditions of 50℃ 
for 2min, 95℃ for 10min followed by 40 cycles at 94℃ for 15s and 60℃ for 
1min per cycle. All Reagents and consumables needed for the PCR reaction 
were purchased from Applied Biosystems, USA. 
 
2.2.6.2 Stem-loop qPCR  
Real-time PCR was used to measure the changes in miRNAs expression upon 
a particular treatment. 18.67μl of the TaqMan miRNA mixture (section 2.1.6.4) 
was mixed with 1.33μl of miRNA RT product (section 2.1.5.2) and loaded 
into 96 well optical plates. The plates were sealed with a clear plastic cover 
and the PCR reaction was carried out on ABI PRISM 7900 cycler with 
thermal cycling conditions of 30℃ for 2min, 95℃ for 10min followed by 40 
cycles at 94℃. All reagents and consumables needed for the PCR reaction was 
purchased from Applied Biosystems, USA. The miRNA specific primes were 
purchased as MicroRNA Assay kits (Applied Biosystems, USA). 
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2.2.7 Extraction of total protein from cells/brain tissue 
Total protein of brain tissue/cells was extracted from the remaining organic 
phase after chloroform extraction (Invitrogen, USA) (section 2.1.2.1) 
according to the manufacturer‘s protocol. Briefly, 300μl of 100% ethanol was 
added to the organic phase and the samples were mixed by inversion. The 
samples were stored at room temperature for 3min and sedimented at 
12,000rpm for 5min at 4℃. The supernatant was transferred to a fresh tube 
and 1.5ml of isopropanol was added. After 30min incubation at room 
temperature, the protein was precipitated by centrifugation at 12,000rpm for 
10min at 4℃. The supernatant was discarded and the pellet was washed 3 
times with 1ml of 0.3M guanidine hydrochloride in 95% ethanol (section 
2.1.7.1). During each wash cycle, the pellet was kept in the wash solution for 
20 mins at room temperature and centrifuged at 7,500rpm for 5min at 4℃. 
After the final wash, the pellet was vortexed and stored in 2ml of 100% 
ethanol for 20min and centrifuged at 7,500rpm for 5min at 4℃. The 
supernatant was discarded and the pellet was vacuum-dried and dissolved in 
the solubilisation buffer (section 2.1.7.2). The sample was stored at -20℃ for 
future use. 
 
2.2.8 Determination of protein concentration 
Bradford‘s reagent (Bio-Rad, USA) was diluted 5x using autoclaved water. 
2μl of the protein sample was then added to 1ml of the diluted Bradford‘s 
reagent and incubated at room temperature for 15min prior to absorbance 
measurement at a wavelength of 595nm. Bovine serum albumin (2-10ug) was 
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used to generate the standard graph and the concentration of the unknown 
protein samples was determined from it. 
 
2.2.9 Tris-Tricine SDS-PAGE 
The protein extracted from tissues or cells were separated using Tris-Tricine 
SDS-PAGE. For preparation of resolving (12%) and stacking (4%) see section 
2.1.8.5. The resolving gel was prepared first and allowed to set before the 
stacking gel was cast. A 1mm ―comb‖ was placed at the top of the stacking gel 
to create wells for sample loading. The gel was assembled in a vertical 
electrophoresis unit and filled with the upper and lower buffers (section 
2.1.8.2 & 2.1.8.3). Protein samples (40ug) were mixed with 2x sample buffer 
(section 2.1.8.4) and heated for 10min at 100℃. The samples were loaded into 
the gel and electrophoresis was carried out at 120V for about 1.5hr. 
 
 
2.2.10 Western Blot 
The SDS-PAGE gel was carefully removed and soaked in transfer buffer 
(section 2.1.9.1) for 15min. Nitrocellulose membrane (Amersham 
International, UK) cut to the dimension of the gel, 2 pieces of scotchbrite and 
2 sheets of 3MM paper were soaked in the transfer buffer for 30min. They 
were then assembled on the blotting panel in the following order: scotchbrite, 
3MM paper, gel, nitrocellulose membrane, 3MM paper and scotchbrite. 
Precaution was taken to ensure that air bubbles were not present between the 
membrane and the gel. The blotting assembly was then secured in the transfer 
apparatus and filled with pre-cooled transfer buffer. Electro-blotting was 
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carried out for 110V for 1hr. At the end of blotting, the apparatus was 
disassembled and the membrane was blocked for 60min in blocking solution 
(section 2.1.9.4). This was followed by 1hr incubation with affinity purified, 
polyclonal anti-HIF-1α (Santa Cruz, USA) antibody at a dilution of 0.5ug/ml 
in 0.5% blocking solution. After three washes of 10min each in PBST (section 
2.1.9.3), the membranes were incubated for 1hr at room temperature with 
horseradish peroxidase-conjugated goat anti-rabbit (Bio-Rad, USA) secondary 
antibodies at a dilution of 1:10000 in 0.5% blocking solution. The 
chemiluminescent (ECL) substrate was used to detect the activity of 
horseradish peroxidase. The membranes were then washed 2 times for 20min 
each in PBST and visualised via enhanced chemiluminescence (Supersignal; 
pierce, USA) with variable exposures (Kodak-MS film). Films of Western blot 
were scanned and labelling intensities of the bands were quantitated using 
Image J software. 
 
2.2.11 Cell culture 
 
2.2.11.1 Primary cortical neuronal cultures 
The cortices were dissected from E15 mouse embryos and washed with Hanks‘ 
balanced salt solution (HBSS,14025-092, Gibco, Invitrogen, USA). The 





 (14175-095, Gibco, Invitrogen, USA) for 30min at 37℃ and 
neutralized with 1 mg/ml trypsin inhibitor (T6522, Sigma, USA). Single cells 
were obtained by gentle trituration in Neurobasal medium (21103-049, Gibco, 
Invitrogen, USA) supplemented with B27 (17504-044, Invitrogen, USA), L-
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glutamine and Penicillin-Streptomycin (Gibco, Invitrogen, USA). The cells 
were counted by trypan blue and seeded on poly-D-lysine coated 24 well 
plates at a density of 120,000 cells/cm
2
. Cultures were maintained at 37 ºC 
with 5% CO2 in a tissue culture incubator. The purity level of each culture was 
evaluated using immunofluorescent techniques. 
 
2.2.11.2 HeLa cells culture 
HeLa cells were cultured using DMEM. The medium was supplemented with 
10% fetal bovine serum (FBS), 50U of penicillin and 50ug/ml of streptomycin. 





2.2.12.1 miRNA transfection 




transfection reagent (Ambion, 
USA) was diluted by Opti-MEM (Gibco, USA) at a ratio of 1:49μl and 
incubated at room temperature for 10min. The miRNA (Ambion, USA) was 
diluted to the appropriate concentration in 50μl Opti-MEM. Then, the diluted 
transfection reagent and the miRNA solution were mixed to make the miRNA 
final concentration 30 nM (this concentration has been optimised in our lab) 
and incubated at room temperature for further 20min. Cells were seeded at a 
density of 2.5 x 10
4
 per well in 24-well plates at the same time of preparing 
transfection solution. The 100μl of miRNA – transfection reagent mixture was 
added drop-wise to the wells. Total of 500μl of complete medium was added 
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to the wells after 24hr of incubation. At 48hr, transfection was stopped and 
cells were collected for RNA extraction. The miRNAs expression was 
quantitated by real-time PCR by comparing to the cells transfected with 
negative control miRNA (Ambion, USA). 
 
2.2.12.2 miRNA and reporter plasmid transfection 
For miRNA-mRNA interaction studies, anti or pre miRNA was co-transfected 
with luciferase reporter plasmids containing the target recognition sites. For 
miRNA transfection, lipofectamine transfection reagent (Invitrogen, USA) 
was complexed with Opti-MEM (Gibco, USA) at a ratio of 1.5: 150μl and 
incubated at room temperature for 10min. The anti or pre miRNA (Ambion, 
USA) was diluted in 150μl Opti-MEM to obtain a final concentration of 30nM. 
The diluted transfection reagent and the miRNA complex were then mixed at a 
ratio of 1:1 and incubated at room temperature for further 20min. Cells were 
pre-seeded 24hr earlier at a density of 6.5 x 10
4
/ per well in 24-well plates. 
The wells were washed with 300μl of Opti-MEM followed by the addition of 
300μl of the miRNA-transfection reagent mixture. The cells were left in the 37℃ 
CO2 incubator for 3hr. At the end of the 3hr incubation, plasmid transfection 
preparation was done. For plasmid transfection, lipofectamine transfection 
reagent and Opti-MEM was mixed at a ratio of 3:150μl and incubated for at 
room temperature for 10min. The luciferase plasmid was diluted in 150μl 
Opti-MEM to obtain a final concentration of 200nM. 10ng of pRL-CMV 
(Promega Madison USA) vector was used to determine transfection efficiency. 
The diluted transfection reagent and the plasmids were then mixed at a ratio of 
1:1 and incubated at room temperature for further 20min. At the end of the 3hr 
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incubation, the medium was aspirated and the cells were washed using Opti-
MEM.300μl and the plasmid-transfection reagent mixture was added to the 
cells. The cells were left in the 37℃ CO2 incubator for another 3hr. At the end 
of the 3hr, the medium was replaced with complete medium (DMEM) and the 
cells were left to grow for 48hr, following which luciferase assays were 
performed. 
 
2.2.13 Luciferase assay 
To study the miRNA-mRNA interaction, the Dual-luciferase® Reporter (DLR) 
assay system was used (Promega, Madison, USA). This assay allows the 
simultaneous expression and measurement of two individual reporter enzymes 
within a single system. The Firefly Luciferase expression is used to show the 
effect of miRNA and its target mRNA interaction, while the activity of the co-
transfected Renilla luciferase is used as the internal control serving as the 
baseline response. Firefly and Renilla luciferases, because of their distinct 
evolutionary origins, have different enzyme structures and substrate 
requirements. These differences make it possible to selectively discriminate 
between their respective bioluminescent reactions. After 48hr transfection, the 
medium was aspirated and the cells were washed with PBS two times. The 
cells were lysed by 100μl of passive lysis buffer per well leaving on a shaker 
for 10min with gentle agitation and collected in a 0.6μl tube. After 
centrifuging at maximum speed for 2min, the cell lysate was transferred into a 
separate tube. Total of 25μl of the cell lysate was transferred into a white 
optical plate in a luminometer. After adding 25μl Dual-GloTM luciferase 
substrate, the firefly luciferase activity was measured. To quench the firefly 
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luciferase activity and read the Renilla luciferase activity, 25μl of Stop & 
Glo
TM
 reagent was added and the luminescence was measured. 
 
2.2.14 MTT Assay 
3-(4, 5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay is 
a colorimetric assay used to measure cells viability under the different 
experimental conditions. It measures the reduction of yellow MTT into an 
insoluble, coloured formazan product by the activity of mitochondrial 
enzymes in viable cells. At the end of a treatment procedure, concentrated 
MTT was added into each well to a final concentration of 0.5mg/ml and  
incubation at 37℃ for 60min away from light. Then the MTT-containing 
medium was removed and formazam crystals were dissolved in 200μl DMSO 
(MP Biomedical, USA) with gentle shaking for 10min to ensure complete 
dissolution of the crystals. Dissolved crystal solution was transferred to 96 
well plate with triplicates 100μl/well and the absorbance intensities were 
measured at a wavelength of 550nm using a multi-plate scanning 
spectrophotometer (Bio-Rad, Model 680 Microplate reader). 100μl DMSO 
was used as a blank. Viability of the treated cells was expressed as a 
percentage of the untreated control sample. 
 
2.2.15.1 Morphologic Assessment of Apoptosis and Cell Viability Using 
Hoechst/Ethidium Homodimer III Nuclear Staining and Fluorescence 
Microscopy 
Cells subjected to OGD (and/or anti/miR-206 mimic) were stained with 
Hoechst 33342 and Ethidium Homodimer III (EtHD) dye as per the 
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manufacturer‘s protocol (Biotium, USA.). Stained cells were protected from 
light until visualized by fluorescence microscopy (DMIRB, Leica, Leica 
Microsystems Inc, Deerfield, IL USA). Images were captured at 406 
objectives and cell morphology was determined as follows; (1) Viable cells 
had blue-stained normal, smooth nuclei. (2) Apoptotic cells had blue-stained 
nuclei with fragmented/condensed chromatin. A minimum of 3 fields of at 
least 100 cells per field were counted to determine the percentage of apoptotic 
cells from the total number of cells. 
 
2.2.15.2  LDH Assay 
LDH assay was done by using a cytotoxicity detection kit, which provided a 
fast and simple colorimetric method to quantitate cell death based on 
measurement of LDH that is released from damaged cells. LDH is a stable 
cytoplasmic enzyme present in most eukaryotic cells and rapidly released into 
the medium upon loss of membrane integrity. Therefore, the increase of the 
LDH activity in cell culture supernatant is proportional to the number of lysed 
cells. At the end of treatment procedure, culture medium was collected and 
centrifuged for 10min at 14,000 rpm to remove any cellular debris. 100μl of 
the supernatant was transferred to a 96-well plate with each treatment in 
triplicates. The LDH activity in the supernatant was determined using the 
LDH cytotoxicity detection kit purchased from Roche Applied Science (USA). 
The supernatant was added in 100μl of the reaction mixture prepared 
according to the manufacturer‘s protocol and mixed well. Following a 30min 
incubation at room temperature, the relative absorbance was measured at 
490nm using the multi-plate scanning spectrophotometer (Boi-Rad, Model 
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680 Microplate Reader). Total LDH activity in cells was determined by lysing 
the cells with 2% Triton X-100 (BDH Chemical, England) in basal medium 
and subjecting the supernatant to the assay. Cytotoxicity of the treated cells 
was expressed as a percentage of the total cellular LDH activity. 
 
2.2.16 Immuno Cyto-Chemistry (ICC) 
ICC techniques were employed to visualize changes in protein expression 
upon miRNA transfection. The cells were seeded on coverslips which were 
placed in 24-well plates. Cells was transfected with anti or pre miRNAs and 
the plasmid constructs as described in section 2.2.12.2. After 48hr of 
transfection, the cells were washed with PBS to remove traces of medium and 
fixed to the coverslips using 1ml of 4% formaldehyde for 30min. Thereafter, 
the wells were washed 5 times by using PBS and added 0.1% (v/v) Triton® X-
100 in PBS 1ml/well and incubated in room temperature for 30min to make 
hole on cells. Wash the well 5 times again using PBS and remove the 
coverslips from the wells and place on a clean surface. 50μl primary antibody 
(anti-Microtubule-associated protein 2 (MAP2) ) at a concentration of 1μl/ml 
was overlayed on top of each coverslips and incubated at room temperature for 
1hr. After the incubation, the coverslips were washed five times for a total 
duration of 15min in PBS. 50μl of FITC goat anti-mouse IgG (Bio-Rad, USA) 
secondary antibody (dilution of 1:200) was overlayed on the coverslips 
incubating for 1hr away from light which was followed by five times washes 
in PBS for 15min. After that, 50μl Hoechst nuclear stain (section 2.1.11.3) 
was overlayed on the coverslips for 1min, followed by three times washes in 
PBS for 15min. Each coverslips was then mounted (section 2.1.11.4) face 
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down onto a microscope slide and the images were captured using a 
fluorescence microscope (Cal Zeiss LSM510 META). 
 
2.2.17 Oxygen glucose deprivation (OGD)  
Primary neuronal cultures from day 6 were subjected to oxygen glucose 
deprivation (OGD). Glucose free Earle‘s balanced salt solution (EBSS) was 
saturated with a mixture gas of 5% CO2, 95% N2, in a ProOx in vitro chamber 
(BioSpherix, USA) at 37℃ overnight, with O2 maintained at 0.1%. Day 6 
neuronal cultures were washed twice with this medium and incubated in the 
chamber. OGD was terminated by replacing the glucose-free EBSS with 
reperfusion medium (Neurobasal medium with L-glutamine and Penicillin-
Streptomycin, without B27 supplement). Control cultures were treated 
identically, but without exposure to OGD conditions. During reperfusion, the 
cells were maintained in a regular 5% CO2 incubator for 24hr. 
Primary cortical astrocytes OGD process is the same with primary neuron 
cultures. Passage 3 primary astrocytes were used with DMEM media 
containing 10% fetal bovine serum (FBS).   
 
2.2.18 First strand cDNA synthesis for cloning 
Total RNA extracted from rat brain tissue was used for reverse transcription of 
Hif-1α mRNA and the reagents were from (Fermentas) RevertAidTM H Minus 
First Strand cDNA Synthesis Kit (section 2.1.15.1). Briefly, the individual 
components of the kit were thawed on ice. 1ug of total RNA and 1μl (100pmol) 
of random hexamers were aliquoted into a sterile PCR tube containing RNase 
free water. The volume was adjusted to 12μl. The contents in the tube were 
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mixed gently, centrifuged briefly and incubated at 65℃ for 5min. The tube 
was then chilled on ice. The remaining components of the First Strand cDNA 
Synthesis Kit were added to the tube. The contents were mixed and 
centrifuged briefly. The PCR tube was incubated at 25℃ for 10min followed 
at 42℃ for 60min. The reaction was terminated by heating at 70℃ for 5min 
and 1μl of the cDNA product was directly used to perform PCR in a 25μl 
volume. 
 
2.2.19 Polymerase chain reaction (PCR) 
The template used for PCR can be genomic or complementary DNA 
depending on the region of interest. The PCR reaction was prepared in 0.2ml 
PCR tubes on ice according to section 2.1.15.2. 1μl of the template was added 
and the contents were briefly centrifuged. The PCR cycling conditions were 
based on the melting temperatures (Tm) of the primers used and the size of the 
product amplified. Typically the annealing temperature was set 5℃ below the 
primer Tm for 45s while the extension temperature was kept at 72℃. At the 
end of the run, 10μl of the product was analysed on a 1% DNA agarose gel 
(section 2.1.14.3). Once the desired fragment size is obtained, the fragment is 
cut out with a clean and sharp scalpel for DNA extraction. 
 
2.2.20 DNA gel extraction 
The excised PCR fragment was weighed and added QG buffer (Qiagen, 
Germany) with volumes equivalent to 3 times the weight of the gel. The gel 
and buffer mixture was incubated at 50℃ until the gel was completely 
dissolved. Isopropanol was added with volumes equivalent to the weight of the 
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gel and mixed. The sample was transferred to a QIAquick spin column and 
centrifuged at maximum speed for 1min. The flow-through was discarded and 
the column was washed with 0.75ml of PE buffer (Qiagen, Germany) two 
times by centrifuging at maximum speed for 1min. The QIAquick column was 
transferred into a clean 1.5ml microcentrifuge tube and the DNA was eluted 
with 20μl of nuclease free water by centrifuging for 2min at maximum speed. 
The DNA integrity was checked by loading 2μl of DNA to run a 1% agarose 
gel. The remaining DNA extract was used directly for cloning or stored at -
20℃.  
 
2.2.21 Ligation and transformation 
Vector and insert were ligated by the vector: insert molar ratio of 
approximately 1:3 which was recommended to increase the ligation efficiency. 
Usually 50ng of plasmid vector was used for each reaction (section 2.1.15.3). 
The reaction mixture was incubated at room temperature for 30min before the 
addition of competent cells. Competent cells (Invitrogen, USA) from -80℃ 
were thawed on ice 10min before the end of 30min incubation. The ligation 
mixture was added to 50μl of the competent cells and mixed gently. The tube 
was kept in ice for 30min, then heat-shocked at 42℃ for 90s and transferred to 
a 10ml green cap tube by adding 250μl SOC medium (Invitrogen, USA). The 
cells were incubated in a shaker for 1hr at 37℃ before plating them on LB-
agar plates (section 2.1.15.8) with ampicillin (section2.1.15.6). The plates 
were left at 37℃ for about 18hr to allow the colonies to grow at a invert 
position. Single colonies were then picked using sterile toothsticks and re-
grown for 18hr in 1.5ml LB broth (section2.1.15.7) containing ampicillin. 
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2.2.22 Plasmid extraction 
Plasmid extraction was used to extract the plasmid from the grown colonies 
for further analysis of cloned fragments. The individually grown colonies 
(1.5ml) were transferred into an eppendorf tube and centrifuged at maximum 
speed for 2min to pellet the cells. The supernatant was aspirated and the pellet 
was resuspended in 100μl of cold resuspension buffer (section 2.1.15.9.1). The 
resuspended pellet was vortexed vigorously to make sure it was completely 
resuspended. Thereafter, 200μl of fresh lysis buffer (section 2.1.15.9.2) was 
added and the tube was inverted 5-6 times to mix the contents. Following 
which 150μl of cold precipitation buffer (section 2.1.15.9.3) was added to the 
tube and mixed vigorously. This solution neutralized NaOH in the previous 
lysis step while precipitating the genomic DNA and SDS into an insoluble 
white precipitation. The tube was incubated in ice for 10min and centrifuged 
at maximum speed for 10min. The supernatant was aspirated to a new tube, 
3μl of RNase solution was added (section 2.1.15.10) and incubated at 60℃ for 
20min. The tube was then cooled on ice and 450μl isopropanol was added to 
precipitate the plasmid at -80℃ for 30min. The tube was spun at maximum 
speed for 10min after the 30min precipitation. The supernatant was discarded 
and 500μl of 70% ethanol was added to wash the plasmid by spinning for 
10min at maximum speed. The supernatant was aspirated and the pellet was 
air dried before being resuspended in 25μl of nuclease free water. 
 
2.2.23 Restriction enzyme digestion 
To know whether the cloned fragment was inserted in the vector, we carried 
out restriction enzyme digestion. About 1ug of plasmid was added to the 
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restriction enzyme mixture (section 2.1.16) with final volume of 20μl and the 
tubes were incubated at 37℃ overnight. Buffers compatible to both enzymes 
were used if it was double digestion. Following the incubation, the mixture 
was loaded on to a 1% DNA agarose gel (section 2.1.14.3). If the digested 
fragment was needed for further cloning, the fragment was excised out with a 
clean and sharp scalpel and the DNA was extracted from the gel.  
 
2.2.24 Sequencing  
 
2.2.24.1 Cycle sequencing reaction 
The cycle sequencing reaction was prepared in 0.2ml PCR tubes on ice 
according to section 2.1.17.1. Template 1μl (including 100 - 150ng plasmid) 
was added and the contents were briefly centrifuged. The primer used was 
vector specific primer.  The PCR cycling conditions were 96℃ for 30 sec, 50℃ 
for 15sec followed by 60℃ for 4min for total 25 cycles. At the end of the PCR, 
The product was kept on ice for further purification.    
 
2.2.24.2 Purification of extension products and sequencing  
The sequencing PCR product was transferred from PCR tube to 1.5ml 
eppendorf tube for purification according to section 2.1.17.2. In brief, 80μl 
ethanol/sodium acetate solution was added to the cycle sequencing product 
and vortexed briefly to mix well. The tube was incubated on ice for 15min 
followed by centrifuging at 14,000rpm for 20min. The supernatant was 
aspirated and 500μl of 75% ethanol were added to wash the product by 
vortexing half minutes. Then, the tube was centrifuged for 15min. After 
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spinning, the ethanol was removed and the PCR products were dried at 50℃ 
oven for 10min. The dried PCR product was resuspended in 10μl Hi-DiTM 
formamide and vortexed for 1min followed by short spinning. The product 
was then transfer to a microplate, which was heated at 95℃ for 2min and 
cooled down at 4℃. Then, the microplate was loaded to ABI PRISM® 3100 
Genetic Analyzer (Applied Biosystems, USA) for sequencing. All Reagents 
and consumables needed for the sequencing reaction were purchased from 




2.2.25.1 Sample labelling 
All the components of the miRCURY LNA microRNA power labelling kit 
(Exiqon, Denmark) were thawed on ice. Total RNA from the sample or tissue 
of interest was extracted and was prepared to a final concentration of 
500ng/2μl. Prior to miRNA labelling, the sample was treated with Calf 
Intestinal Alkaline Phosphatase (CIP) to facilitate removal of 5‘-phosphates 
from the terminal of the miRNAs. 2μl of the CIP mixture was mixed with the 
RNA sample in a PCR tube. The mixture was incubated in a PCR machine at 
37℃ for 30min to allow the CIP enzyme to function optimally, followed by 95℃ 
for 5min to linearize the miRNA template and snap cooled in ice to terminate 
the reaction. The sample was briefly spun and 8.5μl of the labelling mixture 
was added to it. The miRNAs were labelled with Hy3 fluorophores. Labelling 
of miRNAs was performed in a PCR cycler with heated lid, at 16℃ for 1h 
followed by 65℃ for 15min. The samples were protected from light. At the 
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end of the reaction, the samples were pulsed and left at 4℃ while the 
hybridization chamber was prepared. Hybridization was carried out within 2hr 
of labelling. 
 
2.2.25.2 Sample preparation for hybridization 
The labelling product was diluted by adding 12.5μl of nuclease-free water and 
transferred into a new PCR tube. The sample was added 25μl of 2x 
hybridization buffer (Exiqon, USA) and vortexed to mix and then pulsed down 
(short spin). The sample was then denatured at 95℃ for 2min and snap cooled 
on ice. Pre-wetting of the pipette tips was important before sample loading. 
Hence a tube containing 50μl 1 x hybridization buffer in nuclease free water 
was prepared and incubated at 56℃. 
 
2.2.25.3 Setting up of hybridization chamber 
The MAUI hybridization chamber was switched on and pre-heated to 56℃. 
The miRNA array chip (miRBase version 12.0) was warmed on the pre-heated 
block for 5min. The chip was then loaded onto a chip holder. A cover was 
aligned onto the exposed surface of the array chip according to the 
manufacturer‘s instructions (Exiqon Denmark). The exposed chip surface was 
then sealed with cover. The enclosed chip assembly was placed back into the 
MAUI hybridization chamber until sample loading. 
 
2.2.25.4 Loading of sample for miRNA array 
The pipette tips were pre-wetted with the hybridization plus water mixture 
before loading sample. Forty-five, μl of the sample was slowly injected into 
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the chip via the chip cover‘s inlet port by avoiding introduction of bubbles. 
Sample loading was stopped when the fluid was observed to reach the outlet 
port of the cover. The excess fluids were wiped away and the ports were 
sealed with an adhesive tape. The enclosed chip assembly was then loaded 
back onto the pre-heated MAUI hybridization chamber. The assembly was 
enclosed with a pre-wet humidity casing and closed shut. The slides were then 
incubated at 56 ℃ for 16hr.  
 
2.2.25.5 Washing miRNA array slides 
The enclosed chip assembly was removed from the MAUI hybridization 
chamber and slotted back into the chip holder at the end of the hybridization 
process. The holder was then soaked in 400μl of pre-warmed Buffer A. 
Keeping the holder submerged, the cover of the chip was gently peeled away. 
The exposed chip was then carefully slotted out of the holder and transferred 
to a rack which was immersed in a dish containing 200ml of the prewarmed 
Buffer A. The chip was then rinsed by gently plunging the rack for 2min. Care 
was taken to ensure that the chip was kept submerged throughout the washing 
procedure. The rack was then transferred to 200ml of Buffer B at room 
temperature and the chip was temporarily stored here while the rest of the 
chips were disassembled and rinsed by gently plunging the rack for 2 min. 
Then they were moved to another dish containing fresh Buffer B solution and 
the procedure was repeated again for 2min. A third wash was done in the 
similar manner using Buffer C. The final wash was done in 200ml absolute 
ethanol for 1min. The chips were dried by centrifugation at 1000rpm for 5min 
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after the washes and scanned immediately at 532nm as the fluorophores on the 
slides are susceptible to degradation by ozone in the atmosphere. 
 
2.2.25.6 Scanning of miRNA array chips and data analysis 
Scanning of the miRNA array chips was performed using the InnoScan 700 
Microarray scanner (Innopsys, France) and the signal intensity was quantified 
using the Mapix software (Innopsy, France). Background substraction and 
normalization were performed on the raw signal intensity data using the 
internal control inherent in the chip. Statistical comparisons between controls 
and test samples were performed using ANOVA. p-value < 0.05 was 
considered to be statistically significant. Hierarchical clustering plot was 
generated using TIGR multiple experimental view software 
(http://www.tm4.org/mev/) [200]. For human sample, hierarchical clustering 
plot was generated using Partek Genomics Suite 6.6 (Partek Inc, USA). 
 
2.2.26 mRNA array 
 
2.2.26.1 cRNA amplification and purification 
The Illumina® TotalPrep RNA amplification kit was used to amplify and 
generate biotinylated RNA for hybridization with Illumina® array. Reverse 
transcription to synthesize the first cDNA strand was performed with 500ng of 
total RNA which was diluted to a final volume of 11μl with nuclease-free 
water. 9μl of the reverse transcription master mixture (section 2.1.19.1) was 
added to the RNA sample and incubated for 2hr at 42℃. At the end of 
incubation, the samples were pulsed down and 80μl of the second strand 
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master mixture (section 2.1.19.2) was added. The samples were pulsed and 
incubated further at 16℃ for 2hr. 250μl of cDNA binding buffer was added to 
each sample to purify out the synthesized cDNA. The cDNA sample and the 
binding buffer were mixed thoroughly and pulsed down and the solution was 
transferred onto the cDNA filter cartridge. The filter cartridge was centrifuged 
for 1min at 10,000 x g and the flow-through was discarded. The cDNA filter 
cartridge was then washed with 500μl of wash buffer and transferred to a new 
tube to prevent carry-over of the wash buffer. The cDNA was eluted with 20μl 
nuclease-free water which was pre-warmed to 55℃ and transferred into a PCR 
tube. 7.5μl of the in vitro transcription master mixture (section 2.1.19.3) was 
added to each PCR tube. After mixing them thoroughly, the samples were 
pulsed down and placed in the thermal cycler at 37℃ for up to 14hr. At the 
end of the incubation, the reaction was terminated by adding 75μl nuclease-
free water, bringing the total volume to 100μl. The amplified cRNA was 
purified to remove the excess enzymes, salts and unincorporated nucleotides. 
350μl of cRNA binding buffer was added to each cRNA sample followed by 
250μl of 100% ethanol. The components were mixed by pipetting the mixture 
up and down 3 times and transferred onto the cRNA filter cartridge. The filter 
cartridge was centrifuged for 1min at 10,000 x g and the flow-through was 
discarded. The cRNA filter cartridge was then washed with 650μl of wash 
buffer and transferred to a new tube to prevent carry-over of the wash buffer. 
The cRNA was eluted with 200μl of nuclease-free water pre-warmed to 55℃. 
The cRNA concentration was determined by ND-1000 Spectrophotometer 
(NanodropTM, Thenmo Fisher Scientific, USA.) at 260nm and the integrity 




The labelled cRNA was quantitated and 750ng of it (section 2.2.26.1) was 
used for hybridization to an array according to the Illumina Sentrix human ref-
8 beadchip protocol. A maximum of 5μl of cRNA was mixed with a 10μl 
GEX-HYB hybridization solution (Illumina Inc, San Diego, USA). The 
preheated 15μl assay sample was dispensed onto the large sample port of each 
array and incubated at 58℃ for 18hr. Microarrays were then washed twice in 
E1BC buffer (Illumina Inc, San Diego, USA) at room temperature for 5min. 
After blocking for 5min in 4ml of 1% (w/v) Blocker Casein in phosphate 
buffered saline Hummarsten grade (Pierce Biotechnology Inc, Rockford, IL), 
array signals were obtained after a 10min incubation in 2ml of 1ug/ml Cy3-
streptavidin (Amersham Biosciences, Buckinghamshire, UK) solution and 1% 
blocking solution. After a final wash in E1BC buffer, the arrays were dried 
and scanned.  
 
2.2.26.3 Scanning of mRNA array chips and data analysis 
Scanning of the mRNA array chips was performed using the BeadArray 
Reader and the signal intensities were qualified using the BeadStudio software. 
Background subtraction and normalization were performed on the raw signal 
intensity data using the internal controls inherent in the chip. Statistical 
comparisons between controls and test samples are performed using ANOVA.  
p-value < 0.05 was considered to be statistically significant. Hierarchical 





2.2.27 Statistic analysis 
For miRNA and mRNA microarray analysis see sections 2.2.25.6 and 2.2.26.3 
respectively. Statistical evaluations were performed using two-tailed t-tests or 
in case of multiple comparisons using One-way ANOVA with significance 
level p value < 0.05. Pearson correlation was used to test the relationship 






















3     microRNA PROFILING IN EMBOLIC MIDDLE CEREBRAL     
       ARTERY OCCLUSION  
 
3.1   Introduction 
MiRNAs are short, single-stranded RNAs that could bind to complementary 
sequences in mRNAs and therefore inhibit mRNA or protein expression. 
Individual miRNA may target numerous mRNAs which encode multiple 
components of the complex intracellular networks. Hence dysregulated 
expression of miRNAs could eventually disrupt the proper functioning of the 
biological system. Expression of many miRNAs was found to be dynamically 
regulated during brain development in neurogenesis and neuronal maturation 
[201, 202]. Genetic deletion of Dicer disrupting miRNA biogenesis is a widely 
used strategy to investigate the role of miRNAs in neurodevelopmental 
processes. In mice, deletion of Dicer results in deficits in brain development, 
failure to develop appropriate neuronal phenotype, neuronal atrophy, severe 
growth defects and early death [203, 204].  
Specific miRNAs have been implicated in neuronal differentiation and 
maintenance of neuronal phenotype. For instance, the brain-enriched miRNA, 
miR-124 promoted neuronal gene expression in differentiating neural 
progenitor cells [205].  miR-132 was shown to be rapidly upregulated in the 
primary visual cortex of neonatal rodents after eye opening and was delayed 
by dark rearing [206]. Inhibition of miR-132 in mice prevented ocular 
dominance plasticity and affected the maturation of dendritic spines, 
demonstrating its critical role in the regulation of visual cortex circuits [206]. 
miRNAs can also regulate neuroplasticity as well as help to maintain the 
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neuronal activity related to learning and memory [207]. These findings show 
that miRNAs regulate the development and maintenance of healthy neurons 
and therefore miRNA dysfunction may contribute to neurodevelopmental 
abnormalities and neurological disorders.  
miRNAs have been found to play important role in the major neurological 
diseases, such as ischemic stroke. In 2008, Jeyaseelan et al [188] first reported 
the miRNA profiling of rats subjected to transient focal cerebral ischemia 
through MCAo. The study demonstrated the dysregulation of miRNAs in the 
acute phase of ischemic stroke at 24 and 48hr in both brain and blood. 
Interestingly, 10 miRNAs (rno-miR-290, -451, -494, -320, let-7a, let-7i, -185, 
-150, -107, -103) have been found to be presented in both the blood and brain 
at 24 and 48hr reperfusion times, which indicated the potential of using blood 
miRNAs as biomarker to reflect brain ischemia condition upon stroke.  In 
addition, this study also showed that miRNAs were actively regulated and that 
their expression pattern changes with reperfusion time, thereby indicating 
temporal expression during ischemic injury. This temporally dysregulated 
miRNA expression was also demonstrated by another study [208], which 
evaluated 238 miRNAs and found 8 of them (miR-140, -145, -214, -290, -324-
3p, -324-5p, -331 and -344-3p) showed increased expression while 12 
miRNAs (miR-153, 26b, -29b, -29c, -204, -30e, -338, -341, -376b-5p, -377, -
664 and -98,) displayed a downregulation for at least four out of the five 
reperfusion time points (between 3hr and 3days). Lim et al [209] compared 
the miRNA profiling before and after MK801 (a non-competitive antagonist of 
NMDA receptor) treatment in rats subjected to MCAo and found that the 
expression of some miRNAs returned to almost normal after MK801 treatment. 
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This indicates that miRNAs are crucial in ischemic stroke progression and 
hence can be used as potential targets of stroke therapy [209]. So far, several 
miRNAs have been used to treat ischemic stroke in animal studies and 
demonstrated beneficial effect upon cerebral ischemia. For example, by 
infusion of antagomir of miR-145 in lateral ventricle of brain, Dharap et al 
[208] observed reduced damage of infarct with increased superoxide 
dismutase-2 (SOD2) expression, a validated target of miR-145. By 
intraventricular injection of anti miR-320, brain infarct volume was 
significantly reduced in MCAo model with the activation of the direct miR-
320-target genes Aqp4 and Aqp1 [192]. Besides these animal studies, miRNA 
profiling in patients with cerebral ischemia has shown temporal expression 
that coincided with stroke progression. Interestingly, miRNA expression 
patterns found in stroke patients' blood could distinguish the subtypes of 
stroke as well as indicate the prognosis of patients [190].  
miRNAs could provide us with a promising approach for cerebral ischemia 
diagnosis and treatment. However, miRNA expression studies on cerebral 
ischemia in both human and animal models have focused mainly on the acute 
phase of ischemic stroke so far. Clinically, it is known that recovery, 
characterized as neurogenesis, angiogenesis and synaptogenesis, is crucial for 
stroke patients. The recovery mechanism in cerebral ischemia is still largely 
unknown. miRNAs as crucial regulators of mRNA expression are thought to 
play similar but important roles in recovery phase as in acute phase of 
ischemic stroke. To test this hypothesis, a detailed study on miRNA 
expression in embolic stroke models during both acute (0, 3, 6, 12 and 24hr) 
and recovery phases (48, 72, 120 and 168hr) has been initiated.   
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3.2 Laser Doppler flowmetry and neurological assessment 
Rats (n=6) were subjected to embolic middle cerebral artery occlusion 
(eMCAo) and sacrificed at 0, 3, 6, 12, 24, 48, 72, 120 and 168hr post 
occlusion. The cerebral blood flow was measured using laser-doppler 
flowmetry (section 2.2.1.1.5). Left MCA occluded rats that exhibited 
approximately 80% drop in cerebral blood flow for at least 1hr were included 
in this study (Figure 3.1). 
The neurological status of the rats post occlusion was evaluated according to 
section 2.2.1.1.6. The rats were evaluated at 3, 6, 12, 24, 48, 72, 120 and 168hr 
after surgery and scored between 0 and 4, relative to the performance of the 
control rats. The animals scored under 3 between 3 - 168hr were excluded 
from the MCAo group.  
 
3.3 Infarct volumes 
The histological analysis of brain infarct volumes was carried out according to 
the method described in section 2.2.1.1.7. In brief, after 0, 3, 6, 12, 24, 48, 72, 
120 and 168hr post occlusion, the rats were euthanized, the whole brain was 
harvested and sectioned into 2mm slices and incubated in 2,3,5-
triphenyltetrazolium chloride (TTC) stain for one hour. In the ipsilateral 
hemisphere (infarct area), the penumbral and core regions remained unstained 











Figure 3.1 Cerebral blood flow measured by Laser-Doppler Flowmetry upon 
middle cerebral artery occlusion. Cerebral blood flow (in blood perfusion unit BPU) 
was measured in the area of the left middle cerebral artery at pre occlusion, upon 




















Figure 3.2 Brain slices and infarct volumes of eMCAo model. (A) Brain slices 
stained with TTC for 0 - 168hr eMCAo (n = 6 for each time point). Red indicates 
viable cells while white indicates nonviable cells. (B) Histogram shows the 
percentage of infarct volumes at 0, 3, 6, 12, 24, 48, 72, 120 and 168hr after MCAo. 
Brain slices were stained with TTC prior to the measurement of the infarct size. 
Infarct volume at 24hr post occlusion is significantly the maximum (350 ± 30 mm
3
 ) 
than that of other time points (p < 0.05),  thus the infarct volume at 24hr is set as 








volume became visible and measurable only from 6hr. Since several studies 
have reported that the infarct volume in rat models peaked at 24hr, we 
considered the 24hr time point as the maximum (100±9.52%) and calculated 
the respective time points based on this. Infarct volume in rats subjected to 
MCAo showed that the area of injury gradually increased from 6hr (20.58 ± 
6.86%) to 24hr (100 ± 9.52%) and then declined progressively from 48hr until 
168hr (43.99 ± 4.4%) post-occlusion (Figure 3.2B). 
 
3.4 miRNA profiling in acute (0 - 24hr) and recovery (48 - 168hr) phases 
of eMCAo       
Ischemic brain slices were collected and total RNA was extracted from these 
brain slices (section 2.2.3.1). The concentration and integrity of RNA were 
determined using RNA gel electrophoresis (section 2.2.4.1). The integrity of 
small RNA species (miRNAs) was verified using denaturing gel (15% 
polyacrylamide) electrophoresis (section 2.2.4.2). Total RNA from brain slices 
of respective rats were subjected to miRNA microarray as described (section 
2.2.25). The analysis of miRNA array was carried out and the clustering was 
generated using TIGR MeV (Multiple Experimental Viewer) software and 
statistical analysis was performed using Partek
®
 Genomics Suite 6.6 (Partek 
Inc, USA). 
A total of 346 miRNAs were detected in our profiling analysis from the total 
RNA extracted from the ipsilateral brain of eMCAo rats and showed 
differential expression in the brain during cerebral ischemia. 12 microRNAs,  
rno-miR-7b, -138, -143, -181a*, -301a, -328, -330, -336, -376a, 376b-3p, -412, 
-539 were not found to have significant changes in expression (One-way 
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ANOVA p value < 0.05) at all time points under study and were therefore 
discarded from subsequent analysis. The expression pattern of the remaining 
334 miRNAs was depicted in the heat map (Figure 3.3) (Supplementary Table 
1, p132). While a large number of miRNAs was downregulated during the 
initial stages (0-12hr) of MCA occlusion, from 24hr post-occlusion onward 
most of the miRNAs demonstrated a reverse trend (upregulation) and 
continued to increase in expression until 168hr (Figure 3.3). We identified 
three groups of miRNAs which demonstrated different expression patterns 
across the time points. The first group of miRNAs included rno-miR-1*, -10a-
5p, -10b, -18a, -20b-3p, -26b*, -96, -133a/b, -196a/b/c, -224, -296*, -297,  -
301b, -324-3p, -343, -380, -421, -448, -449, -484, -501, -532-3p, -543 and -
671 which displayed decreasing expression from 0 to 168hr. The second group 
of miRNAs which comprised of rno-miR-15b, -17, -19a/b, -20a, -21, -25, -
27a/b, -142-3p, -142-5p, -146a, -181d, -196a*, -199a-3p, -223, -298, -338, -
339-5p, -363*, -374, -382*, -423-3p, -425, -743a/b and -760-5p displayed 
increasing expression through all time points (Table 3.1). Finally, the third 
group of miRNAs which included rno-miR-21*, -30c-1*, -206, -290, -291a-5p, 
-300-5p, -503, -542-5p, -874 and -877 displayed an upregulation from 0 to 
24hr and then gradually decreased from 48 to 168hr (Table 3.1). Moreover, 
the third group of miRNAs also exhibited an expression profile that reflected 
the progression of infarct volume. In order to look for miRNAs with 
significant changes while progressing from acute to recovery phase, we 
compared their expression in acute phase (0 to 24hr) versus recovery phase 
(48 to 168hr). At the same time, we also did Pearson correlation test by 






Figure 3.3 Heat maps of the miRNAs expression profiles at different times 
following MCAo. The signal log ratio values (vs normal rats) were used to construct 
the hierarchical clustering using the Euclidean distance and average linkage method, 
carried out on both the samples column and the miRNAs rows. Only significantly 
different (ANOVA single factor, p value < 0.05) miRNAs were included for analysis. 
Green: downregulation; Red: upregulation. (A) The expression of 334 statistically 
significant miRNAs is represented in the heat map. (B) Cluster of miRNAs that 
showed a decrease in expression during the progression of cerebral ischemia (rno-
miR-196a, -196b, -196c, -224, -324-3p); (C) Cluster of miRNAs that showed an 
increase in expression during the progression of cerebral ischemia (rno-miR-21, -142-
3p/5p, -146a); (D) Cluster of miRNAs that showed an expression which positively 
correlated with infarct volume during the progression of cerebral ischemia (rno-miR-
206, -290, -291a-5p and -30c-1*). 
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Table 3.1 MicroRNA profiling data for the selected three groups of miRNAs. Signal log ratios of miRNAs which were significantly altered across all 
time points with statistical significance (1-way ANOVA p value < 0.05 ) were listed. These three groups of miRNAs showed distinct expression pattern that 
correlated with either acute phase (green), recovery phase (red) or infarct volume (bold and italics).  
 
miRNAs SLR values p value 
0hr 3hr 6hr 12hr 24hr 48hr 72hr 120hr 168hr 
rno-miR-1* 0.63 -1.45 -1.08 -2.80 -1.61 -4.52 -4.72 -4.09 -4.25 1.89E-07 
rno-miR-10a-5p 1.10 1.73 1.35 0.62 -1.30 -5.37 0.43 -4.94 -5.09 0.001211 
rno-miR-10b -0.03 1.78 -0.69 -1.91 -0.51 -3.54 -3.73 -3.10 -3.26 2.09E-07 
rno-miR-133a -0.60 -1.27 -0.52 -0.95 -4.14 -1.54 -1.65 -6.78 -2.50 7.86E-06 
rno-miR-133b -0.04 0.50 1.50 -0.03 -1.86 -1.14 -6.43 -5.80 -5.96 8.9E-08 
rno-miR-141 -2.22 0.56 -0.42 -3.25 -1.53 -5.61 -5.80 -0.15 -5.33 5.45E-16 
rno-miR-196a 0.10 -0.18 -0.32 -4.04 -3.63 -7.00 -7.19 -6.56 -6.72 5.48E-09 
rno-miR-196b -0.92 -0.46 -1.11 -3.69 -3.12 -6.67 -6.86 -6.23 -6.39 0.016733 
rno-miR-196c -0.64 -0.34 -0.41 -3.62 -3.99 -6.49 -6.68 -6.06 -6.22 8.53E-08 
rno-miR-18a -3.15 1.01 -0.76 -4.15 -3.48 -4.45 -4.64 -4.02 -4.17 3.81E-05 
rno-miR-20b-3p -2.32 -0.45 0.96 -3.06 -1.90 -6.05 -6.24 -5.61 -5.77 1.42E-09 
rno-miR-211 -0.09 -0.41 0.70 0.20 -3.19 -1.85 -1.60 -6.37 -6.53 1.41E-06 
rno-miR-224 -0.93 -0.06 -0.51 -3.60 -3.16 -5.50 -5.69 -5.06 -5.22 0.000809 
rno-miR-26b* 0.16 -0.74 -0.57 -4.01 -2.12 -7.11 -7.30 -6.68 -6.83 0.00031 
rno-miR-296* -1.54 -0.89 -0.55 -1.86 -3.80 -2.40 -4.75 -7.92 -8.07 0.005702 
rno-miR-297 0.10 -0.35 0.60 -0.08 -2.51 -4.20 -2.22 -2.14 -2.15 0.000444 
rno-miR-301b -0.47 1.47 0.56 -1.71 -1.25 -4.38 -4.57 -3.95 -4.11 0.000112 
rno-miR-324-3p -0.60 -0.79 -0.80 -2.54 -4.29 -5.81 -3.63 -7.83 -7.99 9.74E-07 
rno-miR-343 -0.20 -0.64 -0.40 -3.99 -3.27 -7.09 -7.28 -6.66 -6.81 0.022446 
rno-miR-380 -0.23 1.73 0.77 -1.85 -0.84 -4.76 -4.95 -4.32 -4.48 2.88E-06 
rno-miR-421 -1.70 0.54 0.61 -2.36 -2.13 -5.29 -5.48 -4.85 -5.01 2.78E-05 






miRNAs SLR values p value 
0hr 3hr 6hr 12hr 24hr 48hr 72hr 120hr 168hr 
rno-miR-449a -0.02 -0.54 0.48 -1.43 -4.22 -2.35 -2.70 -3.24 -7.48 0.00201 
rno-miR-484 -3.04 -2.98 -4.41 -4.71 -5.12 -8.89 -9.08 -8.46 -8.61 5.5E-14 
rno-miR-501 0.02 -0.69 -0.01 -2.35 -3.70 -7.50 -7.69 -7.07 -7.23 9.41E-08 
rno-miR-532-3p -1.58 -0.80 -0.38 -1.08 -2.15 -5.96 -6.15 -5.53 -5.69 0.000291 
rno-miR-543 -1.14 -1.82 -1.41 -5.09 -4.70 -8.41 -8.60 -7.98 -8.14 3.05E-07 
rno-miR-671 -0.70 -0.06 -0.49 -3.65 -2.86 -6.96 -7.15 -6.52 -6.68 5.43E-08 
rno-miR-96 2.83 -0.19 -0.43 -3.05 -2.68 4.22 -6.29 -5.66 -5.82 0.000114 
rno-miR-142-3p -0.77 -0.84 -1.21 -0.14 0.94 3.36 2.71 4.65 4.01 2.46E-13 
rno-miR-142-5p 0.22 -0.05 -0.25 0.15 1.01 2.37 1.82 3.41 2.56 6.89E-06 
rno-miR-146a -0.33 -1.04 -1.11 0.09 0.00 1.71 1.93 3.52 3.15 5.47E-12 
rno-miR-15b -0.35 -0.57 -0.87 -0.35 -0.14 1.14 1.39 2.02 1.54 3.8E-08 
rno-miR-17 -0.49 -0.68 -0.68 -0.16 0.41 1.12 1.28 1.83 1.66 0.00136 
rno-miR-181d -1.27 -0.23 -0.90 -0.10 0.47 0.39 0.82 0.80 0.99 0.003132 
rno-miR-196a* -0.17 -0.23 0.17 0.40 -0.23 0.35 0.77 1.04 1.14 1.14E-06 
rno-miR-199a-3p 0.80 0.34 0.24 0.74 -1.00 2.17 2.76 4.12 3.53 4.91E-13 
rno-miR-19a -0.55 0.10 -0.42 -0.14 0.39 1.23 1.35 2.37 1.82 2.29E-08 
rno-miR-19b -0.69 -0.16 -0.59 -0.16 0.23 1.23 1.33 2.34 1.98 2.45E-09 
rno-miR-20a -0.54 -0.54 -1.05 -0.19 0.22 1.13 1.21 1.85 1.72 4.7E-06 
rno-miR-21 -0.55 -0.54 -1.04 -0.18 1.13 2.62 2.48 3.07 2.65 9.1E-18 
rno-miR-223 -0.13 -0.32 -0.26 0.36 1.87 4.85 4.14 4.01 1.73 7.3E-15 
rno-miR-25 -0.84 -0.13 -0.83 -0.36 -0.22 0.52 1.04 1.56 1.34 1.98E-06 
rno-miR-27a -0.51 0.20 -0.59 -0.17 0.62 0.91 1.23 2.01 1.41 5E-06 
rno-miR-27b -0.81 0.55 -0.02 0.11 -1.56 0.46 1.14 1.47 1.43 8.63E-06 
rno-miR-298 0.37 -0.37 0.30 0.33 0.18 0.51 1.04 1.71 1.20 1.61E-11 
rno-miR-338 -1.99 -1.28 -1.88 -0.61 -0.39 0.94 0.92 1.49 1.39 3.47E-06 






miRNAs SLR values p value 
0hr 3hr 6hr 12hr 24hr 48hr 72hr 120hr 168hr 
rno-miR-363* -0.93 0.51 0.25 0.01 -0.61 0.13 1.25 1.87 1.46 7.63E-05 
rno-miR-374 -0.93 -0.34 -0.85 -0.38 0.05 0.48 0.68 1.54 1.45 0.000711 
rno-miR-382* -0.17 -0.57 -0.35 0.51 1.42 1.15 1.08 1.37 1.52 0.011576 
rno-miR-423 -0.53 -0.76 -0.37 0.48 1.41 1.23 1.26 1.68 1.41 4.15E-05 
rno-miR-425 -0.30 -0.39 -0.53 0.05 0.70 1.07 1.20 1.90 1.72 0.000242 
rno-miR-743a 0.99 0.85 -0.14 0.74 2.00 2.64 3.69 3.82 2.90 0.00036 
rno-miR-760-5p 0.99 -1.24 -1.09 1.01 1.42 2.16 2.11 2.09 2.13 1.1E-07 
rno-miR-206 -0.59 0.36 0.77 1.49 2.67 2.15 1.67 1.67 1.32 3.08E-11 
rno-miR-21* -0.83 0.44 2.03 1.72 3.53 1.90 0.85 1.46 1.62 3.93E-06 
rno-miR-290 -0.53 -0.81 -0.11 0.48 2.00 1.87 1.33 1.39 1.05 0.001202 
rno-miR-291a-5p -1.16 -0.79 0.45 1.48 2.83 2.19 0.96 1.15 0.82 0.000846 
rno-miR-300-5p -0.64 -0.29 1.02 0.95 2.25 0.92 0.47 0.57 0.59 0.049824 
rno-miR-30c-1* -0.34 -0.85 -0.29 0.70 2.00 1.62 1.74 0.68 -0.07 1.78E-09 
rno-miR-503 -0.41 -0.48 0.56 0.67 2.28 1.01 0.50 0.73 0.54 0.000286 
rno-miR-542-5p 0.09 0.29 0.24 1.32 2.86 2.53 2.54 2.07 1.52 0.008303 
rno-miR-874 -0.52 0.25 0.15 1.00 2.49 2.03 2.01 2.57 2.04 0.000225 











expression values against each time point. From the first group of miRNAs, 
we found that rno-miR-196a/b/c, -224 and -324-3p demonstrated significant 
downregulation in recovery phase (p value < 0.05 Figure 3.3B) and the 
Pearson correlation R values were 0.92, 0.93, 0.92, 0.90 and 0.90 respectively.  
The downregulation of these miRNAs was closely related to post occlusion 
time which suggested their potential to be used as a biomarker for stroke 
progression. Within the second miRNA group, rno-miR-21, -142-3p, -142-5p 
and -146a showed a significant upregulation (p value < 0.05 Figure 3.3C) in 
recovery phase compared to acute phase and the corresponding Pearson 
correlation R values were 0.83, 0.89, 0.86 and 0.92 respectively. The 
upregulation of these miRNAs also closely correlated to time which may be 
used to indicate recovery upon ischemic stroke. Interestingly, the third group 
of miRNAs was found to display a similar expression pattern when compared 
to the changes in infarct volume. Expression of rno-miR-30c-1*, -206, -290 
and -291a-5p highly correlated with the infarct volume with Pearson 
correlation R values of 0.96, 0.95, 0.97 and 0.95 respectively (Figure 3.3D). 
These miRNAs could serve as the potential biomarkers to reflect infarct sizes 
and hence may indicate the severity of ischemic stroke. 
 
3.5 mRNA profiling upon recovery (12 - 168hr) phases of eMCAo 
An independent DNA microarray study was carried out on eMCAo rat brain 
samples that were subjected to 12, 24, 48, 72, 120, 168hr of reperfusion using 
Affymetrix® mRNA microarray platform (section 2.2.26). The RNA used for 
mRNA array was the same with that for miRNA array. The analysis of mRNA 
array was carried out and the clustering was generated using TIGR MeV 
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(Multiple Experimental Viewer) software and statistical analysis was 
performed using Partek
®
 Genomics Suite 6.6 (Partek Inc, USA). 
A total of 22522 genes was detected in our profiling analysis and these genes 
demonstrated differential expression from 12 to 168hr upon cerebral ischemia. 
The heat map of these mRNAs was shown in Figure 3.4A. The 12hr samples 
were clustered together with 24 and 48hr which formed the acute phase of 
cerebral ischemia compared to the recovery phase cluster which was 
composed of 72, 120 and 168hr. Principle component analysis (PCA) is a 
statistical procedure that uses an orthogonal transformation to convert a set of 
observations of possibly correlated variables into a set of values of linearly 
uncorrelated variables called principal components. PCA (Figure 3.4B) 
displays the progression of ischemia stroke from 12 to 168hr temporally, 
which is similar to that presented in heat map. The mRNA profiling results 
demonstrated a similar pattern with miRNA profiling data. Hence, both 
mRNA and miRNA expression profiles can differentiate acute and recovery 
phase of ischemic stroke. 
 
In order to find out whether these mRNAs and miRNAs shared related 
functions, pathway analysis was carried out for miRNAs and mRNAs in 
recovery phase (from 48 to 168hr). mRNAs that showed significant changes (p 
value < 0.05, SLR > 1 or < -1) between recovery phase (from 48 to 168hr) 
were selected for pathway analysis. The top ten pathways of mRNAs were 
GABAergic synapse, ribosome, morphine addiction, neuroactive ligand-
receptor interaction, regulation of actin cytoskeleton, proteasome, 







Figure 3.4 Heat map and principal component analysis of the mRNAs that were 
dysregulated at different times following MCAo. (A) Heat map of mRNA array. 
The signal log ratio values (vs normal rats) were used to construct the hierarchical 
clustering using the Euclidean distance and average linkage method, carried out on 
both the samples column and the mRNAs rows. Green: downregulation; Red: 




signaling pathway (Table 3.2). Similarly, the top ten pathways of miRNAs 
were shortlisted. They included regulation of actin cytoskeleton, metabolic 
pathways, hedgehog signaling pathway, ribosome, GABAergic synapse, 
arrhythmogenic right ventricular cardiomyopathy (ARVC), proteasome, 
dopaminergic synapse, morphine addiction and inositol phosphate metabolism 
(Table 3.2). Comparing both sets of data, eight common pathways, namely 
GABAergic synapse, ribosome, morphine addiction, regulation of actin 
cytoskeleton, proteasome, dopaminergic synapse, metabolic pathways and 
hedgehog signaling pathway can be identified (Table 3.2). These findings 
suggest a high correlation between both our miRNA and mRNA array data.  
 
3.6 Pathways involved in the progression of cerebral ischemia 
 
3.6.1 Pathway analysis for all the individual time points displaying stroke 
progression 
Significantly expressed miRNAs (p value < 0.05, SLR > 1 or < -1) were 
selected for each time point and used for pathway analysis. These selected 
miRNAs were emphasized in bold in Supplementary Table 1. The progression 
of the pathological processes in ischemic stroke was drawn by using closely 
related pathways and the number of dysregulated genes which were 
represented by enrichment scores (Figure 3.5). The detailed pathway 
enrichment scores are listed in Table 3.3. Citrate cycle (TCA cycle) pathway 
was selected to represent energy failure and hypermetabolism, calcium 
signaling to indicate excitotoxicity, peroxisome pathway in relation to 






Table 3.2 Top ten pathways of mRNAs and miRNAs in recovery phase (48 to 168 
hr) of cerebral ischemia. Significantly expressed mRNAs and miRNAs (p value < 
0.05, SLR > 1 or < -1) were selected for pathway analysis. Pathways in bold were the 
common pathways between mRNAs and miRNAs.   
  
Pathway Name 





GABAergic synapse 13.4898 1.39E-06 
Ribosome 13.0858 2.07E-06 




Regulation of actin cytoskeleton 11.5315 9.82E-06 
Proteasome 11.5046 1.01E-05 
Dopaminergic synapse 10.5574 2.60E-05 
DNA replication 8.5078 0.000202 
Metabolic pathways 8.46366 0.000211 
Hedgehog signaling pathway 8.09298 0.000306 
Pathway name  





Regulation of actin cytoskeleton 13.1026 2.04E-06 
Metabolic pathways 11.7729 7.71E-06 
Hedgehog signaling pathway 9.7883 5.61E-05 
Ribosome 9.29429 9.19E-05 
GABAergic synapse 8.5552 0.000193 
Arrhythmogenic right ventricular 
cardiomyopathy (ARVC) 
7.71879 0.000444 
Proteasome 7.66095 0.000471 
Dopaminergic synapse 7.62288 0.000489 
Morphine addiction 7.51023 0.000547 





Figure 3.5 Graph representing the main pathological mechanisms occurring during cerebral ischemia. Infarct area (represented by white circle) 
becomes visible from about 6hr, reaches maximum at 24hr and decreases during recovery. The penumbra region which represents the ongoing ischemic 









Table 3.3 Enrichment score of pathways selected to represent the progression of pathological processes in ischemic stroke. Significantly expressed 
miRNAs (p value < 0.05, SLR > 1 or < -1) for each time point were selected for pathway analysis. Pathways closely related to the major pathological 
processes were selected. Enrichment score was performed by chi-square to indicate the lead genes of a biological category.     
  
Pathway Enrichment Score 
0hr 3hr 6hr 12hr 24hr 48hr 72hr 120hr 168hr 
Energy Metabolism 4.43 4.39 5.88 4.64 4.94 4.04 5.11 5.07 4.78 
Citrate cycle (TCA cycle) 4.75 4.10 5.99 4.23 4.92 5.25 5.12 5.70 5.70 
Peroxisome pathway 5.85 5.02 3.97 5.69 4.92 4.49 5.28 4.78 4.80 
Calcium signaling pathway 4.66 3.52 3.68 5.26 6.53 5.97 4.48 5.58 4.99 
Complement and coagulation cascades 1.77 2.50 2.73 2.04 1.64 1.43 1.58 1.57 1.57 










inflammation and the coagulation cascade to reflect processes that occur 
during haemostatic activation. It is therefore evident that miRNAs pathway 
analysis could present pathological process of cerebral ischemia. A sharp 
increase in the dysregulation of TCA cycle at 6hr after the onset of ischemia 
was observed, which suggested major energy failure. This corresponded to the 
time point when the infarct volume became visible and measurable. Extensive 
changes in oxidative stress and excitotoxicity followed subsequently and this 
was probably triggered by the energy failure. Profile of the calcium signaling 
pathway suggested excitotoxicity that peaked at 24hr and it correlated with the 
maximum infarct volume. Unfortunately, we could not test the pathway 
significance between different time point since the enrichment analysis by 
computational method only provide one enrichment score for each time point.      
 
3.6.2 Pathway analysis for the acute and recovery phases 
Having identified the crucial time points and the corresponding processes 
occurring during the progression of stroke, the differences between the acute 
and recovery phases was examined. By using the significantly expressed 
miRNAs (p value < 0.05, SLR > 1 or < -1), 252 pathways were generated for 
acute and recovery phases. Based on the dysregulated miRNAs, the top ten 
pathways that could be affected in the acute phase (0 to 24hr) were shortlisted. 
They were the regulation of actin cytoskeleton, phosphatidylinositol signaling 
system, metabolic pathways, hedgehog signaling pathway, inositol phosphate 
metabolism, arrhythmogenic right ventricular cardiomyopathy (ARVC), 
HTLV-I infection, GABAergic synapse, DNA replication and purine 





   B 
 
Figure 3.6 Pathway analysis of miRNAs that were dysregulated in early and late 
time points after eMCAo. Top ten pathways with minimum enrichment score of 5.5 
were selected. (A) Top ten pathways for miRNAs in earlier time points of eMCAo 
model; (B) Top ten pathways for miRNAs in later time points of eMCAo. ARVC- 
Arrhythmogenic right ventricular cardiomyopathy. 
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recovery phase (48 to 168hr) comprised of regulation of actin cytoskeleton, 
metabolic pathways, hedgehog signaling pathway, ribosome, GABAergic 
synapse, arrhythmogenic right ventricular cardiomyopathy (ARVC), 
proteasome, dopaminergic synapse, morphine addiction and inositol phosphate  
metabolism (Figure 3.6B). There were three pathways that were common for 
both acute and recovery phase; regulation of actin cytoskeleton, metabolic 
pathways, hedgehog signaling pathway and they all ranked within the first 
four pathways in both phases. Among the top ten pathways, 
phosphatidylinositol signaling system, HTLV-I infection, DNA replication 
and purine metabolism were only displayed in acute phase, whereas ribosome, 
proteasome, dopaminergic synapse, and morphine addiction were only 
reflected in recovery phase. Phosphatidylinositol signaling could activate 
excitotoxicity and other processes including DNA damage and repair [210]. 
This was followed by ribosome and proteasome activity in the recovery phase 
which indicated that DNA repair mechanisms were in operation for recovery 
[210]. Furthermore, the late phase active dopaminergic synapses, GABA 
synapses and morphine addiction pathway may reflect the recovery in 
neuronal transmitter [211]. 
 
3.6.3 Pathway indicating neuronal rescue after cerebral ischemia 
Neuronal repair is crucial for brain system recovery after cerebral ischemia. It 
was reported that brain ischemia activated neuronal stem and precursor cells 
(NSC and NPC) to migrate to the injured area and contribute to angiogenesis, 
neurogenesis and synaptogenesis [212]. The major pathway correlated to NSC 
and NPC proliferation, migration and differentiation to promote neuronal 
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repair following ischemic stroke are Hedgehog, Notch, Wnt and TGF-β 
signaling pathways [213 - 218]. In this study, the genes of the above-
mentioned pathways were found to be upregulated, which indicated the 
participation of these pathways in post ischemic recovery. The pathway 
analysis also showed that these four pathways were crucial for stroke recovery. 
Hedgehog signaling pathway was ranked as the top four pathways in both 
acute phase and recovery phase while TGF-β, Wnt and Notch signaling 
pathways ranked higher in the recovery phase of ischemic stroke with 
statistically significant enrichment p values (Table 3.4). This indicated these 
four pathways may be important for stroke recovery. The possible miRNAs 
and their validated target mRNAs of these four pathways involved into 
neuronal recovery after cerebral ischemia were presented in Figure 3.7. This 
study also showed that fibrosis related miRNAs were (Figure 3.7) presented in 
TGF-β and Wnt pathway. This indicated that fibrosis may be involved in 
stroke recovery and possibly participated in neuronal repair.   
 
3.7 Real-time quantitation of miRNAs and mRNAs  
The selected mRNA-miRNA expression in the Hedgehog, Notch, Wnt and 
TGF-β signaling pathways were validated by real-time PCR according to 
section 2.2.6 (Figure 3.8). miR-206 expression peaked at 24hr and gradually 
decreased until 168hr while its target, Bdnf exhibited an opposing trend. miR-
125b-5p showed an opposite profile to Smo only at 24hr. Brain specific miR-
124 was downregulated throughout all the observed time points but its target 
Jag1 exhibited upregulation at 0hr and 24hr. miR-146a consistently increased 
from 0hr to 168hr whereas the expression of its targets Notch1, Smad4 and 
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Irak1 consistently decreased. Similarly, miR-34a expression at 0, 24 and 
168hr negatively correlated to its targets, Smad4, Jag1 and Wnt3. miR-133b 
was found to be downregulated at all time points, while Tgfb1 remained 
upregulated. miR-21 demonstrated reverse expression to Pdcd4 at 0 and 24hr  
while Fas ligand (Faslg) exhibited negative correlation at 0, 24 and 168hr. 
This validated real-time PCR results were in parallel with the results from the 




Table 3.4 Four selected pathways and their ranks in early and late time points. 
Significantly expressed miRNAs (p value < 0.05, SLR > 1 or < -1) were used for 
pathway analysis for both acute phase (0hr to 24hr) and recovery phase (48hr to 
168hr). The ranks of Hedgehog, TGF-β, Wnt and Notch signaling pathways were 
presented by percentage (total pathway number as 100%). Enrichment p value was 
used to indicate pathway significance (p value < 0.05 meaning statistically 









point rank (%) 
Enrichment 
p value 
Hedgehog 1.6% 0.0009 1.1% 5.61E-05 
TGF-β 35.0% 0.14 15.0% 0.01 
Wnt 20.0% 0.06 16.0% 0.01 





Figure 3.7 Hedgehog, Notch, Wnt and 
TGF-β signaling pathways showing 
mRNAs and the miRNAs involved. 
Fibrosis-related miRNAs are shown in 
bold italic fonts. The miRNAs selected 
from this study are underlined. All targets 
for miRNAs were selected from 
published and validated data. mTOR - 
mammalian target of rapamycin; PI3K - 
Phosphatidylinositol 3-kinases; STAT3 - 
signal transducer and activator of 
transcription 3; Pdcd4 - programmed cell 
death 4; Reck - reversion-inducing-
cysteine-rich protein with kazal motifs; 
Dll1 - delta-like 1; Jag1 -  jagged 1; 
WISP2 - WNT1-inducible signaling 
pathway protein 2; Shh - sonic hedgehog; 
Smo - Smoothened; Bdnf - brain derived 
neurotrophic factor; Hoxb8 - homeobox 
B8; NICD - Notch internal cellular 
domain; Hes3 - hairy and enhancer of 
split 3; Fzd - Frizzled; Dvl - dishevelled; 
Gsk3b - glycogen synthase kinase-3beta; 
Apc - adenomatous polyposis coli; 
Tgfbr2 - transforming growth factor beta 









A Figure 3.8 Comparison of 
miRNA expression with its 
corresponding mRNA targets. 
(A) Quantitative stem-loop RT-
PCR of selected miRNAs at 0, 24 
and 168hr ipsilateral brain 
samples of eMCAo rats. (B) Real-
time PCR of respective validated 
mRNA targets at 0, 24 and 168 hr 
ipsilateral brain samples of 
eMCAo rats. Data presented as 
mean ± SD (n =3). Relative 
expression (
ΔΔ
Ct ) was calculated 
based on eMCAo controls as 
calibrator and 18s as endogenous 
control. Statistically significant 
differences are tested at p < 0.05 




Smad4 and Irak1; miR-
34a/Smad4, Jag1 and Wnt3; miR-









3.8 miR-206 as a predictive marker of infarct volume 
Based on previous microarray study, miRNA expression profiles were 
obtained in both acute and recovery phases of cerebral ischemic rat model. 
The expression of several miRNAs was found to closely correlate to infarct 
volume. These miRNAs were miRNA-206, -290, -291a-5p and -30c-1* with 
Pearson correlation coefficient R values of 0.96, 0.95, 0.97 and 0.95 
respectively. Among them, miR-206 has been found to be highly expressed at 
24 and 48hr brain samples in intraluminal suture MCAo model [188, 208, 209]. 
Administration of MK-801, a glutamate receptor antagonist, and 
phospholipase A2 (PLA2) were found to decrease miR-206 expression as well 
as infarct volume in rats subjected to MCAo [209, 219]. Infarct caused by 
cerebral artery occlusion contributes to the major neurological deficiency and 
to a certain extent correlates to the severity of cerebral ischemia. Henceforth, 
further study on miR-206 may provide a clue on its implication in cerebral 
ischemia, thereby revealing its potential use in reducing infarct damage.    
In order to validate that the expression of miR-206 followed infarct volume, 
the experiment was repeated using an independent cohort of eMCAo model 
for the same time points from 0 to 168hr. By applying the same inclusion 
criteria as described previously, rats with successful eMCAo were included in 
this study. Similarly, the infarct volume was quantitated according to section 
2.2.1.1.7.  
eMCAo brain samples at different time points with varying infarct sizes were 
randomly selected (averaging from 50 mm
3
 to 380 mm
3 
n=3 for each infarct 
size). The RNA was extracted from brain samples and the concentration and 
integrity of RNA were determined using RNA gel electrophoresis (section 
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2.2.4.1). The integrity of small RNA species (miRNAs) was verified using 
denaturing gel (15% polyacrylamide) electrophoresis (section 2.2.4.2). 
Quantitative stem-loop PCR was used to quantify miR-206 expression and 
data were presented as box plot in Figure 3.9. A positive linear relationship 
between miR-206 expression and infarct sizes was observed with a Pearson 
correlation value R = 0.88. This positive correlation suggested the possible 
implication of miR-206 in ischemic cell death. With that in mind, further miR-
206-related mechanisms for cell death were examined. 
 
3.9 Expression of miR-206 in primary neuronal culture  
miR-206 has been reported to function as a proapoptotic factor in cancer [220], 
myocardial infarction [221] as well as neurological disorder, such as AD [222] 
and abnormal development of neural cells [223]. It could also play a 
proapoptotic role in cerebral ischemia, which may explain the higher miR-206 
expression correlated to a larger infarct volume. At the same time, it was of 
interest to find out whether modulation of miR-206 expression could influence 
the percentage of ischemic cell death. To prove this hypothesis, an in vitro 
study by using primary neuronal culture subjected to OGD according to 
section 2.2.17 was performed. Cells were transfected with anti and pre miR-
206 respectively. Morphologic Assessment of Apoptosis and Cell Viability 
Using Hoechst/Ethidium Homodimer III Nuclear Staining was performed 
according to section 2.2.15.1. Realtime PCR was used to quantify the 
expression of miR-206 and its gene targets. Immunocytochemistry (section 
2.2.16) was carried out to demonstrate the neuron viability and growth. MAP2 









Figure 3.9 miR-206 correlated with increasing infarct volume in vivo.  miR-206 
expression was validated by qRT-PCR in an independent cohort of eMCAo models 












is a neuron-specific cytoskeletal protein that is enriched in dendrites during 
neuron development and hence used to stain neuritis in this study. miR-206 
expression was found to increase significantly at 4hr OGD (fold change value 
1.476 ± 0.09, p < 0.05). Therefore, the 4hr OGD time point was selected for 
the following study. Regulation of miR-206 expression was carried out 
independently by transfecting either pre or anti miR-206 to the primary 
neuronal culture during reperfusion following 4hr of OGD according to 
section 2.2.12.1. At the end of 24hr reperfusion, cells were collected for 
further analysis. miR-206 expression was found to increase significantly (p < 
0.01) when 30 nM miR-206 mimic was added to primary neuronal culture 
during the reperfusion period (Figure 3.10A). On the other hand, the miR-206 
expression decreased significantly (p < 0.01) when anti miR-206 was added 
(Figure 3.10A) during reperfusion. Meanwhile, it was observed that anti miR-
206 could increase neuron viability significantly. When pre miR-206 was 
introduced, it led to significant increase in cell apoptosis even higher than that 
of cells with 4hr OGD alone (Figure 3.10A, 3.10B). Therefore, miR-206 
seems to be a proapoptotic factor in primary neurons subjected to OGD. Gap 
junction protein, alpha 1 (Gja1), Otx2 and brain-derived neurotrophic factor 
(Bdnf) genes have been reported to be targeted by miR-206 and they were also 
found to play important roles in neuronal development and diseases [222 - 
228]. The expression of genes, Gja1 (p < 0.05), Otx2 (p < 0.01) and Bdnf (p < 
0.01) showed a significant increase in neuronal cells when they were 
transfected with anti miR-206 during reperfusion period (Figure 3.10C). This 















Figure 3.10 Effect of modulating miR-206 expression on cell viability during 
reperfusion following OGD. (A) miR-206 expression was significantly increased in 
the presence of pre miR-206 (p < 0.01) and significantly decreased when cells were 
transfected with anti miR-206 (p < 0.01) during reperfusion. Expression value was 
calculated as relative expression compared to vehicle transfected controls. Cells 
transfected with anti miR-206 demonstrated significantly increased cell viability 
compared to cells subjected to OGD and transfected with vehicle (p < 0.05), whereas 
cells transfected with pre miR-206 showed significantly reduced cell viability 
compared to cells subjected to OGD transfected with vehicle (p < 0.05). Data shown 
are the mean ± SD, n=3. (B) Neurons subjected to OGD displayed increased 
apoptosis and degenerated neurites. Cells transfected with anti miR-206 after OGD 
showed increased cell survival and maintenance of neurites as compared to cells 
subjected to OGD. Cells transfected with pre miR-206 displayed increased apoptosis 
and degeneration of neurites as compared to cells subjected to OGD only. (C) 
Expression of Gja1, Otx2 and Bdnf showed negative correlation to miR-206 
expression. Expression of Gja1 (p < 0.05), Otx2 (p < 0.01) and Bdnf (p < 0.01) 
significantly increased in neuronal cells that were transfected with anti miR-206 
during reperfusion period. Relative expression was calculated based on vehicle 
transfected controls as calibrator and 18s as endogenous control. Statistically 







3.10 Anti miR-206 reduces infarct volume in eMCAo models 
Having proven that anti miR-206 could reduce neuronal cell death in in vitro 
ischemic condition, the effect of miR-206 in embolic stroke model was 
examined. Administration of pre and anti miR-206 by ICV in rat brain was 
performed within 1hr post eMCAo according to section 2.2.24.2. A minimum 
of six rats was used for each group receiving either pre or anti miR-206 
treatment. Realtime PCR was performed to measure miR-206 expression in 
the ipsilateral brain samples of eMCAo model treated with either pre or anti 
miR-206. The infarct volume was quantitated according to section 2.2.1.1.7. 
As expected, miR-206 expression increased significantly (relative expression 
value 75.15 ± 0.02, p < 0.01) in pre miR-206 treated samples but decreased 
greatly (relative expression value 0.56 ± 0.03, p < 0.01) in anti miR-206 
treated samples. Anti miR-206 also significantly reduced the infarct volume 
by 60% compared to the vehicle group (transfection reagent alone) whereas 
pre miR-206 did not show any reduction of infarct volume (Figure 3.11A, 
3.11B). This result was in conjunction with the result from our neuronal in 
vitro study and suggested that anti miR-206 could reduce ischemic cell death 
















Figure 3.11 Analyses of brain sections of eMCAo rats injected with pre or anti 
miR-206. (A) Histological analysis of brain sections. TTC stained coronal brain 
sections (2 mm thick) of rats injected with 50 pmoles of anti or pre miR-206. ICV 
injections were given within 1hr after embolus occlusion (n = 6).Viable cells were 
stained pink whilst dead cells remained white.  (B) Infarct volume of eMCAo rats 
treated with anti or pre miR-206. Infarct volumes were expressed as a percentage of 
the vehicle ± SEM. Statistically significant differences are tested at p < 0.05 






Supplementary Table 1 Expression of 334 dysregulated miRNAs upon eMCAo. The miRNAs expression was presented as signal log ratio (SLR). 
miRNA values in bond were used for pathway analysis. 
miRNAs SLR values   
ID 0hr 3hr 6hr 12hr 24hr 48hr 72hr 120hr 168hr p value 
rno-let-7a -0.48 -0.93 -1.03 -0.43 0.08 0.24 -0.07 0.07 0.35 0.000897 
rno-let-7b -0.67 -1.05 -1.01 -0.43 0.26 0.16 0.03 0.34 0.65 1.66E-07 
rno-let-7b* -0.79 -1.27 -1.16 -0.76 -0.41 0.11 -0.34 -0.31 0.02 0.00021 
rno-let-7c -0.56 -1.04 -1.12 -0.38 0.25 0.20 -0.11 0.10 0.49 0.0005 
rno-let-7d -0.75 -0.63 -0.88 -0.34 0.16 0.15 0.17 0.43 0.63 8.16E-08 
rno-let-7d* -0.49 -0.96 -0.63 -0.05 0.23 0.31 -0.14 0.44 0.56 0.007666 
rno-let-7e -1.09 -1.36 -0.69 -0.12 0.82 0.64 0.16 0.53 0.39 0.035818 
rno-let-7e* -0.80 -0.59 -0.87 -0.66 -3.93 -0.34 -0.62 -1.36 -0.81 0.00015 
rno-let-7f -0.49 -0.85 -0.98 -0.46 -0.12 0.09 -0.14 -0.04 0.31 6.6E-08 
rno-let-7i -0.59 -0.97 -1.02 -0.59 -0.11 -0.09 -0.34 -0.15 -0.05 1.63E-05 
rno-let-7i* -0.70 1.81 -0.80 -0.74 -1.02 -2.00 -2.19 -1.56 -1.72 3.28E-05 
rno-miR-1 -0.38 0.01 -1.10 0.94 -1.59 2.11 1.38 -5.60 -1.82 0.001475 
rno-miR-1* 0.63 -1.45 -1.08 -2.80 -1.61 -4.52 -4.72 -4.09 -4.25 1.89E-07 
rno-miR-100 -0.40 -0.48 -0.79 -0.34 0.22 0.40 0.09 0.44 0.63 6.8E-05 
rno-miR-101a -1.08 -1.11 -1.44 -0.56 -0.08 0.62 0.08 0.70 0.98 0.001383 
rno-miR-101a* -0.70 3.84 -0.80 -1.70 0.44 -2.00 -2.19 -1.56 -1.72 0.002471 
rno-miR-101b -0.80 -0.84 -1.05 -0.47 0.23 0.33 0.13 0.86 0.91 2.42E-07 
rno-miR-103 -0.82 -0.82 -1.09 -0.49 -0.03 0.20 -0.24 -0.18 0.23 4.12E-06 
rno-miR-106b -0.36 -0.82 -0.86 -0.54 0.02 0.18 -0.14 0.42 0.45 8.7E-07 











miRNAs SLR values   
ID 0hr 3hr 6hr 12hr 24hr 48hr 72hr 120hr 168hr p value 
rno-miR-107 -0.67 -0.05 -0.31 -0.28 0.22 0.49 0.52 0.77 0.91 0.002409 
rno-miR-10a-3p 0.03 -0.69 0.00 0.82 1.40 1.28 0.90 0.28 0.28 3.95E-08 
rno-miR-10a-5p 1.10 1.73 1.35 0.62 -1.30 -5.37 0.43 -4.94 -5.09 0.001211 
rno-miR-10b -0.03 1.78 -0.69 -1.91 -0.51 -3.54 -3.73 -3.10 -3.26 2.09E-07 
rno-miR-122 -0.34 -0.63 -0.46 -1.09 -1.04 -1.92 -1.38 -2.12 -1.16 4.01E-07 
rno-miR-124 -0.62 -0.75 -0.72 -1.62 -1.02 -1.92 -2.11 -1.49 -1.64 0.031352 
rno-miR-124* -0.72 -0.64 -0.88 -0.31 -0.67 0.07 -0.32 -0.34 0.16 2.26E-05 
rno-miR-125a-3p -0.36 -1.02 -0.38 -0.09 0.53 0.49 0.38 -0.24 -0.10 3.39E-05 
rno-miR-125a-5p -0.71 -1.01 -0.96 -0.54 -0.01 0.07 -0.27 -0.18 0.17 3.68E-07 
rno-miR-125b* -0.48 -0.36 0.78 0.80 1.48 0.18 -0.25 0.57 0.79 6.63E-06 
rno-miR-125b-3p -0.43 -0.42 0.70 0.66 1.54 0.17 0.26 0.71 0.84 1.1E-07 
rno-miR-125b-5p -0.21 -0.35 -0.49 -0.72 0.00 -0.63 -0.82 -0.20 -0.35 0.000358 
rno-miR-126 -0.42 -0.78 -0.89 -0.35 0.07 0.46 0.03 0.02 0.03 0.000575 
rno-miR-126* -0.75 -0.60 -1.07 -0.17 0.08 0.85 0.68 0.85 0.71 2.75E-06 
rno-miR-127 -0.30 -0.95 -0.77 -0.47 0.09 0.33 -0.16 0.19 0.27 2.01E-05 
rno-miR-128 -0.96 -0.77 -0.92 -0.30 0.18 0.44 -0.11 -0.37 0.18 0.039145 
rno-miR-129 -0.57 -0.74 -0.32 -0.05 0.76 0.45 0.00 -0.06 0.17 0.000112 
rno-miR-129* -0.54 -0.41 -0.46 -0.31 0.23 0.34 0.24 0.22 0.15 3.07E-11 
rno-miR-130a -0.21 -0.82 -0.93 -0.47 0.11 0.64 0.25 0.62 0.61 6.18E-07 
rno-miR-130b -0.22 -0.37 1.03 1.16 2.14 1.11 1.07 1.46 1.33 0.001334 
rno-miR-132 -0.89 -0.55 -0.76 -0.11 0.58 0.40 -0.12 -0.46 0.03 0.02104 







miRNAs SLR values   
ID 0hr 3hr 6hr 12hr 24hr 48hr 72hr 120hr 168hr p value 
rno-miR-133b -0.04 0.50 1.50 -0.03 -1.86 -1.14 -6.43 -5.80 -5.96 8.9E-08 
rno-miR-134 0.60 0.86 0.21 0.28 -2.27 0.47 1.00 1.28 0.57 5.66E-07 
rno-miR-135a -0.35 -0.74 -1.14 -0.52 -0.20 0.06 -0.12 0.22 0.21 3.88E-06 
rno-miR-135a* 0.80 -0.13 1.42 -2.58 -1.00 -4.38 -4.57 -3.95 -4.11 1.07E-06 
rno-miR-135b -0.42 -0.62 -0.75 -0.38 -0.11 0.11 0.04 0.22 0.11 0.000129 
rno-miR-136 -2.29 -2.40 -2.63 -0.96 -0.34 1.17 0.21 1.54 1.96 5.42E-05 
rno-miR-136* -0.40 -0.52 -0.74 -0.26 -0.05 0.25 -0.37 -0.15 0.13 4.03E-06 
rno-miR-137 -0.84 -0.42 -0.84 -0.39 0.13 0.40 0.01 0.57 0.73 9.65E-07 
rno-miR-138* -0.69 -1.06 -0.84 -0.23 0.41 0.29 0.42 0.71 0.68 0.008421 
rno-miR-139-3p 0.79 0.67 1.81 1.53 -1.88 0.71 1.60 0.57 -0.54 1.39E-07 
rno-miR-139-5p -0.82 -0.77 -0.17 -0.60 0.08 -0.84 -0.47 -1.24 -0.50 5.38E-05 
rno-miR-140 -0.90 -1.14 -1.28 -0.57 0.12 0.42 0.24 0.69 0.73 0.014471 
rno-miR-140* -0.09 -0.76 -0.42 -0.45 -0.01 0.36 0.14 0.41 0.38 0.000127 
rno-miR-141 -2.22 0.56 -0.42 -3.25 -1.53 -5.61 -5.80 -0.15 -5.33 5.45E-16 
rno-miR-142-3p -0.77 -0.84 -1.21 -0.14 0.94 3.36 2.71 4.65 4.01 2.46E-13 
rno-miR-142-5p 0.22 -0.05 -0.25 0.15 1.01 2.37 1.82 3.41 2.56 6.89E-06 
rno-miR-144 0.36 2.27 -0.30 1.11 0.66 -0.20 -0.95 -1.63 -3.09 1.88E-11 
rno-miR-145 -0.38 0.15 -0.37 -0.18 0.24 0.61 0.64 0.93 0.80 1.41E-07 
rno-miR-146a -0.33 -1.04 -1.11 0.09 0.00 1.71 1.93 3.52 3.15 5.47E-12 
rno-miR-146b -0.56 -0.89 -0.89 -0.46 0.08 0.58 0.34 1.38 1.18 2.33E-09 
rno-miR-147 -2.58 1.87 3.01 4.75 1.43 4.89 4.21 4.71 3.60 3.84E-09 







miRNAs SLR values   
ID 0hr 3hr 6hr 12hr 24hr 48hr 72hr 120hr 168hr p value 
rno-miR-148b-5p -0.70 -0.83 1.29 -1.70 -1.02 -2.00 -2.19 -1.56 -1.72 0.011315 
rno-miR-150 0.16 -0.07 -0.51 -0.81 -0.45 -1.17 -1.64 -0.48 -0.76 0.002129 
rno-miR-151 -0.34 -0.63 -0.78 -0.37 -0.04 0.16 -0.07 -0.01 0.32 3.06E-07 
rno-miR-151* -0.43 -0.66 -1.13 -0.18 -3.59 0.37 0.16 0.50 0.54 0.000819 
rno-miR-152 0.79 -0.28 -0.07 0.20 -2.28 0.60 0.27 1.39 1.04 2.85E-05 
rno-miR-153 -0.18 -0.57 -0.26 -0.66 0.24 0.01 -0.50 -0.35 -0.24 1.5E-07 
rno-miR-154 -0.36 0.31 0.02 0.09 -3.18 0.14 0.97 0.04 0.62 0.000981 
rno-miR-15b -0.35 -0.57 -0.87 -0.35 -0.14 1.14 1.39 2.02 1.54 3.8E-08 
rno-miR-16 -0.60 -0.60 -0.82 -0.57 -0.16 0.47 0.13 0.63 0.84 7.64E-07 
rno-miR-17 -0.49 -0.68 -0.68 -0.16 0.41 1.12 1.28 1.83 1.66 0.00136 
rno-miR-17-3p -0.04 -0.06 0.77 1.03 -1.92 1.77 1.71 2.77 2.58 4.16E-09 
rno-miR-181a -1.05 -0.79 -1.48 -0.44 0.06 0.71 0.66 0.83 1.13 5.41E-07 
rno-miR-181b -0.78 -0.92 -1.36 -0.49 0.00 0.41 0.25 0.44 0.80 0.002547 
rno-miR-181c -0.84 -0.01 -0.12 0.12 0.71 1.07 1.14 1.16 1.23 0.000169 
rno-miR-181d -1.27 -0.23 -0.90 -0.10 0.47 0.39 0.82 0.80 0.99 0.003132 
rno-miR-182 3.63 -4.41 -1.25 -2.87 -1.72 4.70 2.42 -5.14 0.91 0.000216 
rno-miR-183 1.13 -0.28 -0.99 0.85 1.39 2.34 1.60 0.92 1.52 9.38E-12 
rno-miR-184 -0.68 -0.85 -0.43 -0.09 0.72 0.33 0.61 0.95 0.94 2.48E-09 
rno-miR-185 -0.29 -0.62 -0.65 -0.35 0.14 -0.07 -0.09 -0.06 0.15 2.75E-05 
rno-miR-186 -0.59 -0.75 -0.84 -0.48 -0.07 0.26 -0.08 0.18 0.36 0.000804 
rno-miR-187 -0.02 -1.42 -0.63 -1.75 -1.15 -1.60 0.61 -2.72 -1.70 0.002444 
rno-miR-188 -0.65 -0.83 -0.80 -2.09 -4.46 -4.03 -1.55 -1.56 -4.50 3.01E-12 
5 
 
miRNAs SLR values   
ID 0hr 3hr 6hr 12hr 24hr 48hr 72hr 120hr 168hr p value 
rno-miR-18a -3.15 1.01 -0.76 -4.15 -3.48 -4.45 -4.64 -4.02 -4.17 3.81E-05 
rno-miR-190 -0.63 -0.93 -1.20 -0.50 -0.28 0.10 -0.51 -0.13 0.23 0.000688 
rno-miR-191 -0.33 -0.90 -0.87 -0.55 0.10 0.19 -0.11 -0.07 -0.14 2.19E-05 
rno-miR-192 -1.21 -1.65 -1.17 -0.10 0.47 0.87 0.68 0.46 0.74 9.77E-06 
rno-miR-193 -0.35 -0.51 -0.57 -0.33 0.49 1.39 0.62 1.84 1.59 1.02E-07 
rno-miR-193* -1.58 1.51 4.22 -1.60 -0.59 -2.88 -3.07 -2.45 -2.61 2E-10 
rno-miR-194 -0.51 -0.69 -0.62 -0.46 -0.23 0.01 0.01 0.10 0.61 0.001361 
rno-miR-195 -0.69 -0.94 -1.16 -0.51 -0.22 0.25 -0.15 0.25 0.51 0.000925 
rno-miR-196a 0.10 -0.18 -0.32 -4.04 -3.63 -7.00 -7.19 -6.56 -6.72 5.48E-09 
rno-miR-196a* -0.17 -0.23 0.17 0.40 -0.23 0.35 0.77 1.04 1.14 1.14E-06 
rno-miR-196b -0.92 -0.46 -1.11 -3.69 -3.12 -6.67 -6.86 -6.23 -6.39 0.016733 
rno-miR-196c -0.64 -0.34 -0.41 -3.62 -3.99 -6.49 -6.68 -6.06 -6.22 8.53E-08 
rno-miR-199a-3p 0.80 0.34 0.24 0.74 -1.00 2.17 2.76 4.12 3.53 4.91E-13 
rno-miR-199a-5p 1.19 0.51 -0.91 -1.62 -1.05 -4.63 0.99 3.61 3.16 2.36E-08 
rno-miR-19a -0.55 0.10 -0.42 -0.14 0.39 1.23 1.35 2.37 1.82 2.29E-08 
rno-miR-19b -0.69 -0.16 -0.59 -0.16 0.23 1.23 1.33 2.34 1.98 2.45E-09 
rno-miR-200a -0.70 -0.83 -0.80 -1.70 -1.02 -2.00 -2.19 -1.56 -1.72 0.001185 
rno-miR-200b 0.35 0.07 1.22 0.01 -2.52 -6.60 -1.81 0.93 -1.00 0.001245 
rno-miR-200c -2.21 0.21 -0.11 2.73 0.24 1.57 2.52 2.85 -3.23 4.25E-05 
rno-miR-203 -0.29 -1.14 -2.23 -0.12 -1.01 1.11 0.98 0.91 1.23 7.73E-11 
rno-miR-204 -0.01 -0.15 -0.48 0.05 0.50 -0.69 -0.48 -0.01 0.42 1.08E-10 











miRNAs SLR values   
ID 0hr 3hr 6hr 12hr 24hr 48hr 72hr 120hr 168hr p value 
rno-miR-205 -0.07 -0.20 0.00 0.55 -2.73 0.49 0.49 -0.16 -1.36 9.16E-08 
rno-miR-206 -0.59 0.36 0.77 1.49 2.67 2.15 1.67 1.67 1.32 3.08E-11 
rno-miR-207 -0.82 -0.57 -0.85 -0.23 0.63 0.71 1.06 1.53 1.45 5.41E-06 
rno-miR-208 -0.71 -0.11 0.30 0.68 1.75 0.68 1.02 1.84 1.31 5.04E-05 
rno-miR-20a -0.54 -0.54 -1.05 -0.19 0.22 1.13 1.21 1.85 1.72 4.7E-06 
rno-miR-20a* -1.57 0.23 0.75 -1.40 -2.40 -1.72 -3.61 -5.99 -6.15 0.008187 
rno-miR-20b-3p -2.32 -0.45 0.96 -3.06 -1.90 -6.05 -6.24 -5.61 -5.77 1.42E-09 
rno-miR-20b-5p -0.54 -0.85 -0.62 -0.09 -2.54 1.10 2.70 2.98 2.95 2.51E-08 
rno-miR-21 -0.55 -0.54 -1.04 -0.18 1.13 2.62 2.48 3.07 2.65 9.1E-18 
rno-miR-21* -0.83 0.44 2.03 1.72 3.53 1.90 0.85 1.46 1.62 3.93E-06 
rno-miR-210 0.21 0.48 1.03 0.41 -1.44 0.96 1.76 2.04 1.33 0.000162 
rno-miR-211 -0.09 -0.41 0.70 0.20 -3.19 -1.85 -1.60 -6.37 -6.53 1.41E-06 
rno-miR-212 -0.43 -0.73 -0.50 -0.05 0.52 0.27 -0.13 0.04 0.22 6.34E-07 
rno-miR-214 -0.43 -1.02 -0.03 0.14 1.30 -0.10 0.32 1.18 0.98 0.001795 
rno-miR-215 1.00 1.01 4.49 2.25 0.15 1.34 0.58 2.37 2.14 6.83E-05 
rno-miR-216a 0.66 3.06 5.70 0.49 1.70 -2.10 -2.29 -1.66 -1.82 0.000941 
rno-miR-217 -0.70 -0.83 -0.80 -1.70 0.39 -2.00 -2.19 -1.56 -1.72 0.000679 
rno-miR-218 -1.02 -0.93 -1.47 -0.45 -0.16 0.31 -0.47 0.04 0.49 0.000347 
rno-miR-218* -0.04 0.20 -0.16 -0.31 -2.56 -0.29 -0.98 -0.70 -0.10 9.82E-07 
rno-miR-219-1-3p -1.11 2.17 -1.21 -2.11 -0.31 -2.41 -2.60 -1.97 -2.13 0.001795 
rno-miR-219-2-3p -0.60 -0.68 -0.97 -0.44 -0.28 0.15 0.24 0.28 0.58 2.34E-06 
rno-miR-219-5p -0. 58 0.15 -0.71 -0.64 -0.26 -0.19 -0.94 0.46 1.02 1.52E-09 
7 
 
miRNAs SLR values   
ID 0hr 3hr 6hr 12hr 24hr 48hr 72hr 120hr 168hr p value 
rno-miR-22 -0.68 -0.96 -0.69 -0.63 -0.06 -0.14 -0.39 -0.35 -0.16 1.06E-05 
rno-miR-22* -0.51 -0.62 -0.60 -0.22 0.10 0.25 0.06 0.41 0.51 0.000158 
rno-miR-221 -1.09 -0.97 -0.97 -0.47 0.07 0.35 0.06 0.11 0.38 7.87E-06 
rno-miR-222 -0.53 -0.99 -1.05 -0.55 -0.03 0.16 -0.40 -0.28 0.18 1.07E-06 
rno-miR-223 -0.13 -0.32 -0.26 0.36 1.87 4.85 4.14 4.01 1.73 7.3E-15 
rno-miR-224 -0.93 -0.06 -0.51 -3.60 -3.16 -5.50 -5.69 -5.06 -5.22 0.000809 
rno-miR-23a -0.65 -0.69 -0.91 -0.32 0.24 0.73 0.52 0.71 0.72 2.31E-06 
rno-miR-23a* -0.93 -0.52 0.37 0.50 -2.10 0.11 0.36 0.20 0.46 4.85E-07 
rno-miR-23b -0.67 -0.69 -0.82 -0.32 0.20 0.32 0.17 0.34 0.46 2.61E-08 
rno-miR-24 -0.81 -0.73 -0.72 -0.46 0.21 0.25 0.14 0.38 0.56 3.07E-06 
rno-miR-24-1* -0.62 -0.81 -0.83 -0.48 0.02 0.29 -0.03 0.68 0.75 0.000382 
rno-miR-24-2* -1.13 -0.72 -1.34 0.07 0.52 1.24 0.87 1.21 1.42 2.83E-05 
rno-miR-25 -0.84 -0.13 -0.83 -0.36 -0.22 0.52 1.04 1.56 1.34 1.98E-06 
rno-miR-25* -0.19 -0.12 -0.15 0.68 -1.70 0.83 1.15 0.45 0.67 2.64E-05 
rno-miR-26a -0.61 -1.02 -1.00 -0.45 0.10 0.04 -0.34 -0.34 0.17 9.78E-10 
rno-miR-26b -0.56 -0.87 -0.88 -0.43 -0.13 0.10 -0.21 -0.08 0.33 0.017974 
rno-miR-26b* 0.16 -0.74 -0.57 -4.01 -2.12 -7.11 -7.30 -6.68 -6.83 0.00031 
rno-miR-27a -0.51 0.20 -0.59 -0.17 0.62 0.91 1.23 2.01 1.41 5E-06 
rno-miR-27a* 0.84 0.62 1.37 -1.48 -0.11 -4.47 -1.14 -4.04 -4.20 0.006995 
rno-miR-27b -0.81 0.55 -0.02 0.11 -1.56 0.46 1.14 1.47 1.43 8.63E-06 
rno-miR-28 -0.51 -0.59 -0.81 -0.38 0.12 0.31 0.18 0.37 0.60 0.01123 







miRNAs SLR values   
ID 0hr 3hr 6hr 12hr 24hr 48hr 72hr 120hr 168hr p value 
rno-miR-290 -0.53 -0.81 -0.11 0.48 2.00 1.87 1.33 1.39 1.05 0.001202 
rno-miR-291a-3p -0.28 -1.25 -1.57 -0.59 -4.55 0.41 0.60 0.91 1.30 7.69E-07 
rno-miR-291a-5p -1.16 -0.79 0.45 1.48 2.83 2.19 0.96 1.15 0.82 0.000846 
rno-miR-292-3p 2.85 -1.08 -1.05 1.26 1.14 -2.25 -2.44 -1.81 -1.97 1.41E-09 
rno-miR-292-5p -0.41 0.96 1.80 -1.34 0.14 1.04 -0.82 -3.80 -3.95 3.88E-07 
rno-miR-296 0.55 -0.43 0.59 1.77 1.75 1.64 0.96 1.05 0.68 7.68E-06 
rno-miR-296* -1.54 -0.89 -0.55 -1.86 -3.80 -2.40 -4.75 -7.92 -8.07 0.005702 
rno-miR-297 0.10 -0.35 0.60 -0.08 -2.51 -4.20 -2.22 -2.14 -2.15 0.000444 
rno-miR-298 0.37 -0.37 0.30 0.33 0.18 0.51 1.04 1.71 1.20 1.61E-11 
rno-miR-299 0.62 0.14 1.28 1.38 1.56 1.34 0.54 0.26 0.49 0.000611 
rno-miR-29a -0.13 -0.31 -0.55 -0.68 0.27 -0.55 -0.74 -0.12 -0.27 0.000116 
rno-miR-29a* -1.17 -1.00 -1.16 -0.53 0.14 0.37 0.07 0.40 0.61 0.002007 
rno-miR-29b -0.23 0.02 -0.07 -0.68 -0.26 -0.49 -0.40 0.28 0.15 0.000679 
rno-miR-29b-1* 0.20 0.04 0.45 0.22 -0.63 -0.35 0.08 -1.58 -0.89 1.21E-08 
rno-miR-29b-2* -0.49 0.27 -0.20 0.45 -3.08 -0.19 0.53 0.24 0.60 5.32E-07 
rno-miR-29c -0.64 -0.57 -0.94 -0.34 0.15 0.66 0.57 0.89 0.98 0.000262 
rno-miR-29c* -0.33 -0.23 -0.31 -0.19 0.18 0.15 0.07 0.13 0.46 1.47E-06 
rno-miR-300-3p -0.19 -0.45 0.00 0.06 0.59 0.28 0.26 0.58 0.51 5.37E-06 
rno-miR-300-5p -0.64 -0.29 1.02 0.95 2.25 0.92 0.47 0.57 0.59 0.049824 
rno-miR-301b -0.47 1.47 0.56 -1.71 -1.25 -4.38 -4.57 -3.95 -4.11 0.000112 
rno-miR-30a -0.21 -0.57 -0.67 -0.45 0.05 -0.12 -0.35 0.19 0.16 0.006673 







miRNAs SLR values   
ID 0hr 3hr 6hr 12hr 24hr 48hr 72hr 120hr 168hr p value 
rno-miR-30b-3p -0.33 -0.83 -0.04 -0.10 0.56 -0.15 -0.29 0.44 0.67 1.2E-15 
rno-miR-30b-5p -0.43 -0.92 -0.99 -0.34 0.37 0.22 -0.01 0.21 0.37 0.012142 
rno-miR-30c -0.43 -1.00 -1.01 -0.44 0.07 0.30 -0.10 -0.03 0.28 1.15E-11 
rno-miR-30c-1* -0.34 -0.85 -0.29 0.70 2.00 1.62 1.74 0.68 -0.07 1.78E-09 
rno-miR-30c-2* -0.37 -0.54 0.09 -0.85 -3.04 -0.68 -1.64 -6.79 -2.10 3.78E-08 
rno-miR-30d -0.37 -0.86 -0.94 -0.64 0.05 0.44 -0.40 0.17 0.28 1.92E-05 
rno-miR-30d* 1.24 3.07 -1.82 3.00 0.49 1.71 3.16 -2.58 -2.74 0.020823 
rno-miR-30e -0.48 -0.36 -0.60 -0.50 0.14 -0.02 -0.56 -0.01 0.30 0.000316 
rno-miR-30e* -0.49 -0.64 -0.88 -0.48 0.03 -0.17 -0.41 -0.33 0.09 1.76E-05 
rno-miR-31 0.22 -0.64 0.70 -0.46 -0.13 0.26 -0.35 0.45 0.36 6.04E-07 
rno-miR-32 -0.87 -0.82 -1.60 -0.50 -0.14 0.55 0.14 1.49 1.39 3.13E-08 
rno-miR-320 0.13 -0.41 -0.69 -0.11 0.13 0.55 0.48 0.58 0.49 0.001091 
rno-miR-322 -0.63 -0.98 -0.94 -0.18 0.39 0.54 0.37 0.88 1.13 0.000317 
rno-miR-322* -0.70 -0.83 -0.80 -1.70 -0.48 -2.00 -2.19 -1.56 -1.72 0.046877 
rno-miR-323 -0.39 -0.55 -0.61 -0.19 0.36 0.48 0.36 0.87 0.80 6.65E-05 
rno-miR-323* 0.50 0.88 0.11 1.02 -2.03 -3.34 -0.41 -5.63 -5.79 0.00026 
rno-miR-324-3p -0.60 -0.79 -0.80 -2.54 -4.29 -5.81 -3.63 -7.83 -7.99 9.74E-07 
rno-miR-324-5p -0.98 -2.12 -1.71 -1.65 -2.09 -0.93 -2.01 -1.45 -1.18 9.89E-08 
rno-miR-325-3p -0.34 -0.73 -0.82 -0.48 0.08 -0.04 -0.25 0.09 0.02 0.001231 
rno-miR-325-5p -0.30 -0.66 -0.68 -0.11 0.03 -0.05 -0.02 0.08 0.42 1.99E-08 
rno-miR-326 -0.59 -0.96 -0.44 0.19 1.47 1.22 0.59 0.90 0.76 0.000151 







miRNAs SLR values   
ID 0hr 3hr 6hr 12hr 24hr 48hr 72hr 120hr 168hr p value 
rno-miR-329 -0.38 -0.77 -0.39 -0.29 0.07 -0.10 -0.34 0.13 0.15 4.33E-05 
rno-miR-33 -0.74 0.42 -0.57 -0.53 -0.19 -0.64 -0.76 0.78 0.68 0.000159 
rno-miR-330* -0.34 -0.93 -0.58 -0.31 0.16 0.00 -0.41 0.24 0.23 3.8E-07 
rno-miR-331 -0.20 -0.76 -0.58 -0.40 -0.10 0.29 -0.42 0.28 0.42 0.002899 
rno-miR-335 -0.14 -0.74 -0.38 -0.26 0.30 0.23 0.15 -0.15 -0.27 0.006367 
rno-miR-337 0.03 -0.79 -0.25 -0.33 0.07 -0.37 -0.88 -1.16 -1.46 0.00012 
rno-miR-338 -1.99 -1.28 -1.88 -0.61 -0.39 0.94 0.92 1.49 1.39 3.47E-06 
rno-miR-338* -0.41 -0.66 -1.00 -0.44 -0.35 0.07 0.12 0.06 0.47 2.7E-05 
rno-miR-339-3p -2.25 1.43 -2.35 -1.21 0.11 -3.55 -3.74 -3.11 -3.27 8.93E-10 
rno-miR-339-5p -0.02 -0.83 -0.21 -0.12 -0.46 1.05 0.92 2.23 2.05 0.011019 
rno-miR-340-3p -0.77 -0.89 -0.60 -0.39 0.19 0.55 0.51 1.47 1.04 2.48E-11 
rno-miR-341 -0.48 -0.94 -0.81 -0.31 0.08 0.53 0.08 0.34 0.33 0.010456 
rno-miR-342-3p -0.18 -0.66 -0.59 -0.34 0.11 0.14 0.13 0.41 0.46 1.48E-05 
rno-miR-342-5p 0.00 -0.15 1.61 0.64 1.06 0.52 0.72 1.43 1.44 3.62E-06 
rno-miR-343 -0.20 -0.64 -0.40 -3.99 -3.27 -7.09 -7.28 -6.66 -6.81 0.022446 
rno-miR-344-3p 0.10 0.01 0.32 0.14 -0.14 0.56 0.27 0.96 0.71 0.005814 
rno-miR-344-5p 0.04 0.10 -0.71 0.59 -1.73 0.77 1.27 -0.66 -0.09 5.62E-06 
rno-miR-345-3p -0.38 -0.90 -0.57 -0.10 -1.19 0.50 0.71 -0.76 -0.20 1.57E-06 
rno-miR-345-5p -0.14 0.01 0.28 0.21 1.08 0.18 0.17 0.81 0.65 0.001295 
rno-miR-346 -0.11 -0.18 0.17 0.13 -2.92 -0.40 0.45 -1.78 -0.66 6.66E-05 
rno-miR-347 -0.82 -0.62 -1.41 -0.67 0.11 0.54 0.73 0.84 0.89 2.59E-07 







miRNAs SLR values   
ID 0hr 3hr 6hr 12hr 24hr 48hr 72hr 120hr 168hr p value 
rno-miR-34a -0.51 -0.65 -0.89 -0.37 -0.09 0.25 -0.12 0.54 0.54 6.24E-06 
rno-miR-34b 0.15 -0.34 -0.57 -0.17 0.28 -0.33 0.31 0.58 0.85 9.88E-07 
rno-miR-34c -0.22 -0.39 -0.60 -0.23 0.34 -0.54 0.62 0.58 0.96 4.5E-07 
rno-miR-34c* -0.36 -0.65 -0.35 -0.28 0.09 -0.49 -0.10 0.53 0.51 0.025967 
rno-miR-350 -0.17 -0.20 -0.26 -0.12 0.36 0.50 0.49 0.55 0.57 0.02805 
rno-miR-351 -0.26 -0.39 0.08 0.45 1.62 1.05 0.51 0.77 0.33 2E-08 
rno-miR-352 -0.65 -0.47 -0.82 -0.11 0.38 0.38 0.34 0.39 0.72 3.17E-06 
rno-miR-361 -0.45 -0.96 -0.87 -0.32 0.42 0.22 0.14 0.55 0.43 8.19E-08 
rno-miR-363 -0.70 0.56 -0.80 -0.50 -1.02 -2.00 1.79 -1.56 -1.72 3.44E-13 
rno-miR-363* -0.93 0.51 0.25 0.01 -0.61 0.13 1.25 1.87 1.46 7.63E-05 
rno-miR-365 -0.44 -0.38 -0.43 -0.32 0.17 0.50 0.42 0.88 0.78 0.00192 
rno-miR-369-3p -0.18 -0.41 -0.71 -0.37 -0.10 0.09 -0.15 -0.06 -0.06 0.001095 
rno-miR-369-5p -0.34 -0.89 -1.00 -0.25 0.16 0.27 -0.20 -0.35 0.14 0.000186 
rno-miR-370 -0.78 -0.87 -0.83 -1.52 -0.92 -1.89 -1.95 -1.69 -1.78 2.28E-08 
rno-miR-374 -0.93 -0.34 -0.85 -0.38 0.05 0.48 0.68 1.54 1.45 0.000711 
rno-miR-375 -1.18 -1.11 -0.84 -0.52 -0.82 0.00 0.58 1.03 0.94 7.63E-06 
rno-miR-376a* -0.32 -0.19 -0.26 -0.12 0.42 0.27 0.04 0.18 0.36 6.1E-09 
rno-miR-376b-5p -0.98 -0.51 -0.75 0.00 -0.01 0.37 0.12 0.09 0.49 7.9E-07 
rno-miR-376c -0.60 -0.87 -0.05 -0.10 0.78 0.01 -0.09 0.22 0.13 6.33E-06 
rno-miR-377 -0.43 0.39 -0.43 0.04 -3.58 0.31 0.48 0.91 0.77 5.55E-09 
rno-miR-378 -0.17 -0.86 -0.78 -0.48 0.03 0.34 0.31 0.92 0.37 0.038672 







miRNAs SLR values   
ID 0hr 3hr 6hr 12hr 24hr 48hr 72hr 120hr 168hr p value 
rno-miR-379 -0.37 -0.77 -0.81 -0.37 0.16 0.00 -0.21 -0.30 -0.12 1.63E-05 
rno-miR-379* -0.21 0.06 0.00 -0.01 -3.06 -0.30 -0.21 -0.59 -0.17 3.88E-08 
rno-miR-380 -0.23 1.73 0.77 -1.85 -0.84 -4.76 -4.95 -4.32 -4.48 2.88E-06 
rno-miR-381 -0.38 -0.46 0.02 0.06 0.63 0.09 -0.03 0.47 0.40 8.99E-06 
rno-miR-382 -0.30 -0.77 -0.59 -0.04 0.59 0.33 0.15 0.31 0.39 0.030811 
rno-miR-382* -0.17 -0.57 -0.35 0.51 1.42 1.15 1.08 1.37 1.52 0.011576 
rno-miR-383 -0.42 -1.12 -0.47 -0.40 0.13 -0.35 -0.47 -0.89 -0.46 4.29E-06 
rno-miR-384-3p -0.70 -0.63 -0.98 -0.38 -0.09 0.16 -0.31 0.03 0.36 4.14E-05 
rno-miR-384-5p -0.49 -0.54 -0.67 -0.33 0.17 0.17 -0.27 -0.12 0.17 1.93E-05 
rno-miR-409-3p 0.58 -0.06 0.74 -0.10 -3.17 -0.58 -1.36 -1.98 -2.32 4.55E-08 
rno-miR-409-5p 0.17 0.02 0.20 0.39 1.12 0.80 0.91 1.60 1.25 1.35E-05 
rno-miR-410 -0.62 -0.98 -0.80 -0.52 0.24 0.49 0.36 0.24 0.28 0.000195 
rno-miR-411 -0.07 -0.39 -0.74 -0.72 -0.43 -0.97 -1.39 -1.35 -0.94 1.92E-07 
rno-miR-421 -1.70 0.54 0.61 -2.36 -2.13 -5.29 -5.48 -4.85 -5.01 2.78E-05 
rno-miR-423 -0.53 -0.76 -0.37 0.48 1.41 1.23 1.26 1.68 1.41 4.15E-05 
rno-miR-425 -0.30 -0.39 -0.53 0.05 0.70 1.07 1.20 1.90 1.72 0.000242 
rno-miR-429 -0.70 -0.83 -0.80 -1.70 -1.02 -2.00 -2.19 -1.56 -1.72 1.12E-07 
rno-miR-431 1.20 1.11 0.90 1.34 -1.60 1.60 2.09 0.11 -5.10 4.58E-06 
rno-miR-433 0.09 -0.62 -0.63 -0.19 0.08 0.45 0.13 0.25 0.17 8.5E-06 
rno-miR-434 -0.36 -0.87 -0.97 -0.49 -0.14 0.10 -0.14 -0.18 -0.11 1.63E-06 
rno-miR-448 1.15 0.35 0.57 0.75 0.18 -4.94 -3.58 -6.46 -1.67 0.01316 







miRNAs SLR values   
ID 0hr 3hr 6hr 12hr 24hr 48hr 72hr 120hr 168hr p value 
rno-miR-450a -1.22 -0.23 -2.49 -0.50 -0.89 -1.57 -1.25 -7.55 -7.70 0.005049 
rno-miR-451 0.49 1.67 -0.88 0.75 1.08 -0.28 -0.98 -4.11 -9.41 2.2E-10 
rno-miR-455 0.34 0.51 0.33 -0.21 -1.38 -0.17 -0.27 -3.01 -1.92 0.00201 
rno-miR-463 -1.88 -3.48 -3.45 -0.03 -1.17 -4.64 -0.60 -4.21 -4.37 2.35E-06 
rno-miR-466b -0.54 -0.76 0.46 0.28 1.30 0.16 0.18 0.30 0.41 0.000241 
rno-miR-466c -0.60 -1.07 0.12 -0.10 0.90 -0.34 -0.59 0.00 0.10 0.000247 
rno-miR-471 0.16 -0.19 1.30 -0.01 -2.67 -0.62 -0.68 -0.44 -0.10 0.010256 
rno-miR-483 -1.11 -1.30 -0.75 -1.09 1.99 -0.94 -1.44 -1.92 -1.90 0.000595 
rno-miR-484 -3.04 -2.98 -4.41 -4.71 -5.12 -8.89 -9.08 -8.46 -8.61 5.5E-14 
rno-miR-485 -0.18 -0.26 -0.43 -0.06 -3.99 -0.25 -0.30 -0.68 -0.09 0.002745 
rno-miR-487b -0.53 -0.76 -0.98 -0.41 -0.52 0.55 0.41 0.99 1.15 0.019114 
rno-miR-488 -1.10 -0.92 -0.77 -0.66 -0.86 -0.22 -0.57 -0.18 0.30 4.04E-06 
rno-miR-489 -0.70 -0.83 -0.80 -1.70 -0.07 -2.00 -2.19 -1.56 -1.72 6.69E-07 
rno-miR-494 -0.61 -0.27 -0.36 -0.09 1.19 0.96 0.65 1.04 0.95 8.09E-08 
rno-miR-495 -0.09 -0.22 -0.37 -0.18 -0.29 0.24 -0.05 0.08 0.19 0.038535 
rno-miR-497 -1.21 -0.61 -0.37 -0.02 0.47 0.72 0.51 1.39 1.42 0.002247 
rno-miR-499 -0.54 -0.39 -1.49 -0.51 -3.64 0.34 -0.20 0.02 0.41 0.001621 
rno-miR-500 0.26 -0.40 -0.85 0.68 -2.82 1.42 1.47 2.05 1.68 0.004936 
rno-miR-501 0.02 -0.69 -0.01 -2.35 -3.70 -7.50 -7.69 -7.07 -7.23 9.41E-08 
rno-miR-503 -0.41 -0.48 0.56 0.67 2.28 1.01 0.50 0.73 0.54 0.000286 
rno-miR-505 0.01 -0.69 -0.31 -0.27 -3.72 0.19 -0.21 0.04 0.19 0.012202 







miRNAs SLR values   
ID 0hr 3hr 6hr 12hr 24hr 48hr 72hr 120hr 168hr p value 
rno-miR-532-5p 2.05 1.37 1.71 -2.00 -1.02 1.37 2.01 2.35 1.58 3.46E-06 
rno-miR-540 0.12 0.61 1.39 1.86 -0.11 1.71 2.18 2.64 1.52 6.24E-05 
rno-miR-541 0.00 -0.90 -0.86 -0.42 -0.23 -0.07 -0.58 -0.60 -0.34 0.006557 
rno-miR-542-3p -0.22 -0.04 -0.47 0.15 0.46 0.56 0.93 1.66 1.41 0.030874 
rno-miR-542-5p 0.09 0.29 0.24 1.32 2.86 2.53 2.54 2.07 1.52 0.008303 
rno-miR-543 -1.14 -1.82 -1.41 -5.09 -4.70 -8.41 -8.60 -7.98 -8.14 3.05E-07 
rno-miR-543* -1.75 1.73 2.32 -1.95 -0.57 -4.37 -4.56 -3.94 -4.10 0.000413 
rno-miR-551b -0.92 -0.99 -0.76 -0.39 0.47 0.47 0.06 0.40 0.47 7.28E-08 
rno-miR-598-3p -0.69 -0.36 -0.25 -0.23 -0.20 0.14 0.29 0.29 0.50 2.33E-06 
rno-miR-598-5p 2.41 2.00 1.59 -1.70 0.06 -2.00 -2.19 -1.56 -1.72 0.000183 
rno-miR-652 -0.12 -0.77 -0.98 -0.36 -0.41 0.45 0.44 0.95 0.93 5.14E-08 
rno-miR-664 -0.39 -0.98 -0.65 -0.36 0.36 0.24 -0.42 0.42 0.40 0.001206 
rno-miR-671 -0.70 -0.06 -0.49 -3.65 -2.86 -6.96 -7.15 -6.52 -6.68 5.43E-08 
rno-miR-672 -0.22 -0.82 -0.56 -1.09 -0.95 -1.19 -1.46 -1.54 -1.43 0.003133 
rno-miR-673 -0.70 -0.83 -0.80 0.59 -1.02 -2.00 -2.19 -1.56 -1.72 0.044473 
rno-miR-674-3p -0.27 -0.79 -0.97 -0.36 0.42 0.25 -0.20 -0.27 0.03 5.21E-16 
rno-miR-674-5p -0.65 -0.85 -0.78 -0.45 -0.03 0.18 0.12 0.12 0.18 0.007403 
rno-miR-708 0.02 -0.61 -0.64 -0.46 -0.28 -0.14 -1.02 -0.59 -0.23 0.029646 
rno-miR-708* -0.74 -1.12 -1.49 -0.15 0.83 0.71 -0.08 -0.81 -0.02 7.27E-05 
rno-miR-742 -0.44 -1.16 -0.73 -0.39 0.12 0.19 -0.33 0.38 0.40 0.002297 
rno-miR-743a 0.99 0.85 -0.14 0.74 2.00 2.64 3.69 3.82 2.90 0.00036 







miRNAs SLR values   
ID 0hr 3hr 6hr 12hr 24hr 48hr 72hr 120hr 168hr p value 
rno-miR-758 0.97 2.81 0.66 -0.10 -1.75 -5.18 -1.83 -4.75 -4.90 7.04E-06 
rno-miR-760-3p -0.71 -0.74 -0.61 -0.85 -0.61 -0.70 -0.81 -0.87 -1.15 0.003131 
rno-miR-760-5p 0.99 -1.24 -1.09 1.01 1.42 2.16 2.11 2.09 2.13 1.1E-07 
rno-miR-770 0.05 -0.97 -0.25 -0.61 -3.62 -0.36 -0.99 -0.49 -0.36 0.006461 
rno-miR-7a 0.20 -0.67 0.23 -0.29 0.82 -0.51 0.07 0.44 0.09 0.000699 
rno-miR-7a* -0.96 -0.28 -0.60 0.27 0.12 1.11 0.51 -0.10 0.78 0.000454 
rno-miR-871 -3.89 -0.65 -0.22 -3.21 -2.06 -5.19 -5.38 -4.75 -4.91 5.05E-06 
rno-miR-872 -1.14 -0.65 -1.05 -0.39 -0.37 0.68 0.56 0.97 1.10 1.37E-07 
rno-miR-872* -0.61 -0.98 -0.30 0.10 1.22 1.06 0.59 0.98 0.96 1.41E-09 
rno-miR-873 -0.74 -0.45 -0.41 -0.08 0.10 0.84 0.21 -0.06 0.53 0.000154 
rno-miR-874 -0.52 0.25 0.15 1.00 2.49 2.03 2.01 2.57 2.04 0.000225 
rno-miR-877 -0.43 -0.24 1.32 1.31 2.13 0.50 0.61 0.93 0.71 0.000194 
rno-miR-878 0.40 -0.17 -0.39 0.84 -2.49 0.19 1.19 0.50 0.94 5.29E-05 
rno-miR-879 0.61 0.77 0.84 -1.48 -3.01 -7.56 -2.76 -7.12 -7.28 0.003014 
rno-miR-880 3.50 3.84 3.73 3.70 1.30 -2.32 2.65 -1.88 3.40 0.018422 
rno-miR-881 -0.70 -0.13 -0.80 -1.70 -1.02 -2.00 -2.19 -1.56 -1.72 8.13E-05 
rno-miR-883 0.25 0.01 0.84 0.65 -1.84 0.56 1.27 1.89 2.31 5.47E-05 
rno-miR-9 -0.55 0.01 -0.36 -0.44 -0.13 -0.31 -0.50 0.13 -0.03 0.006382 
rno-miR-9* -0.59 -0.66 -0.64 -0.47 0.09 -0.13 -0.38 -0.35 -0.19 0.003377 
rno-miR-92a -0.42 0.03 -1.00 -2.05 -4.04 -7.51 -1.97 -7.08 -7.23 1.91E-05 
rno-miR-92b -0.14 -0.68 -0.58 -0.37 0.30 0.32 0.15 0.71 0.72 3.75E-06 







miRNAs SLR values   
ID 0hr 3hr 6hr 12hr 24hr 48hr 72hr 120hr 168hr p value 
rno-miR-96 2.83 -0.19 -0.43 -3.05 -2.68 4.22 -6.29 -5.66 -5.82 0.000114 
rno-miR-98 -0.38 -0.69 -1.07 -0.37 -0.16 0.11 -0.03 0.04 0.25 0.001994 
rno-miR-99a -0.52 -0.32 -0.85 -0.40 0.13 0.48 0.16 0.68 0.80 0.006007 
rno-miR-99a* 0.21 -0.19 -0.27 0.17 -3.12 -0.95 -1.03 -0.08 0.34 0.004873 
rno-miR-99b 0.02 -0.59 -0.71 -0.21 0.36 0.29 0.35 0.50 0.44 2.4E-20 


















4      miRNAS REGULATING THE TRANSCRIPTION FACTOR      
        HYPOXIA INDUCIBLE FACTOR-1α  
 
4.1   Introduction 
In the previous study, miRNA profiling in a eMCAo model were obtained, 
which indicated crucial functions for miRNAs in cerebral ischemia. Next, it 
needs to know whether the interaction between specific miRNAs and their 
targets can bring about beneficial effects in cerebral ischemia. Hypoxia is an 
ischemia-aggravating factor which occurs immediately upon cerebral vascular 
occlusion and contributes to the extension of ischemic cascade. Hence, 
hypoxia inducible factor-1α (HIF-1α), the master transcription factor that 
regulates hypoxic events would be a good candidate to target for the treatment 
of ischemic stroke.  
Hypoxia inducible factor-1α (HIF-1α) is a master transcriptional factor in 
response to hypoxia in various diseases [17]. It is composed of α and β protein 
subunits which included three isoforms respectively. The isoforms of HIF-α 
subunit are: HIF-1α, HIF-2α, and HIF-3α and isoforms of HIF-1β also named 
aryl-hydrocarbon receptor nuclear transporter (ARNT) are ARNT1, ARNT2, 
and ARNT3 [229, 230]. Both α and β subunits belong to the basic Helix-
Loop-Helix/PER-ARNT-SIM (bHLH-PAS) family. Most of the studies focus 
on α subunit, which was regulated by oxygen concentration whereas β subunit 
is stable with changes in oxygen concentration. HIF-1α is composed of basic 
Helix-Loop-Helix (bHLH), PER-ARNT-SIM (PAS), oxygen dependent 
degradation domain (ODD), N-terminal transactivation domain (NAD) and C-





domains (including PAS-a and PAS-b) are required for heterodimer formation 
as well as DNA binding [232]. Oxygen-dependent degradation domain 
mediates HIF-1α degradation while transactivation domain interacts with 
coactivator such as p300/CBP to transcriptionally activate the downstream 
genes [233, 234]. 
HIF-1α is found to be ubiquitously expressed in tissues under normoxic 
conditions and induced under hypoxic conditions in most of the cell types, 
which suggests that it plays a general role in oxygen homeostasis. In contrast 
to HIF-1α, HIF-2α and HIF-3α have limited expression patterns [235, 236]. 
The functions of HIF-3α are still unclear. It may act as a suppressor to inhibit 
HIF-1α mediated gene expression [237]. To date, HIF-1α is the most studied 
isoform of HIF-α in terms of function and the expression pattern in tissues. 
HIF-1α regulates the expression of a broad range of downstream genes that 
facilitate cellular adaptation to low oxygen conditions. These genes include 
those coding for molecules that participate in angiogenesis [238], 
erythropoiesis [239], cell proliferation [240] and apoptosis [241, 242]. HIF-1α 
plays both prosurvival and prodeath role by regulating these downstream 
genes. The prosurvival function of HIF-1α is mediated via improving 
angiogenesis, proliferation and neurogenesis [238 - 240] whereas prodeath 
function is mediated through apoptosis by activation of apoptotic factors such 
as BCL2/adenovirus E1B 19 kd-interacting protein 3 (BNIP3) and p53 [241, 
242]. It is assumed that the dual function of HIF-1α is altered according to the 
severity and duration of the injury as well as the cell types [31].  
HIF-1α was found to be crucial in numerous pathological processes of 





response to hypoxia [31]. In 1996, Wiener et al first reported that Hif-1α 
mRNAs were induced in the brains of rats exposed to reduced oxygen 
concentration for 30 to 60min [243]. In cerebral ischemia model, Hif-1α 
mRNA expression increased 1.5–1.7 fold after 7.5hr of ischemia and was 
consistently upregulated until 24hr in the penumbra region [244]. Protein 
expression of HIF-1α and HIF-1β was found to be significantly increased 20hr 
post reperfusion in a transient ischemic stroke model [245]. In a transient 
global ischemia model induced by cardiac arrest and resuscitation, HIF-1α 
expression increased as early as 1hr and remained upregulated for 7 days [246]. 
The significant changes in HIF-1α expression upon ischemic injury implied 
that HIF-1α may play an important role in cerebral ischemia. Subsequent 
studies further shed light on the possible function of HIF-1α in cerebral 
ischemia. It was found that HIF-1α protein presented biphasic expression in 
neuron of transient ischemic stroke animal model. The early phase activation 
of HIF-1α protein was 6hr after stroke onset accompanied by increased 
expression of downstream proapoptotic genes such as Bnip3, phorbol-12-
myristate-13-acetate-induced protein 1 (Noxa) and BCL2/adenovirus E1B 19 
kDa protein-interacting protein 3-like (Nix) while in the late phase, HIF-1α 
protein activation occurred at 72hr with increased expression of protective 
genes such as Vegfa, erythropoietin (Epo), and Glut1 [19, 20]. The biphasic 
expression of HIF-1α indicated that different therapeutic approach has to be 
considered for application between the early and late phase of ischemic stroke. 
Studies demonstrated that inhibition or knock-down Hif-1α in the early phase 
of cerebral ischemia eventually led to reduced infarct volume [20, 247]. 





regulating vascular endothelial growth factor a (VEGFA) [248], matrix 
metalloproteinase-9 (MMP9) [249], aquaporin 4 (AQP4) and aquaporin 9 
(AQP9) [30, 250] upon brain ischemic injury. These studies indicated that 
inhibition of HIF-1α expression could reduce brain edema by inhibiting 
VEGFA, MMP-9, AQP4 and AQP9 expression.  
To date, several miRNAs have been reported to regulate human HIF-1α 
mRNA in cancer and hypoxia, including miR-17, -18a, -20a/b, -22, -138, -155, 
-199a-5p and -519c [251 - 257]. However, the implication of miRNAs in the 
regulation of Hif-1α during cerebral ischemia remains unexplored. This part of 
the study aims to identify miRNAs that could directly regulate Hif-1α 
expression and subsequently its downstream genes upon cerebral ischemia. 
 
4.2 Measurements of infarct volume, HIF-1α mRNA as well as protein in 
the eMCAo model 
Rats (n = 6) subjected to eMCAo were sacrificed at several end points as 
follows, 0, 3, 6, 12, 24, 48, 72, 120 and 168hr. By applying the same inclusion 
criteria as described in Chapter 3, rats with successful eMCAo were included 
in this study. The rats in these categories (eMCAo group) were selected and 
euthanized to harvest the brain samples for further studies. The brain slices of 
these rats were stained with TTC and infarct volumes on the ipsilateral region 
were measured. Infarct volume was quantitated according to section 2.2.1.1.7.  
The infarct volume peaked at 24hr (100 ± 69.52%) and then declined 
progressively from 48hr until 168hr (43.99 ± 64.4%) post-occlusion (Figure 





time points, both its mRNA and protein level in the brain tissue were also 
measured. HIF-1α mRNA and protein demonstrated a similar biphasic 
expression pattern; increasing from the onset of ischemic stroke and peaking 
at 6hr post occlusion. The expression decreased subsequently at 24hr which 
then gradually increased again at 72hr, followed by a gradual decrease towards 
168hr (Figure 4.1A, 4.1B).   
 
4.3 Bioinformatics prediction of miRNAs targeting Hif-1α 
Having seen the functional importance of HIF-1α, there is a need to look for 
modulators that could regulate the expression of this gene. miRNA has been 
identified to be the endogenous regulator of gene expression. To assess the 
miRNAs that could target Hif-1α, a bioinformatic search was performed using 
the following databases, TargetScan, microRNA.org, Pictar, Diana microT, 
miRGen and RegRNA databases [258 - 261]. miRNAs that are conserved in 
both rodent and human and predicted by at least two databases were 
shortlisted. The search yielded 12 miRNAs (miR-17, -18a, -20a, 20b-5p, -93, -
135a/b, -138, -199a-5p, -203, -335, -338) that could potentially target Hif-1a 
(Table 4.1). miR-17, -18a, -20a, -20b-5p, -135a/b, -203, -335, -338 and -93 
have been found to be differentially and significantly (p < 0.05) expressed in 
the  miRNA profiling analysis of eMCAo samples carried out in this study 
(Figure 4.2). Of these, miR-17, -18a, -20a and 20b-5p have been previously 










Figure 4.1 HIF-1α mRNA and protein expression at 0, 3, 6, 12, 24, 48, 72, 120 
and 168hr after eMCAo. (A) Hif-1α mRNA expression at each time point upon 
cerebral ischemia. Hif-1α mRNA was measured by quantitative RT-PCR and 
presented by relative expression (mean ± SD with n=3) compared to eMCAo control 
as calibrator and 18s as endogenous control. Statistically significant differences are 
tested at p < 0.05 significance. *p < 0.05. (B) HIF-1α protein expression at each time 
point upon cerebral ischemia. HIF-1α protein expression was measured by Western 
blotting. The intensity of the protein bands were measured using Image J software 
and presented as percentage of control (%). Statistical analysis is carried out using 










Table 4.1 miRNAs predicted to target 3'UTR of Hif-1a. miRNA:Hif-1a target 
prediction was carried out using microRNA.org, TargetScan, miRGen, Pictar, Diana 
microT and RegRNA. Among the significantly and differentially dysregulated 
miRNAs, the previously reported and validated miRNAs are underlined. In silico is 
an expression used to mean "performed on computer or via computer simulation." In 
this study, in silico prediction was based on miRNA prediction databases. 
 
Selection Criteria miRNAs 
miRNAs that are conserved between rodent and 
human and identified by in silico prediction  (in at 
least 2 of the six databases used) 
miR-17, -18a, -20a, -20b-5p, 
-135a, -135b, -138,  -199a-
5p, -203, -335, -338, -93 
The expression of miRNAs that were confirmed by 
microarray profiles on ipsilateral brain samples of 
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Figure 4.2 Heat map of predicted miRNAs and Hif-1a expression in eMCAo 
model. miRNA expression presented by relative expression from the miRNA array 
data. The differential expressed miRNAs that were statistically significant (one-way 
ANOVA p value <0.05) are included. Hif-1α mRNA expression presented as relative 








HIF-1a [30, 31]. Thus, miR-135a, -203, -335, -338 and -93 were selected for 
further analysis as candidate miRNAs that target Hif-1α. miR-135a which 
differs by only one nucleotide from miR-135b was chosen instead of miR-
135b for this study. miR-17 and -20a were used as positive controls in our 
study as they have been reported to be the strongest regulators of HIF-1α 
transcript [30]. The predicted binding sites of the selected miRNAs on the 3‘ 
UTR of Hif-1α mRNA in rat and human are shown in Figure 4.3.  
 
4.4 Cloning of Hif-1a cDNA 
The most common method for validating miRNA:target interaction is through 
the use of reporter gene assays. The 3'UTR region of the target gene is usually 
cloned downstream of a reporter gene such as luciferase. Thus in order to 
screen and validate miRNAs that could modulate Hif-1α, the next step was to 
clone this gene. Although only the 3‘UTR was of interest, both the 5' UTR and 
CDS were also cloned separately for future studies. The sequence of Hif-1α 
was obtained from NCBI database and specific primers were designed to 
amplify the 5'UTR, CDS and 3'UTR regions (Table 4.2). The Hif-1α mRNAs 
was generated as five fragments (Hif-1α A-E) (Figure 4.4 & 4.5). Each of 
these fragments were sub-cloned into TOPO vector independently (Figure 4.6) 
and sequenced for verification. Restriction sites were introduced at the ends of 
the fragments once the Hif-1α 3'UTR sequences were verified. This was done 
by re-designing the ends of the original primers with specific restriction sites 
such as (Spe1/Sac1 and HindⅢ/Sac1) (Table 4.2). The fragments were then 






|NM_001530.3| AGGGTGAAGA ATTACTCAGA GCTTTGGATC AAGTTAACTG AGCTTTTTCT TAATTTCATT CCTTTTTTTG ---------- ---------- --------GA 2916 
|NM_024359.1| AGGGTGAAGA ATTACTCAGA GCTTTGGATC AAGTTAACTG AGCTTTT-CC TAATCTCATT CCTTTGATTG TTAATTTTTG TGTTCAGTTG TTGTTGTTGT 2553 
              ********** ********** ********** ********** ******* *  **** ***** ***** :***                            *: 
 
|NM_001530.3| CACTGGTGGC TCATTACC-- ---------- ---------- --TAAAGCAG TCTATTTATA TTTTCTACAT CTAATTTTAG AAGCCTGGCT ACAATACTGC 2992 
|NM_024359.1| CTGTGGGGTT TCGTTTCTGT TGGTTGTTTT GGACACTGGT GGCTCAGCAG TCTATTTATA TTTTCTATAT CTCATTT-AG AGGCCTGGCT ACAGTACTGC 2652 
              *: *** *   **.**:*                          :.*****    ********** ******* ** **.**** ** *.******** ***.****** 
                                                       uguaAAAAGCAAU AACGAGAAcu miR-335(site1) 
                                                           |||   ||:  |||||||       
|NM_001530.3| ACAAACTTGG TTAGTTCAAT TTTGATCCCC TTTCTACTTA ATTTACATTA ATGCTCTTTT TTAGTATGTT CTTT-AATGC TGGATCACAG ACAGCTCATT 3091 
|NM_024359.1| ACCAACTCAG ATAGTTTAG- TTTGGGCCCC TTCCTCCTTC ATTTTCACTG ATGCTCTTTT T-ACCATGTC CTTCGAATGC CAGATCACAG ------CACA 2744 
              **.**** .* :***** *.  ****. **** ** **.***. ****:** *. ********** * *  ****  ***  *****  .********       ** : 
                                                                 
|NM_001530.3| TTCTCAGTTT TTTGGTATTT AAACCATTGC ATTGCAGTAG CATCATTTTA AAAAATGCAC CTTTTTATTT ATTTATTTTT GGCTAGGGAG TTTATCCCTT 3191 
|NM_024359.1| TTCACAGCTC CCCAGCATTT -CACCAATGC ATTGCTGTAG TGTCGTTT-- -AAAATGCAC CTTTTTATTT ATTTATTTTT GGTGAGGGAG TTTGTCCCTT 2840 
              ***:*** *     .* ****  .****:*** *****:****  .**.***    ********* ********** ********** **  ****** ***.****** 
 
|NM_001530.3| TTTCGAATTA TTTTTAAGAA GATGCCAATA TAATTTTTGT AAGAAGGCAG TAACCTTTCA TCATGATCAT AGGCAGTTGA AAAATTTTTA CACCTTTTTT 3291 
|NM_024359.1| ATTG-AATTA TTTTTAATGA AATGCCAATA TAATTTTT-T AAGAAGGCAG TAAATCTTCA TCATGATGAT AGGCAGTTGA AAATTTTTTA CTCATTTTTT 2938 
              :**  ***** ******* .* .********* ******** * ********** ***.  **** ******* ** ********** ***:****** *:*.****** 
 
|NM_001530.3| TTCACATTTT ACATAAATAA TAATGCTTTG CCAGCAGTAC GTGGTAGCCA CAATTGCACA ATATATTTTC TTAAAAAATA CCAGCAGTTA CTCATGGAAT 3391 
|NM_024359.1| T-CATGTTTT ACATGAA-AA TAATGCTTTG CCAGCAGTAC ATGGTAGCCA CAATTGCACA ATATATTTTC TT-AAAAATA CCAGCAGTTA CTCATG-CAT 3034 
              * ** .**** ****.** ** ********** ********** .********* ********** ********** ** ******* ********** ****** .** 
                                                                                aguuGUUUUA GUGACUACGA Cu miR-338 
                                                                                    |:       :||||||| | 
|NM_001530.3| ATATTCTGCG TTTATAAAAC TAGTTTTTAA GAAGAAATTT TTTTTGGCCT ATGAAATTGT TAAACCTGGA ACATGATGCT GTTAATCATA TAATAATGAT 3491 
|NM_024359.1| ATATTCTGCA TTTATAAAAC TAGTTTTTAA GAAGAAACTT TTTTTGGCCT ATGGAATTGT TAAGCCTGGA TCATGATGCT GTTGATCTTA TAATGAT--- 3131 
              *********. ********** ********** ******* ** ********** ***.****** ***.****** :***** . * ***.***:** ****.**    
                                          gUAU CCUUAUUUCG GUAu miR-135a                                                                                      
                                           | | :|::|||||| ||| 
|NM_001530.3| TCTTAAATGC TGTATGGTTT ATTATTTAAA TGGGTAAAGC CATTTACATA ATATAGAAAG ATATGCATAT ATCTAGAAGG TATGTGGCAT TTATTTGGAT 3591 
|NM_024359.1| TCTTAAA--C TGTATGGTT- --TCTTTATA TGGGTAAAGC CATTTACATG ATATAGAGAG ATATGCTTAT ATCTGGAAGG TATATGGCAT TTATTTGGAT 3226 
              *******  * *********    *.****:* ********** *********. *******.** ******:*** ****.***** ***.****** ********** 
                                                 
|NM_001530.3| AAAATTCTCA ATTCAGAGAA ATCATCTGAT GTTTCTATAG TCACTTTGCC AGCTCAAAAG AAAACAATAC CCTATGTAGT TGTGGAAGTT TATGCTAATA 3691 
|NM_024359.1| AAAATTCTCA ATT--GAGAA GTTATCTGGT GTTTCTTTA- ---CTTTACC GGCTCAAAAG AAAACAG-TC CCTATGTAGT TGTGGAAGCT TATGCTAATA 3319 











|NM_001530.3| TTGTGTAACT GATATTAAAC CT-AAATGTT CTGCCTACCC TGTTGGTATA AAGATATTTT GAGCAGACTG TAAACAAGAA AAAAAAAATC ATGCATTCTT 3790 
|NM_024359.1| TTGTGTAATT GATATTAAAC ATTAAATGTT CTGCCTATCC TGTTGGTATA AAGACATTTT GAGCATACTG TAAACAA--- ---AAAAATC ATGCATTGTT 3413 
              ******** * ********** .* ******* ******* ** ********** **** ***** ***** **** *******       ******* ******* ** 
 
 
                                                          ggacgugcuu guCGUGAAA miR-93 
                                                          ggacgugaua uuCGUGAAA miR-20a 
                                                          ggacgugaca uuCGUGAAA miR-17              AC CAGGAUUUGU AAAGU miR-203 
                                                                       |||||||                     |   || |    | ||||| 
|NM_001530.3| AGCAAAATTG CCTAGTATGT TAATTTGCTC AAAATACAAT GTTTGATTTT ATGCACTTTG TCGCTATTAA CATCCTTTTT TTCATGTAGA TTTCAATAAT 3890 
|NM_024359.1| AGTAAAATTG CCTAGTATGT TAATTTGTTG AAAATACGAT GTTTGGTTTT ATGCACTTTG TCGCTATTAA CATCCTTTTT TTCATATAGA TTTCAATAAT 3513 
              ** ******* ********** ******* *  *******.** *****.**** ********** ********** ********** *****.**** ********** 
                                                                                                 
|NM_001530.3| TGAGTAATTT TAGAAGCATT ATTTTAGGAA TATATAGTTG TCACAGTAAA TATCTTG--- --------TT TTTTCTATGT ACATTGTACA AATTTTTCAT 3979 
|NM_024359.1| TGAGTAATTT TAGAAGCATT ATTTTAGAAA TATAGAGTTG TCATAGTAAA CATCTTGTTT TTTTTTCTTT TTTTCTATGT ACATTGTATA AATTTTTCAT 3613 
              ********** ********** *******.** **** ***** *** ****** ******            ** ********** ******** * ********** 
             ugUAAAAAGCA A--UAA CGA GAAcu miR-335 (site2) 
               ||||||| | |   || ||| ||| 
|NM_001530.3| AATTTTTCAT TCCTTTTGCT CTTTGTGGTT GGATCTAACA CTAACTGTAT TGTTTTGTTA CATCAAATAA ACATCTTCTG TGGACCAGGC AAAAAAAAAA 4069 
|NM_024359.1| AATTTTTCAT TCCCTT-GCT CTTTGTAGTT GGGTCTAACA CTAACTGTAC TGTTTTGTTA TATCAAATAA ACATCTTCTG TGGACCAGGA AAAAAAAAAA 3702 
              *** ** *** ******.*** **.******* *********  ********** ********* ********** *********.  **********  
                    
|NM_001530.3| AAAAAAAAAA AAA--- 4082 
|NM_024359.1| AAAAAAAAAA AAAAAA 3718 




Figure 4.3 3'UTR sequence of the Hif-1α gene for both rat and human. The sequence was retrieved from NCBI GenBank Database (hsa NM_001530.3 
and rno NM_024359.1). The predicted binding sites of selected miRNAs (miRNA-17, -20a, -135a, -203, -335, -338 and -93) to the 3'UTR of Hif-1α mRNA 















Table 4.2 Primers used for amplification of the CDS and 3'UTR of Hif-1α. The 
table lists the specific primers used to amplify the CDS and 3'UTR region of Hif-1α 
into TOPO vector. For directional cloning into pMIR vectors, the primers were 





Sequence of primers used for TOPO 
cloning (5' to 3') 
Restriction 
sites 
Hif-1α A Forward ACCGATTCGCCATGGAGGG  
Hif-1α A Reverse AAGCTTCGCTGCGTGTTTG  
Hif-1α B Forward GTCTAGGGATGCAGCACGATCTCG  
Hif-1α B Reverse TGGGTCTGCTGGAATCCTGT  
Hif-1α C Forward GTCTCCATTACCTGCCTCTGAAAC  
Hif-1α C Reverse AGCTCAGTTAACTTGATCCAAAGC  
Hif-1α D Forward GCTCCCATACAAGGCAGCAG Sac1 
Hif-1α D Reverse ACAGCATCATGATCCAGGCTT Spe1 
Hif-1α E Forward TCAAAGCTTTCATGATCCAGGCT HindⅢ 





Figure 4.4 Schematic representation of the Hif-1α mRNA. The solid black line 
represents the mRNA of Hif-1α composed of 5'UTR, CDS and 3'UTR region (not 
drawn to scale). CDS region starts from ATG and ends at TGA. P(A) represents the 
poly A signal on the mRNA. The Hif-1α mRNA was amplified as five separate 
fragments (A-E) using sequence specific primers and among them fragments for 
3'UTR are D and E. The forward primer for fragment D sits about 72bp upstream of 











Figure 4.5 Amplification of Hif-1α mRNA. The mRNA of Hif-1α was amplified 
using sequence specific primers.  The marker (1:100 bp) was located on the first line 





Figure 4.6 Image of the pCR4-TOPO vector. The pCR4-TOPO vector was used for 
sub-cloning of the amplified PCR products. PCR products from the agarose gel were 









again. The sequences including the presence of the restriction sites were 
verified by sequencing. The correct fragments were then excised using the 
appropriate restriction enzymes and sub-cloned into pMIR luciferase vector 
(Figure 4.7).  
 
4.5 Luciferase reporter assays 
Reporter assay to study the interaction between the miRNAs and their targets 
are often performed in HeLa cells. It is a commonly used cell line since they 
are easily transfected. The Hif-1α 3'UTR constructs were then co-transfected 
together with their respective anti or pre miRNAs into cells. Changes in the 
luciferase activity were measured 48hr after transfection. Cells transfected 
with anti miR-17, -20a, -335 and -93 exhibited an increase in the relative 
luciferase activity, whereas pre miR-17, -20a, -335 and -93 caused a reduction 
in luciferase activity (Figure 4.8). miR-135a, -203 and -338 did not show 
significant changes in luciferase activity (Figure 4.8). Site-directed 
mutagenesis of the miR-335 and -93 recognition sites located on the Hif-1α 
3‘UTR abolished interactions between the miRNAs and its HIF-1α target 
(Figure 4.9). The mutated sequences of miR-335 and -93 are shown in Table 
4.3. These results indicate that miR-335 and -93 directly target Hif-1α mRNA. 
The results obtained suggested that Hif-1α gene expression can be regulated in 
both rat and human by miRNAs such as miR-17, -20a, -135a, -203, -335, -338 
and -93 to be conserved in human and rodent. These miRNAs have also been 
found to be highly expressed in rat brain and significantly dysregulated upon 











Figure 4.7 Image of the pMIR-Report
TM
 Luciferase vector. The Pmir-Report
TM
 
Luciferase vector was used for reporter gene studies. Gene fragments previously sub-
cloned into the pCR4-TOPO vector were excised using the appropriate restriction 
enzymes. The same enzymes were also used to linearize the Pmir-Report
TM
 
Luciferase vector. The fragments were then separated on an agarose gel and purified 
out prior to ligation. Ligation was performed at an insert to vector ratio of 3:1 (Image 
















Table 4.3 Mutated sequences of miR-335 and -93 in Hif-1a 3'UTR. The seed 
regions were mutated according to the following design for miR-335 and -93. Seed 
regions of miR-335 and -93 are shown in bold italics. Mutations are marked with 
asterisks.   
Fragment Binding of miR-335 to Hif-1α 
                 
Site1           
 
3’  uguaAAAAGCAAUAACGAGAAcu  5’rno-miR-335 
        |||||  |: ||||||| 
2689: 5’  ttcaTTTTCACTGATGCTCTTtt  3’Hif-1α  
 
Site1-mut 
3’  uguaAAAAGCAAUAACGAGAAcu  5’rno-miR-335 
                 |||||  |: *** * * 
   2689: 5’  ttcaTTTTCACTGAGTGTTTGtt  3’Hif-1α mut 
 
Site2 
3’  ugUAAAAAGCAA--UAACGAGAAc 5’rno-miR-335 
            ||||||| ||   |||||||| 
3603: 5’  aaATTTTTCATTCCCTTGCTCTTt 3’Hif-1α  
 
Site2-mut 
3’  ugUAAAAAGCAA--UAACGAGAAc 5’rno-miR-335 
            ||||||| ||   **** * * 
3603: 5’  aaATTTTTCATTCCCGGTGTTTGt 3’Hif-1α mut 
 
Site1&2-intact 
3’  uguaAAAAGCAAUAACGAGAAcu  5’rno-miR-335 
        |||||  |: ||||||| 
   2689: 5’  ttcaTTTTCACTGATGCTCTTtt  3’Hif-1α  
3’  ugUAAAAAGCAA--UAACGAGAAc 5’rno-miR-335 
            ||||||| ||   |||||||| 
   3603: 5’  aaATTTTTCATTCCCTTGCTCTTt 3’Hif-1α 
 
Fragment Binding of miR-93 to Hif-1α 
                 
Site  
           
 
3’  gauggacgugcuuguCGUGAAAc   5’ rno-miR-93 
 |||||||  




3’  gauggacgugcuuguCGUGAAAc   5’ rno-miR-93 
 ** * **  








Figure 4.8 Dual Luciferase assay for selected miRNAs predicted targeting HIF-
1α. Quantitation of the effects of pre or anti miR-17, -20a, -135a, -203, -335, -338 
and -93 interaction with the 3' UTR of Hif-1a. The plasmid constructs together with 
either pre or anti miRNAs were co-transfected into HeLa cells. Luminescence for 
luciferase gene activity in treated samples (pre or anti miRNAs) was obtained 48hr 
post-transfection. Relative luminescence was obtained by normalizing the values 
against control plasmids, pMIR-REPORT
TM
 without any 3'UTR insert. Data 
presented as mean ± SD with n = 3. Statistically significant differences are tested at p 
< 0.05 significance. *p<0.05. Data shown are the mean ± SD, n=3. 
 
 
Figure 4.9 Relative luminescence in plasmid constructs containing miR-335 and 
miR-93 target sites. miR-335 and -93 target sites were identified using regRNA. 
These regions were cloned into luciferase reporter plasmids. Mutated 3'UTR 
constructs were generated using site-directed mutagenesis. Relative luminescence 
was obtained by normalizing against that of control plasmids, pMIR-REPORT
TM 
without any 3'UTR insert. Statistically significant differences are tested at p < 0.05 







reported to directly regulate HIF-1α in lung cancer cells [30]. Among the other 
novel miRNAs, miR-335 that has two binding sites on the 3'UTR of Hif-1α 
was found to be the most promising regulator of Hif-1α (Figure 4.8). Table 4.3 
shows the seed regions of miR-335 and miR-93 that were mutated for 
validation of the binding sites as well as the consequences of mutating them 
by site directed mutagenesis. 
 
4.6 miR-335 regulates Hif-1α in primary neuron subjected to oxygen 
glucose deprivation (OGD) 
In order to prove that miR-335 can regulate Hif-1α upon ischemic condition, 
an in vitro study using primary neuronal culture and OGD was carried out. 
Hif-1α was found to be significantly upregulated in primary neuron cells 
subjected to OGD whereas miR-335 exhibited a downregulation. Both were 
found to show maximum changes in 4hr OGD (Figure 4.10). Hence, 4hr OGD 
was selected for further studies. During OGD reperfusion, primary neurons 
were transfected with anti and pre miR-335 independently and then the 
changes in miR-335 and Hif-1α expression were observed. In pre miR-335 
transfected cells, relative expression of miRNA-335 levels increased by 
133.73 fold compared to OGD control cells (Figure 4.11A). Simultaneously a 
decrease in the Hif-1α mRNA expression was observed (Figure 4.11A) in the 
presence of pre miR-335. Cell death was also significantly reduced as 
compared to OGD control cells (Figure 4.11B). While the introduction of anti 












Figure 4.10 Cell viability and corresponding Hif-1α and miR-335 expression in 
primary neuronal culture subjected to OGD. Neurons subjected to OGD displayed 
decreased cell death. Expression of Hif-1α showed negative correlation to miR-335 
expression. Relative expression (2-
ΔΔ
Ct) was calculated based on vehicle OGD 
controls as calibrator and 18s as endogenous control. Statistically significant 



















Figure 4.11 Cell viability and Hif-1α expression in primary neuronal culture 
transfected with anti and pre miR-335 during reperfusion following OGD. (A) 
miR-335 expression is significantly increased in the presence of pre miR-335 (p < 
0.01) and significantly decreased when cells were transfected with anti miR-335 (p < 
0.01) during reperfusion. Expression value was calculated as relative expression 
compared to vehicle transfected controls. Cells transfected with pre miR-335 during 
reperfusion after OGD showed significantly decreased Hif-1α expression compared to 
cells subjected to OGD and transfected with vehicle; (B) Cells transfected with pre 
miR-335 demonstrated significantly reduced cell death compared to cells subjected to 
OGD and transfected with vehicle (p < 0.05). Relative expression (2-
ΔΔ
Ct) was 
calculated based on vehicle transfected controls as calibrator and 18s as endogenous 
control. Statistically significant differences are tested at p < 0.05 significance. *p < 






(0.022 ± 0.03; Figure 4.11A) and resulted in a significant elevation in Hif-1α 
mRNA expression (Figure 4.11A), exhibiting similar viability as OGD control 
(Figure 4.11B). Altogether, these findings highlighted miR-335 as a modulator 
of Hif-1α expression which could be fine-tuned to improve cell viability 
during OGD in vitro.   
 
4.7 Pre miR-335 reduces infarct volume by reducing Hif-1α and its 
downstream genes  
Having established that miR-335 could directly regulate Hif-1α and therefore 
improve cell viability in OGD conditions (in vitro), the next attempt was to 
investigate whether such regulation was reflected in an in vivo setting. The 
miRNA-335 expression was studied in eMCAo model at the observed time 
points by realtime PCR (Table 4.4). Pre miR-335 was administered in vivo via 
ICV injection to ischemic rats within 1hr after embolus insertion (n=4). Pre 
miR-17 was selected as a positive control in this in vivo setting since miR-17 
has been validated to target HIF-1α and also seems to be a stronger regulator 
than miR-20a and miR-93 despite sharing the same seed region (Figure 4.8). 
Brain samples were harvested at 24hr post occlusion and the mean infarct 
volumes were measured for each experimental category as indicated in Figure 
4.12. Administration of pre miR-335 could reduce the infarct volume by 60% 
while administration of pre miR-17 showed no significant changes in infarct 








Table 4.4 Quantitative stem-loop RT-PCR of miRNA-335 at observed time 
points in ipsilateral brain samples of eMCAo rats. Data presented as mean ± SD (n 
=3). Relative expression (
ΔΔ
Ct ) was calculated based on eMCAo controls as 
calibrator and 18s as endogenous control. Statistically significant differences are 
tested at p < 0.05 significance. *p < 0.05, **p<0.01. 
   
Time (hr) miR-335 relative 
expression 
Time (hr) miR-335 relative 
expression 
0 0.89 ± 0.03* 48 0.69 ± 0.05** 
3 0.66 ± 0.06** 72 0.60 ± 0.01** 
6 0.57 ± 0.03** 120 0.78 ± 0.01* 
12 0.88 ± 0.04* 168 0.93 ± 0.01 
24 1.15 ± 0.01*   
 
 
Figure 4.12 Analyses of brain sections of eMCAo rats injected with pre miR-17 
and -335. Histological analysis of brain sections. TTC stained coronal brain sections 
(2 mm thick) of rats injected with 50 pmoles of pre miR-335 or pre miR-17 after 
eMCAo. ICV injections were given within 1hr after embolus. Surviving cells stained 
pink while dead cells remained white. Infarct volume of rats treated with eMCAo + 
pre miR-335 or pre miR-17. Infarct volumes are expressed as a percentage of the 
vehicle ± SEM, n = 4. Statistically significant differences are tested at p < 0.05 





4.8 Realtime was used to quantify the expression of miRNAs and genes in 
brain samples treated by pre miR-335  
Ischemic brain slices of rats treated by pre miR-335 were collected and total 
RNA was extracted from these brain slices (section 2.2.3.1). The concentration 
and integrity of RNA were determined using RNA gel electrophoresis (section 
2.2.4.1). The integrity of small RNA species (miRNAs) was verified using 
denaturing gel (15% polyacrylamide) electrophoresis (section 2.2.4.2). 
Realtime PCR was used to quantitation of the expression of miR-335, Hif-1α 
and its downstream genes; Bnip3, Aqp4, Aqp9, Mmp9 and Vegfa expression in 
pre miR-335 injection samples. As expected, introduction of miR-335 mimics 
significantly increased miR-335 expression by about 5.97 ± 0.08 fold 
(compared with sham control) while Hif-1α level was reduced by almost 40% 
(relative expression 0.58 ± 0.05 ) (Figure 4.13). Since Hif-1α is known as a 
master transcription factor in hypoxic condition, its indirect effects of 
modulating miR-335 expression on the downstream genes in this eMCAo 
model were examined. The expression of Bnip3, Aqp4, Aqp9, Mmp9 and 
Vegfa genes were verified since they are reported to be regulated by HIF-1α 
during brain ischemic injuries. Downregulation of Hif-1α due to the 
introduction of miR-335 mimics was found to inhibit the expression of most of 
its downstream genes, with the exception of Aqp-4 and Aqp-9 (Figure 4.13). 
Since these genes are also important key players in cerebral ischemia, it is 
possible that the overall changes in their expression synergistically contribute 
to bringing about the beneficial effect of miR-335 in reducing the infarct 












Figure 4.13 Analyses of Hif-1α and its downstream genes expression of eMCAo 
rats injected with pre miR-335. Hif-1α mRNA expression significantly decreased in 
pre miR-335 injection samples (p < 0.01). Bnip3, Mmp9 and Vegfa mRNA 
expressions were significantly downregulated in the pre miR-335 injection samples. 
Aqp4 and Aqp9 mRNA expression did not reduced in pre miR-335 injection samples. 
Relative expression (2-
ΔΔ
Ct) was calculated based on vehicle controls as calibrator 
and 18s as endogenous control. Each gene was measured two times by realtime PCR 
in triplicates. Statistically significant differences are tested at p < 0.05 significance. * 












5      MIRNA PROFILING IN BLOOD SAMPLES OF STROKE    
        PATIENTS  
 
5.1    Introduction 
Previously, the changes in miRNA expression in rats subjected to cerebral 
ischemia have been described (Chapter 3). Specifically, miR-335 has been 
found as a potential therapeutic target that control Hif-1α expression in 
cerebral ischemia (Chapter 4). Nonetheless, experimental data are only useful 
when proven to be translatable in a clinical setting. Therefore, it was necessary 
to look into the changes in miRNA expression in the blood samples of 
ischemic stroke patients.  
For several decades, gene microarray technology has been used to study 
various human diseases [262, 263]. So far, gene expression profiling has been 
extensively studied in the field of cancer in which they can be used for the 
classification of several cancer subtypes [264] and also as prognostic markers 
[265, 266]. In neurological diseases, mRNA microarray has been used to 
profile changes in mRNA expression in epilepsy [267], migraine [268], 
Tourette‘s syndrome [269] as well as stroke [270]. The first gene expression 
profile of acute ischemic stroke patients was demonstrated by Moore et al in 
2005 which was done on peripheral blood mononuclear cells (PBMNs). In this 
study, 190 genes were shown to be significantly dysregulated between the 
ischemic stroke and control groups. Among them, 22 genes were identified as 
crucial for cerebral ischemia in relation to white blood cell activation and 
differentiation as well as those associated with hypoxia and vascular repair 





ischemic stroke onset in several leukocyte subsets of the blood, including 
neutrophils, monocytes, B cells, CD4+ helper T cells, CD8+ cytotoxic T cells 
and natural killer cells of ischemic stroke patients. They found that changes in 
gene expression occurred within 5hr in most patients after ischemic stroke 
[270]. Subsequently, the group reported that mRNA expression could be used 
as a signature to differentiate stroke subtypes. They found that expression 
profile of mRNAs in the blood of cardioembolic stroke patients is distinctive 
from those of large artery stroke patients [272]. Seventy-seven genes were 
significantly dysregulated by at least 1.5-fold and a minimum number of 23 
genes could be used to differentiate large artery stroke from cardioembolic 
stroke with 95.2% specificity and 95.2% sensitivity respectively [272]. They 
also indentified that genes regulated in large-artery stroke are mainly 
expressed in platelets as well as monocytes. Genes regulated in cardioembolic 
stroke mainly function in modulating immune responses to infectious stimuli 
[272]. Subsequent study demonstrated that a group of 41 genes could be used 
to discriminate lacunar from nonlacunar stroke with > 90% sensitivity and 
specificity. Most of these genes were involved in immune response [273] 
during the acute phase of stroke. Thereafter, Jickling et al [274] predicted the 
cause of cryptogenic stroke by using gene expression profiling in conjunction 
with a measurement of infarct location. These studies indicated that cerebral 
ischemia triggered large amount of gene expression changes, which may be 
used for ischemic stroke diagnosis and treatment.   
miRNA microarray has been used to detect the miRNA expression upon 
diseases such as cancer, cardiovascular diseases and stroke. miRNA profiling 





mRNA profiles and thus may enable better diagnosis [275]. miRNA profiling 
of stroke patients was first studied by Tan et al [190] by using the whole 
patients' peripheral blood. In this study, 157 miRNAs were found to be 
significantly dysregulated in the blood samples of ischemic stroke patients. 
Among them, 138 miRNAs were highly expressed and 91 miRNAs were 
poorly expressed. The observed dysregulation of miRNA expression implied 
that changes in miRNA expression could reflect cerebral pathogenesis and 
hence could be considered as potential biomarkers for stroke diagnosis, 
prognosis as well as targets for treatment. Interestingly, they found that like 
mRNA profiling, miRNA profiling could differentiate large artery stroke from 
small vessel stroke. They also found that miRNA profiling could be used to 
discriminate good and poor outcomes of ischemic stroke evaluated by 
Modified Rankin Score (mRS) which was not reported in mRNA profiling 
studies previously. Subsequent study by Tan et al [276] reported miRNA 
profiling in no risk factor stroke patients and demonstrated that miRNAs could 
differentiate non risk stroke patients from those with risk factors. So far, 
miRNA expression study in stroke patients is only limited to atypical patients 
such as young stroke patients with no risk factors [190, 276]. As majority of 
stroke patients are elderly and suffering from the effects of several risk factors, 
an investigation on the gene expression profile is deemed necessary. Hence, a 
miRNA profiling to look at the expression pattern in the acute and recovery 
phases of stroke progression in these patients was carried out in this study. 
Since these patients mainly belong to large artery and small vessel stroke 
subtypes, miRNAs that may be potentially useful in differentiating stroke 





These miRNAs could therefore be useful as biomarkers for the diagnosis of 
stroke subtypes, especially at the early stages of stroke.   
 
5.2 Clinical characteristics of patients under study 
Sixty two (Asian ethnicity) stroke patients admitted to the Stroke Unit at the 
National University Hospital were recruited for the study. The study protocol 
included a standard neurological evaluation with subsequent review and 
follow up review for the outpatients. Blood samples of ischemic stroke 
patients were collected at the following time points:  a) 2 to 10 days after 
admission (baseline), b) after three months (month 3) and c) after twelve 
months (month 12) from the onset of stroke. Ischemic stroke was confirmed 
with MRI scan of the brain. Demographic data for all patients were recorded 
accordingly (Table 5.1). Risk factors, if any, were defined in the following 
manner; Hypertension, blood pressure (BP) above 140/90 mmHg; 
Hyperlipidemia, total cholesterol level ≥ 6.2 mmol/l; triglyceride levels ≥ 1.8 
mmol/l and HDL ≤ 1 mmol/l; Diabetes mellitus, elevated fasting blood 
glucose ≥ 7.0 mmol/l, 2hr post pandrial glucose ≥ 11.1 or HbA1c ≥ 6.5%; 
Transient ischemic attack (TIA), according to symptoms and CT or MRI 
diagnosis. mRS [277] was evaluated upon admission and at month 3 while 
collecting blood samples. Stroke events were classified according to the 
TOAST classification [7] namely, a) Large-artery atherosclerosis (n = 34) and 
b) Small-vessel disease (lacunar) (n = 28). Healthy controls without risk 










Table 5.1 Demographic data of study participants. Study participants were 
categorized as large artery and small vessel stroke. Eighteen healthy people were used 
as control. Values are mean ± SD. Statistically significant differences are tested at p < 
0.05 significance versus control, denoted by*. 
 






Mean Age (years) 58.59±10.18* 60.86±9.86* 40.27±7.8 
Hypertension (%) 28 (82.35%) 25 (89.29%) 0% 
Diabetes (%) 15 (44.12%) 10 (35.71%) 0% 
Hyperlipidemia (%) 27 (79.41%) 21 (75%) 0% 
Prior Stroke or TIA 2 (5.88%) 6 (21.43%) 0% 
Atrial Fibrillation (%) 1 (2.94%) 0 0% 
Ischemic heart 
diseases(%) 
3 (8.82%) 2 (7.14%) 0% 
Mean mRS upon 
admission 
NA 
Mean mRS at month 3   NA 
0-1 18 (52.94%) 21 (75%)  
2 or above 7 (20.59%) 1 (3.57%)  















5.3 miRNA profiling in the whole blood of stroke patients and controls  
Total RNA (+small RNA) was extracted from the blood samples and their 
concentration as well as quality were determined as described in section 
2.2.6.2 and section 2.2.7.2.  miRNA microarray based on  miRBase version 19 
was performed according to section 2.2.22. A total of 78 miRNA microarrays 
was generated from 62 patients.  
Seven hundred and ninety miRNAs were detected in the peripheral blood of 
human ischemic stroke patients and control. By comparing all stroke samples 
(n = 78) with control (n = 18), 463 significantly expressed miRNAs fulfilling 
the following selection criteria: false discovery rate (FDR) and p value < 0.05, 
fold change > 1.2 or < -1.2 were obtained. Hierarchical clustering of these 463 
miRNA profiles demonstrated that stroke samples were clustered together and 
separated from control samples (Figure 5.1). Among these 463 miRNAs, 252 
miRNAs were upregulated (shown in red) and 211 miRNAs were 
downregulated (shown in green) compared to control (Figure 5.1). Extensive 
changes in miRNA expression upon ischemic stroke highlighted their 
immense implication in cerebral ischemia. To observe how miRNA expression 
changes as stroke progresses, the miRNA expression at each different stages 
of stroke; at baseline (n = 31), month 3 (n = 36) and month 12 (n = 11) to that 
of healthy control (n = 18) was compared. The number of differentially 
expressed miRNAs remained more or less same at all three stages of stroke 












Figure 5.1 Hierarchical clustering of 463 miRNA profile. A total of 463 miRNAs 
was differentially expressed (p < 0.05) in all stroke samples (n = 78) when compared 
with the healthy controls (n = 18). The heat map shows a neat cluster of the stroke 
patients separated away from the healthy controls. Red, upregulated miRNAs; green, 













differential expression at baseline (Figure 5.2) while miRNA profiling of the 
month 3 samples resulted in 415 differentially expressed miRNAs (Figure 5.3). 
Interestingly, the number of dysregulated miRNAs decreased to 356 at month 
12 (Figure 5.4). The gradual decrease in the number of dysregulated miRNAs 
could reflect the recovery process taking place in the patients over prolonged 
period of time. Most importantly, individual hierarchical clustering analysis of 
each stage displayed distinct miRNA profiles of stroke patients that were 
different from the healthy controls.  
 
5.4 miRNA expression in large artery stroke   
Having observed the miRNAs that displayed significant difference in 
expression between stroke samples and healthy controls, their differential 
expression in different stroke subtypes, specifically large artery and small 
vessel stroke have been examined. These miRNA profiles could be useful in 
demonstrating the features of stroke subtypes and hence help in differentiating 
different stroke subtypes. Firstly, large artery stroke was examined as it is the 
most common stroke subtype. By applying the same selection criteria as 
before (FDR and p value < 0.05, fold change > 1.2 or < -1.2), the significantly 
expressed miRNAs at baseline (n = 14), month 3 (n = 23) and month 12 (n = 9) 
samples of large artery stroke (versus control n = 18) have been identified 
(Figure 5.5A, 5.5B, 5.5C). Hierarchical clustering of miRNAs identified at 
baseline (402 miRNAs), month 3 (391 miRNAs) and month 12 (430 miRNA) 
again showed the miRNA profiles of the stroke patients grouped away from 
the healthy controls (Figure 5.6). Similar pattern was observed for month 3 











Figure 5.2 Hierarchical clustering of 432 miRNA profile. At baseline (n = 31), a 
total of 432 miRNAs was differentially expressed (p < 0.05) as compared to that of 
healthy controls (n = 18). The heat map shows a neat cluster of the stroke patients 
separated away from the healthy controls. Red, upregulated miRNAs; green, 

















Figure 5.3 Hierarchical clustering of 415 miRNA profile. At month 3 (n = 36), a 
total of 415 miRNAs was differentially expressed (p < 0.05) as compared to that of 
healthy controls (n = 18). The heat map shows a neat cluster of the stroke patients 


















Figure 5.4 Hierarchical clustering of 356 miRNA profile. At month 12 (n = 11), a 
total of 356 miRNAs was differentially expressed (p < 0.05) as compared to that of 
healthy controls (n = 18). The heat map shows a neat cluster of the stroke patients 




















Figure 5.5 Scatter plots of miRNA expression at baseline, month 3 and month 12 
of large artery stroke (versus control). miRNAs were selected based on the fold 
change cutoff at > 1.2 or < -1.2 shown in red and green respectively. (A) Scatter plot 














Figure 5.6 Cluster plot of 402 miRNAs of the large artery stroke samples (n = 14) 
at baseline as compared to healthy controls (n = 18). Hierarchical clustering of 
miRNA profiling data showed that the control samples were separated from large 


















Figure 5.7 Cluster plot of 391 miRNAs of the large artery stroke samples (n = 23) 
at month 3 as compared to healthy controls (n = 18). Hierarchical clustering of 
miRNA profiling data showed that the control samples were separated from large 




















Figure 5.8 Cluster plot of 430 miRNAs of the large artery stroke samples (n = 11) 
at month 12 as compared to healthy controls (n = 18). Hierarchical clustering of 
miRNA profiling data showed that the control samples were separated from large 














large artery samples showed 214 miRNAs to be upregulated and 188 
downregulated miRNAs. At month 3, there were 200 upregulated and 191 
downregulated miRNAs while at month 12, 230 miRNAs with increased 
expression and 200 downregulated miRNAs could be observed. 
In order to gain a better understanding of the function of these dysregulated 
miRNAs, pathway analysis was done on all the three group of samples 
(baseline, month 3 and month 12), after which the top ten pathways have been 
shortlisted. The top ten pathways for each group of samples are summarized in 
Table 5.2.  
Among them, nine pathways involving Wnt signaling pathway, morphine 
addiction, basal cell carcinoma, focal adhesion, hedgehog signaling pathway, 
endocytosis, GABAergic synapse, axon guidance, glutamatergic synapse were 
common for all three groups. Phosphatidylinositol signaling system pathway 
was unique for large artery baseline while mRNA surveillance pathway was 
identified only in large artery month 3 and month 12 samples. 
Phosphatidylinositol signaling pathway can activate cellular signaling via 
secondary messagers such as inositol-1,4,5-trisphosphate (IP3), and 
diacylglycerol (DG). IP3 can activate Ca
2+
 channels and lead to Ca
2+
 release 
from the cellular store, which is one of the major causes of excitotoxicity in 
cerebral ischemia. Furthermore, Phosphatidylinositol signaling pathway is also 
involved DNA damage and repair process that occur in the early phase of 
ischemic stroke [210]. mRNA surveillance pathway is utilized by organisms to 
ensure fidelity and quality of mRNA molecules in the translation of mRNA 
transcripts into proteins. Hence, the activation of this pathway will be 





Table 5.2 Top ten pathways related to the dysregulated miRNAs observed at 
baseline, month 3 and month 12 of large artery stroke. Significantly expressed 
miRNAs (FDR and p value < 0.05, fold change > 1.2 or < -1.2) were selected for 
pathway analysis. 
Pathway Name 
(large artery baseline top ten pathway) 
Enrichment Score Enrichment  
p value 
Wnt signaling pathway 22.8721 1.16625E-10 
Morphine addiction 12.4444 3.93964E-06 
Basal cell carcinoma 12.0545 5.81853E-06 
Focal adhesion 10.7779 2.08557E-05 
Hedgehog signaling pathway 10.1259 4.00303E-05 
Endocytosis 10.0326 4.39452E-05 
GABAergic synapse 9.99104 4.58087E-05 
Axon guidance 9.92037 0.000049163 
Glutamatergic synapse 9.71547 6.03427E-05 
Phosphatidylinositol signaling system 9.16576 0.000104559 
Pathway name  
(large artery month 3 top ten pathway) 
Enrichment Score Enrichment  
p value 
Wnt signaling pathway 23.1638 8.71145E-11 
Morphine addiction 12.9629 2.34571E-06 
Basal cell carcinoma 12.4699 3.84041E-06 
Endocytosis 10.8439 1.95243E-05 
Hedgehog signaling pathway 10.4974 2.76078E-05 
mRNA surveillance pathway 9.54708 7.14097E-05 
Axon guidance 9.21576 9.94596E-05 
Focal adhesion 8.85852 0.000142166 
GABAergic synapse 8.65942 0.000173485 
Glutamatergic synapse 8.38376 0.000228549 
Pathway name  
(large artery month 12 top ten pathway) 
Enrichment Score Enrichment  
p value 
Wnt signaling pathway 24.072 3.51297E-11 
Morphine addiction 12.6743 3.13055E-06 
Basal cell carcinoma 11.6733 8.51847E-06 
Hedgehog signaling pathway 9.78543 5.62653E-05 
Axon guidance 9.32529 8.91409E-05 
Endocytosis 9.30593 9.08838E-05 
Glutamatergic synapse 9.1797 0.000103111 
GABAergic synapse 8.96902 0.000127293 
mRNA surveillance pathway 8.63187 0.000178331 










5.5 miRNA expression in small vessel stroke  
Similar analysis on the small vessel stroke samples were performed to 
compare the three different stages; baseline (n = 17), month 3 (n = 13) and 
month 12 (n = 2) with healthy controls (FDR and p value < 0.05, fold change > 
1.2 or < -1.2) (Figure 5.9A and B). Due to the small sample number for month 
12 group (n = 2), they were excluded in the subsequent analysis for the time 
being. A total of 393 and 365 miRNAs were found to be significantly 
expressed in small vessel at baseline and month 3 respectively when compared 
to controls. Individual hierarchical clustering of miRNA profiles from the two 
groups could differentiate small vessel baseline and month 3 samples from 
control samples (Figure 5.10, 5.11). 221 and 205 miRNAs were found to be 
upregulated at baseline and month 3 small vessel stroke samples compared to 
control respectively whist 172 and 160 miRNAs were downregulated in these 
two stages respectively.  
Pathway analysis on the differentially expressed miRNAs identified from the 
two groups of small vessel stroke samples resulted with top ten pathways as 
listed in Table 5.3. Nine pathways were observed to be common in both 
groups and they were Wnt signaling pathway, morphine addiction, 
glutamatergic synapse, basal cell carcinoma, GABAergic synapse, endocytosis, 
hedgehog signaling pathway, focal adhesion, axon guidance, implying their 
importance in the progression of small vessel stroke. mRNA surveillance 
pathway was unique for small vessel baseline stage while retrograde 
endocannabinoid signalling was unique for small vessel month 3 stage. It is 
well known that large artery stroke is usually more severe than small vessel 











Figure 5.9 Scatter plots of miRNA expression at baseline and month 3 of small 
vessel stroke (versus control). miRNAs were selected based on the fold change 
cutoff at > 1.2 or < -1.2 shown in red and green respectively. (A) Scatter plot of 
















Figure 5.10 Cluster plot of miRNA profiles from small vessel stroke samples at 
baseline. A total of 393 miRNAs was significantly expressed by comparing small 
vessel baseline samples (n = 17) and control (n = 18). Hierarchical clustering of 
miRNA profiling data showed that the control samples were separated from small 

















Figure 5.11 Cluster plot of miRNA profiles from small vessel stroke samples at 
month 3. A total of 365 miRNAs was significantly expressed by comparing small 
vessel month 3 samples (n = 13) and control (n = 18). Hierarchical clustering of 
miRNA profiling data showed that the control samples were separated from small 
















Table 5.3 Top ten pathways related to the dysregulated miRNAs observed at 
baseline and month 3 of small vessel stroke. Significantly expressed miRNAs 




(small vessel baseline top ten pathway) 
Enrichment Score Enrichment  
p value 
Wnt signaling pathway 22.3945 1.88023E-10 
Morphine addiction 13.6688 1.15804E-06 
Basal cell carcinoma 11.6004 9.16197E-06 
Endocytosis 10.4012 3.03948E-05 
Focal adhesion 9.94541 4.79474E-05 
GABAergic synapse 9.81873 5.44227E-05 
Hedgehog signaling pathway 9.69263 6.17368E-05 
mRNA surveillance pathway 9.51892 7.34488E-05 
Glutamatergic synapse 9.28772 9.25535E-05 
Axon guidance 9.17993 0.000103088 
Pathway name  
(small vessel month 3 top ten pathway) 
Enrichment Score Enrichment  
p value 
Wnt signaling pathway 22.8989 1.13537E-10 
Morphine addiction 15.116 2.72405E-07 
Glutamatergic synapse 12.0991 5.56449E-06 
Basal cell carcinoma 11.2596 1.28828E-05 
GABAergic synapse 11.0369 1.60968E-05 
Endocytosis 10.6067 2.47497E-05 
Hedgehog signaling pathway 10.1356 3.96412E-05 
Focal adhesion 10.1146 0.000040486 
Axon guidance 9.95281 4.75936E-05 













baseline of small vessel stroke and in large artery month 3 stage may implicate 
small vessel stroke starts recovering earlier than large artery stroke.  
 
5.6 miRNAs that differentiate large artery and small vessel subtypes in 
acute phase of ischemic stroke 
Up to now, miRNA profiling results showed that stroke condition could be 
easily differentiated at (a) different time points (baseline to month 12) and (b) 
according to different subtypes of stroke (large artery and small vessel stroke). 
Clinically, large artery stroke is characterized to be more severe compared to 
small vessel stroke. Accurate clinical classification of stroke subtypes is 
important in order to deliver an optional intervention. The ability of miRNA 
profiling to do this will therefore be very useful in clinical applications. Hence, 
the miRNA expression profiles at baseline of large artery and small vessel 
samples were further examined carefully. Although a large number of 
significantly expressed miRNAs (294 miRNAs) was commonly found in large 
artery and small vessel, only about 105 and 96 miRNAs that were specific for 
large artery and small vessel respectively could be identified (Figure 5.12).  
Among the 105 miRNAs specific for large artery baseline, 55 miRNAs were 
upregulated and 50 miRNAs were downreuglated (Figure 5.13). By applying a 
more stringent fold change cutoff of 5, 16 significantly upregulated miRNAs 
(hsa-miR-10b-3p, -19a-5p, -1208, -1269a, -1288, -214-5p, -299-5p, -302a-5p, 
-302b-5p, -33a-3p, -520e, -526b-3p, -548h-5p, -548k, -590-3p and -9-5p) and 
6 significantly downregulated miRNAs (hsa-miR-7b-3p, -132-5p, -1267, -









Figure 5.12 Venn diagram showing the number of miRNAs with significant 
changes among the large artery and small vessel stroke samples at baseline. A 
total of 402 and 393 miRNAs were significantly expressed at baseline between large 
artery and small vessel samples respectively from that of control. Among them, 297 
miRNAs were common for both large artery and small vessel stroke. 105 miRNAs 
have been found to be specific for large artery baseline while 96 miRNAs have been 




















Figure 5.13 Scatter plots of 105 miRNAs specific for large artery at baseline. 105 
miRNAs were significantly dysregulated in large artery stroke versus control and 
specific for large artery. Among them, 55 miRNAs were upregulated (red color) and 
50 were downregulated (green color). These miRNAs demonstrated different 











large artery specific miRNAs demonstrated an opposite expression profile in 
small vessel at baseline. These miRNAs were hsa-miR-1, -27a-3p, -27a-5p, -
429, -485-3p, -504, -519a-3p, -569 and -601 (Table 5.4). These miRNAs may 
also be used as potential biomarker to discriminate large artery from small 
vessel in stroke at baseline.  
Among the 96 miRNAs specific for small vessel stroke at baseline, 60 
miRNAs were upregulated and 36 miRNAs were downreuglated (Figure 5.14). 
A fold change of 5 was used as the cutoff. 15 significantly upregulated 
miRNAs (hsa-miR-1185-5p, -152, -367-3p, -372, -432-3p, -448, -486-3p, -
513c-5p, -515-3p, -520g, -586, -627, -648, -760 and -924,) and 4 significantly 
downregulated miRNAs (hsa-miR-135b-5p, -296-3p, -643 and -876-3p) were 
selected (Table 5.5). Another 12 miRNAs specific for small vessel at baseline 
but showing opposite expression in large artery samples at baseline (hsa-let-
7f-2-3p, has-miR-125a-3p, -1307-3p, -1827, -200b-3p, -30c-2-3p, -34c-3p, -
338-5p, -450b-5p, 518c-5p, -519e-5p and -675-3p) have also been selected 
(Table 5.5). These miRNAs may also be used as potential biomarkers to 
discriminate large artery from small vessel in stroke at baseline. 
 
5.7 miRNAs that differentiate large artery and small vessel subtypes 
during recovery phases of ischemic stroke  
miRNA expression analysis from samples representing the recovery phases 
month 3 and month 12 of large artery and small vessel stroke was carried out 
as a separate study. In month 3, there were 391 and 365 miRNAs significantly 













Table 5.4 miRNAs selected to differentiate large artery and small vessel stroke 
subtypes at baseline. miRNAs specific for large artery stroke demonstrated 
upregulation > 5 fold (red), downregulation < -5 fold (green) and opposite expression 
(bold and italic) compared to small vessel stroke were selected. FC, fold change; 
LABL, large artery baseline; SVBL, small vessel baseline. 
 
miRNAs FC(LABL vs. control) FC(SVBL vs. control) Description 
miR-10b-3p 24.484 1.32485 up > 5 FC 
miR-19a-5p 8.34484 3.13806 up > 5 FC 
miR-1208 8.80438 1.24414 up > 5 FC 
miR-1269a 7.17764 1.60878 up > 5 FC 
miR-1288 6.59328 1.70456 up > 5 FC 
miR-214-5p 6.8625 1.80165 up > 5 FC 
miR-299-5p 9.82243 3.14648 up > 5 FC 
miR-302a-5p 6.6149 2.07946 up > 5 FC 
miR-302b-5p 8.70514 2.41546 up > 5 FC 
miR-33a-3p 5.74257 1.12606 up > 5 FC 
miR-520e 9.64331 3.19142 up > 5 FC 
miR-526b-3p 10.0615 1.84443 up > 5 FC 
miR-548h-5p 10.8577 2.37978 up > 5 FC 
miR-548k 18.836 1.37177 up > 5 FC 
miR-590-3p 13.0209 1.03215 up > 5 FC 
miR-9-5p 7.22832 2.17434 up > 5 FC 
let-7b-3p -5.49713 -1.48135 down < -5 FC 
miR-132-5p -5.53454 -1.60247 down < -5 FC 
miR-1267 -6.77478 -1.00935 down < -5 FC 
miR-1272 -7.29481 -1.34455 down < -5 FC 
miR-600 -6.80448 -2.24963 down < -5 FC 
miR-99a-5p -7.34861 -1.73052 down < -5 FC 
miR-1 4.05513 -1.8296 opposite expression 
miR-27a-3p -6.56504 1.27955 opposite expression 
miR-27a-5p -3.28305 1.27889 opposite expression 
miR-429 3.82999 -1.96479 opposite expression 
miR-485-3p -3.03798 1.07546 opposite expression 
miR-504 -13.5383 1.58798 opposite expression 
miR-519a-3p -5.90393 1.1397 opposite expression 
miR-569 6.93352 -1.10582 opposite expression 















Figure 5.14 Scatter plots of 96 miRNAs specific for small vessel at baseline. 96 
miRNAs were significantly dysregulated in small vessel stroke versus control and 
specific for small vessel. Among them, 60 miRNAs were upregulated (red color) and 
36 were downregulated (green color). These miRNAs demonstrated different 





















Table 5.5 miRNAs selected to differentiate large artery and small vessel stroke 
subtypes at baseline. miRNAs specific for small vessel stroke demonstrated 
upregulation > 5 fold (red), downregulation < -5 fold (green) and opposite expression 
(bold and italic) compared to large artery stroke were selected. FC, fold change. 
LABL, large artery baseline; SVBL, small vessel baseline. 
 
miRNAs FC(SVBL vs control) FC(LABL vs control) Description  
miR-1185-5p 5.78525 3.25051 up > 5 FC 
miR-152 7.70672 1.49699 up > 5 FC 
miR-367-3p 7.12094 1.81368 up > 5 FC 
miR-372 7.86437 2.46031 up > 5 FC 
miR-432-3p 6.05823 1.89966 up > 5 FC 
miR-448 6.99635 4.11717 up > 5 FC 
miR-486-3p 5.16894 1.47633 up > 5 FC 
miR-513c-5p 7.53013 2.3892 up > 5 FC 
miR-515-3p 7.71905 1.9568 up > 5 FC 
miR-520g 10.9615 1.88107 up > 5 FC 
miR-586 5.27046 2.01771 up > 5 FC 
miR-627 5.37155 2.39247 up > 5 FC 
miR-648 7.97108 1.40416 up > 5 FC 
miR-760 12.1204 2.39254 up > 5 FC 
miR-924 7.35645 2.7473 up > 5 FC 
miR-135b-5p -8.3809 -2.95552 down < -5 FC 
miR-296-3p -16.561 -1.07935 down < -5 FC 
miR-643 -6.65565 -1.45218 down < -5 FC 
miR-876-3p -6.88425 -2.42312 down < -5 FC 
let-7f-2-3p -3.70397 1.00626 down < -5 FC 
miR-125a-3p 2.79268 -1.73644 opposite expression 
miR-1307-3p 3.34296 -3.00988 opposite expression  
miR-1827 1.63615 -1.04559 opposite expression 
miR-200b-3p 2.65865 -1.78708 opposite expression 
miR-30c-2-3p 5.5785 -1.11047 opposite expression 
miR-338-5p -2.54743 1.2472 opposite expression 
miR-34c-3p -4.50347 1.20679 opposite expression 
miR-450b-5p 16.3056 -1.0759 opposite expression 
miR-518c-5p -3.13404 2.7422 opposite expression 
miR-519e-5p -3.12505 1.10695 opposite expression 











control. 289 miRNAs were found to be common for both large artery and  
control. 289 miRNAs were found to be common for both large artery and 
small vessel stroke at month 3 whist 102 and 76 miRNAs were specific for 
large artery and small vessel stroke at month 3 respectively (Figure 5.15).  In 
month 12, 146 miRNAs were found to be common for both large artery and 
small vessel while 284 miRNAs were found to be specific for large artery 
month 12 and only 2 miRNAs were found to be specific for small vessel 
month 12. This may be due to small sample size (Figure 5.16). These miRNAs 
specific for large artery and small vessel stroke subtypes in month 3 and 
month 12 may play an important role in ischemic stroke recovery and hence 
could be useful to study stroke recovery mechanism. 
5.8 miRNA expression at different time points in all stroke samples and 
stroke subtypes 
Up to now, miRNA expression has been studied in all stroke patients and 
different stroke subtypes at each time point (baseline, 3 month and 12 month). 
The miRNA expression changes were further studied as stroke progression 
(Figure 5.17A, B and C). It was observed that 273 miRNAs were significantly 
expressed across baseline (432), month 3 (415) and month 12 (356) when 
comparing the significantly expressed miRNAs of these three time points in 
all stroke samples. However, 39, 28 and 47 miRNAs were observed to be 
significantly expressed at only baseline, month 3 and month 12 respectively 
(Figure 5.17A). In large artery stroke, 274 miRNAs were found to be 
significantly expressed across all three time points whereas 32, 42 and 81 
miRNAs were found to be only significantly expressed at baseline, month 3 











Figure 5.15 Venn diagram showing the number of miRNAs with significant 
changes identified in the large artery and small vessel stroke samples at month 3. 
A total of 391 and 365 miRNAs were significantly expressed when compared to large 
artery and small vessel samples at month 3. Among them, 289 miRNAs were 
common for both large artery and small vessel stroke. 102 miRNAs have been found 
to be specific for large artery stroke at month 3 and 76 miRNAs have been found to 






















Figure 5.16 Venn diagram showing the number of miRNAs with significant 
changes identified in the large artery and small vessel stroke samples at month 
12. A total of 430 and 148 miRNAs were significantly expressed when compared to 
large artery and small vessel samples respectively at month 12. Among them, 146 
miRNAs were common for both large artery and small vessel stroke. 284 miRNAs 
have been found to be specific for large artery stroke at month 12 and only 2 miRNAs 























Figure 5.17 Venn diagram showing the comparison of miRNA expression across 
all three time points. Significantly expressed miRNAs were compared across all 
three time points (baseline, month 3 and month 12) in all stroke samples (A), large 










miRNAs were significantly expressed across all the time points whereas 83, 
54 and 5 miRNAs were only expressed at baseline, month 3 and month 12 
respectively (Figure 5.17C). These differentially expressed miRNAs across all 
the time points will be further studied to understand their functions. 
 
5.9 miRNAs commonly expressed in ischemic stroke models and human 
stroke patients 
So far, miRNA expression has been studied in ischemic stroke animal model 
and human stroke patients. miRNAs commonly expressed in both ischemic 
conditions were further studied. In previous study, miR-206 expression has 
been correlated to infarct volume and anti miR-206 could reduce infarct 
damage in eMCAo model, which implied that miR-206 may be a potential 
therapeutic target upon cerebral ischemia. miR-206 expression in blood 
samples of human stroke patients was further studied. It was found that miR-
206 expression decreased from baseline (2 to 10 days) to month 3 in large 
artery stroke (Figure 5.18A), small vessel stroke (Figure 5.18B) and all stroke 
samples (combination of large artery and small vessel stroke) (Figure 5.18C). 
miR-206 expression was significantly increased in small vessel baseline and 
all stroke baseline samples when compared to that of the corresponded month 
3. Since baseline and month 3 indicate the acute and recovery phases of 
human cerebral ischemia respectively, miRNA-206 expression pattern in 
human stroke patients is similar to that observed in ischemic rat model. Hence, 
miR-206 may also play an important role in human cerebral ischemia, which 








Figure 5.18 miR-206 expression in the blood of human stroke patients. miR-206 
expression in human stroke samples (A) large artery baseline (LABL) and month 3 
(LAM3). (B) small vessel baseline (SVBL) and month 3 (SVM3). miR-206 
expression in SVBL samples was significantly increased compared to that of SVM3 
(p < 0.05) (C) all stroke baseline (BL) and month 3 (M3). miR-206 expression in BL 
samples was significantly increased compared to that of M3 (p < 0.01). miR-206 
expression was present as fold change compared to control. Y-axis denotes the 
expression of miRNA-206 while x-axis indicates the studied baseline and month 3 
group patients. Black bar of each dot plot indicated the median value of miR-206 in 








The similar expression pattern of miR-206 in ischemic stroke animal models 
and human stroke patients may imply that miRNAs could have the common 
function in rodent and human cerebral ischemia. The three groups of miRNAs 
selected from ischemic stroke models (Chapter 3 Table 3.1) were further 
investigated in blood samples of large artery stroke patients at baseline and 
month 3. Among them, 17 miRNAs were found to be conserved in rats and 
humans and demonstrated the similar expression pattern in both samples from 
acute to recovery phases (Table 5.6). In the first group (Table 5.6 miRNAs 
highlighted in green), miR-196a-5p, -196b-5p, -26b-3p, -297 and -484 showed 
decreased expression from baseline to month 3 in large artery stroke samples. 
In the second group, the expression of miR-17-3p, -181d, -19a-3p, -19b-3p, -
196a-3p, -223-3p, -25-3p, -27b-3p, -374b-5p and -423-3p increased from  
baseline to month 3 in large artery stroke samples (Table 5.6 miRNAs 
highlighted in red). In the third group, miR-30c-1-3p and -877-5p were 
observed to decrease from baseline to month 3 in human stroke samples 
(Table 5.6 miRNAs highlighted in bold). These miRNAs were significantly 
expressed in both ischemic stroke model and human stroke patients‘ blood. 
The similar expression changes of these miRNAs in stroke animal model and 
human stroke patients from acute phase to recovery phase may suggest the 
similar roles they played in both condition. Hence these miRNAs could be 
brought for further study.    
The 105 miRNAs specific for large artery (Figure 5.13) were further 
investigated in ischemic stroke animal models. Among them, fifteen miRNAs 
were found to be conserved in rats and humans and showed either similar or 





(Table 5.7). miR-27a-5p and miR-299-5p displayed similar expression whist 
miR-129-1-3p, -138-1-3p, -196b-5p, -27a-3p, -29a-5p, -297, -340-3p, -429, -
542-5p, -7-1-3p, -9-5p, -92b-3p and -99a-5p showed opposite expression in 
corresponding time points of both samples (Table 5.7).  
 
Table 5.6 The expression of miRNAs selected from ischemic stroke models in 
human stroke patients. miRNAs demonstrated the similar expression pattern in rats 
and humans were shortlisted. The expression was presented as fold change versus 
control. Green color, miRNAs decreased from baseline to month 3; red color, 
miRNAs increased from baseline to month 3; bold, miRNA expression reflected the 
progression of infarct volume in ischemic stroke models decreased from baseline to 




(LABL vs control) 
Fold-Change 
(LAM3 vs control) 
miR-196a-5p 4.00895 2.4345 
miR-196b-5p 3.34316 2.62544 
miR-26b-3p 4.01641 2.98822 
miR-297 2.9256 1.5769 
miR-484 2.37399 1.55024 
miR-17-3p 1.41291 2.31573 
miR-181d 10.6726 16.0224 
miR-19a-3p 1.79772 1.84785 
miR-19b-3p 2.18617 2.45174 
miR-196a-3p -4.00222 -2.80163 
miR-223-3p 2.17837 2.30755 
miR-25-3p 1.54036 1.77809 
miR-27b-3p 10.3574 20.987 
miR-374b-5p 7.32186 8.30613 
miR-423-3p -1.93715 -1.85889 
miR-30c-1-3p -1.46893 -2.85058 












Table 5.7 The expression of miRNAs in ischemic stroke animal models and 
human stroke patients. miRNAs were selected from 105 miRNAs specific for large 
artery stroke and expression was presented as signal log ratio (SLR).  Red colour, 
upregulation; green colour, downregulation. Baseline, 2 – 10 days after stroke onset. 
 
miRNAs Ischemic stroke animal models Human patients 
24hr 48hr 72hr baseline 
miR-129-1-3p 0.233571 0.344058 0.240515 -3.34914 
miR-138-1-3p 0.406804 0.290964 0.424165 -6.53179 
miR-196b-5p -3.11605 -6.66555 -6.85638 3.34316 
miR-27a-5p -0.11074 -4.47359 -1.14085 -3.28305 
miR-27a-3p 0.619816 0.913482 1.23151 -6.56504 
miR-29a-5p 0.144561 0.369469 0.065616 -2.95094 
miR-297 -2.51383 -4.20277 -2.22134 2.9256 
miR-299-5p 1.55696 1.33873 0.535734 9.82243 
miR-340-3p 0.186921 0.554676 0.508601 -1.57938 
miR-429 -1.02353 -1.99816 -2.18898 3.82999 
miR-542-5p 2.86318 2.53379 2.5382 -4.50102 
miR-7-1-3p 0.121653 1.10856 0.51113 -3.9689 
miR-9-5p -0.128197 -0.306147 -0.497743 7.22832 
miR-92b-3p 0.300387 0.324459 0.153171 -1.79899 
















6    DISCUSSION 
 
6.1 Spontaneous recovery in ischemic stroke 
In this study, the temporal changes in miRNA expression in both acute and 
recovery phases were observed in embolic rat stroke models with spontaneous 
recovery. Spontaneous recovery is commonly observed clinically when stroke 
patients display improvement over several days. Maximum arm motor 
function can be achieved in patients (95%) within 9 weeks of stroke onset 
[278] whereas the final level of language function can be achieved (95%) by 6 
weeks post stroke [279]. Similar to our study, Lu et al [280] have observed a 
temporal gene expression profile upon cerebral ischemia at 30min, 4hr, 8hr, 
24hr, 72hr and 168hr in spontaneously recovering rats subjected to MCAo. 
Genes encoding axonal guidance, neurite outgrowth as well as dendritic 
growth and branching were found to improve the spontaneous recovery in 
ischemic stroke animal model [281]. Angiogenesis [282, 283] and 
neurogenesis [284, 285] have also been indicated to contribute to the recovery 
of ischemic stroke. This may imply that miRNAs could play important roles in 
ischemic stroke recovery by regulating gene expression.  
 
6.2 miRNA profiling study upon acute and recovery phases of eMCAo  
A temporal expression of miRNAs was displayed upon eMCAo from 0hr to 
168hr. Most of the miRNAs were found to be downregulated in the acute 
phase (0hr to 24hr) of cerebral ischemia. They became upregulated during the 
recovery phase (48hr to 168hr) (Figure 3.3). Three distinctive groups of 





upon ischemic stroke progression. These includes rno-miR-142-3p, -142-5p, -
146a, -15b, -17, -181d, -196a*, -199a-3p, -19a/b, -20a, -21, -223, -25, -27a/b, -
298, -338, -339-5p, -363*, -374, -382*, -423, -425, -743a and -760-5p. On the 
contrary, rno-miR-1*, -10a-5p, -10b, -18a, -20b-3p, -26b*, -96, -133a/b, -
196a/b/c, -224, -296*, -297,  -301b, -324-3p, -343, -380, -421, -448, -449, -
484, -501, -532-3p, -543 and -671 displayed decreased expression from 0hr to 
168hr. Furthermore, rno-miR-21*, -30c-1*, -206, -290, -291a-5p, -300-5p, -
503, -542-5p, -874 and -877 exhibited an expression profile that reflected the 
progression of infarct volume.   
Some of these miRNAs have been reported to function in cerebral ischemia in 
in vivo or in vitro studies, which supported the findings in this study. miR-21 
is known to be an oncogene and it promotes cancer cells proliferation by anti-
apoptosis. miR-21 expression was found to increase in neurons subjected to 
OGD and overexpression of miR-21 in cortical neurons substantially 
suppressed OGD-induced apoptotic cell death by targeting Faslg, a tumor 
necrosis factor-α family member as well as an important cell death-inducing 
ligand [286]. In our study, miR-21 expression continuously increased and was 
opposite to Faslg mRNA expression (Figure 3.8), which may suggest its 
beneficial function upon cerebral ischemia.  
miR-146a is known as an anti-inflammation miRNA by targeting Toll-like 
receptor signaling pathway [287]. Combination treatment of VELCANT and 
tPA demonstrated significantly reduced infarct volume accompanied by 
increase in miR-146a expression. miR-146a was proved to be neuroprotective 
by directly targeting interleukin-1 receptor–activated kinases 1 (Irak1) in this 





expression upon spontaneous recovery, which may imply that miR-146a is 
protective upon cerebral ischemia.   
miR-223 is well-known to be crucial in regulation of the maturation, 
proliferation, as well as differentiation of myeloid and lymphoid cells [288]. 
miR-223 expression was observed to consistently increase from 0 to 48hr 
during cerebral ischemia in several studies [188, 208, 209]. Recently, miR-223 
has been found to directly target glutamate receptor N-methyl D-aspartate 
receptor subtype 2B (NR2B) and Glutamate receptor 2 (GluR2). miR-223 
deﬁciency resulted in higher levels of NR2B and GluR2, enhanced NMDA-
induced calcium inﬂux, and increased excitatory postsynaptic currents in 
hippocampal neurons. In addition, the absence of miR-223 led to memory 
deﬁcits and increased neuronal cell death following transient cerebral ischemia 
[289]. This explains that miR-223 is neuroprotective during cerebral ischemia 
by targeting glutamate receptors. miR-223 demonstrated continuously 
increased expression upon ischemic stroke progression in this study, which 
may hint its neuroprotective function upon ischemic stroke recovery. 
miR-298 was reported to be upregulated in the brain after transient MCAo 
[188]. It was the only miRNA that was upregulated in both brain and blood 
after all three experimental conditions (ischemic stroke, intracerebral 
hemorrhage, and kainate seizures) identified by Sharp et al [191]. miR-298 
was recently shown to target β-amyloid precursor protein-converting enzyme-
1 (BACE1) and regulate BACE1 protein expression in cultured neuronal cells 
[290]. Since high level of BACE1 was related to Alzheimer disease (AD), it 
may imply the neuroprotective role of miR-298. In this study, miR-298 was 





ischemia progression, which may indicate that it also has a neuroprotective 
function. 
 
6.3 miRNAs in neuronal repair after ischemic stroke 
To understand the mechanism of spontaneous recovery observed in eMCAo 
model, pathway analysis was carried out. Regulation of actin cytoskeleton was 
found to be the highest pathway for both early and late time points. Actin is a 
globular multi-functional protein that forms microfilament and is the most 
abundant intracellular protein in eukaryotic cells [291]. Actin filaments are 
instrumental in all eukaryotic cells for regulating most cellular processes, 
including cell migration, division, and vesicle trafficking. In neurons, actin is 
major component of neuronal cell cytoskeleton [292]. Numerous studies have 
demonstrated the critical role of the actin cytoskeleton in neurite outgrowth, 
regeneration and synapse function [292]. Especially, dynamic remodeling of 
the actin cytoskeleton is thought to be the driving force behind structural 
alterations of dendritic spines [293, 294]. Dendrites play a fundamental role in 
cell-to-cell communication in the brain, as they are the postsynaptic targets of 
most synapses in the brain [295]. Dendritic spines are the recipients of most 
excitatory synapses in the brain, where they participate in the transmission and 
integration of synaptic signaling [296]. Dendrites and dendritic spines were 
immediately damaged upon acute cerebral ischemia [297, 298] Dendritic 
spines proliferation has been proved to be a potential mechanism of stroke 
recovery [299]. Therefore, regulation of actin skeleton pathway is important 





Neuronal repair characterized as angiogenesis, neurogenesis and 
synaptogenesis by activation of neuronal stem and precursor cells (NSC and 
NPC) [212] is the crucial step in cerebral ischemia recovery and miRNAs have 
been reported to function in neuronal repair upon cerebral ischemia [300]. 
Hedgehog, Notch, Wnt and TGF-β signaling pathways are all highly 
conserved pathways [301 - 304] and found to be responsible for fostering NSC 
and NPC proliferation, migration and differentiation to promote neuronal 
repair following ischemic stroke [213 - 218]. The genes of the above-
mentioned pathways were found to be dysregulated in this study, which 
indicated the participation of these pathways in cerebral ischemia and may 
contribute to neuronal repair. Hedgehog signalling pathway was ranked as one 
of the top four pathways in both early and late phases while TGF-β, Wnt and 
Notch signaling pathways ranked higher in the late phase of ischemic stroke 
with statistically significant enrichment p values (Table 3.4). Although the 
function of miRNAs in neuronal repair following cerebral ischemia is still 
unknown, their ability to regulate the above mentioned pathways have been 
demonstrated in cancer and cardiovascular diseases [305 - 308]. 
 
Neuronal repair process upon cerebral ischemia was predicted by using 
miRNAs and their validated mRNAs targets in selected four crucial pathways 
(Figure 3.7). The Pten gene was the common link between these four 
pathways. Notch signalling was known to activate Hedgehog pathway through 
PI3K/AKT and mTOR activation [215], which was also induced by TGF-β 
signaling. Pten, the inhibitor of PI3K/AKT, was targeted by miR-216 andmiR-





Wnt and TGF-β signaling [310, 311]. Therefore, these four pathways could 
cross-talk with each other to regulate neuronal repair.  
miRNA families such as miR-206/133b; miR-200a/141; miR-34a/449a; miR-
17-5p/18a were presented in the pathways, which implied that they may be 
working together to regulate neuronal repair mechanisms.  
miR-21, overexpressed in most tumor types, is known to act as an oncogene 
by targeting many tumor suppressor genes required for proliferation, apoptosis, 
and invasion [312]. It involved TGF-β/Smad signaling, β-catenin/STAT3 
signaling [311, 313] and genes like PTEN [312], Pdcd4 [314], Faslg [286], 
and RECK [311]. In this study, miR-21 was found to be significantly 
upregulated following cerebral ischemia, suggesting that it may play a similar 
role in cerebral ischemia as a NPC regulator. 
miR-34a was known to cause cell cycle arrest and apoptosis in cancer stem 
cells [315] via p53. miR-34a was also reported to target Notch signaling 
pathway to inhibit tumor stem cell invasion by directly binding to NOTCH1, 
DLL1 and JAG1 [316, 317] as well as Wnt signaling pathway by targeting 
WNT1 and WNT3 genes [316, 318] and TGF-β signaling pathway via Smad4 
[319]. In this study, Tp53 and miR-34a were found upregulated, hence could 
inhibit Notch, Wnt and TGF-β signaling by targeting Dll1, Jag1, Wnt1, Wnt3 
and Smad4. p53 was also reported to inhibit Hedgehog signaling [320], 
suggesting that p53 and miR-34a may function as negative regulators of NPC 
proliferation by inhibiting Notch, Wnt, Hedgehog and TGF-β signaling 
pathway following cerebral ischemia. Furthermore, as the same family 
member of miR-34a, miR-449a was reported to bring about cell cycle arrest 





[321, 322]. In this study, miR-449a was downregulated from 12hr to 168hr, 
suggesting that it may have a different role from that of miR-34a in regulating 
the neuronal repair processes in cerebral ischemia. 
 
6.4 Fibrosis in cerebral ischemia recovery 
miRNAs were identified to be involved in fibrosis following cerebral ischemia 
from miRNA profiling data. Fibrosis protects the host from an injurious event 
by deposition of matrix, disruption of the normal tissue architecture, and 
parenchymal destruction [323]. Astrocytes in the central nervous system 
become reactive in response to tissue damage leading to the formation of the 
glial scar. The damaged tissue scar formation in the injured brain is beneficial 
to limit the extension of damage. A cluster of miRNAs was found to be highly 
downregulated during recovery phase in this study (p < 0.05; Figure 3.7 
miRNAs bond and italic). A search for their validated targets showed that 
several of them (miR-18a, -133a/b, -141, -196a, -211, -324-3p and -449a) can 
be linked to fibrosis. Except for miR-324-3p [324], all of them have been 
found to be involved in TGF-β signaling pathway regulation. miR-449a also 
targeted WISP2 in Wnt signaling pathway (Figure 3.7). miR-21, -30c and -
200a were related to fibrosis by regulating extracellular matrix accumulation 
[215, 325, 326]. Guo et al [327] reported TGF-β and Wnt signaling pathways 
were involved in fibrosis. Doyle et al [328] also demonstrated that TGF-β 
increased reactive astrogliosis post stroke. In addition, Lu et al [280] proposed 
that decrease in infarct volume at 3 and 7 days of reperfusion following 





Therefore these two pathways may function in tandem to contribute to 
recovery following cerebral ischemia. 
 
6.5 HIF-1α as a potential target in cerebral ischemia  
 
6.5.1 miR-335 directly targets Hif-1α  
HIF-1α has been widely studied in different diseases and regarded as one of 
the major candidates for gene therapy. Although several miRNAs have been 
reported to target HIF-1α [251 - 257], these were mostly done in cancer cells 
and hence the interaction of miRNAs and Hif-1α in cerebral ischemia is still 
poorly understood. By in silico prediction, miR-17, -20a, -135a, -203, -335, -
338 and -93 that are conserved in human and rodent have been found to target 
HIF-1α. These miRNAs were also highly expressed in rat brain and 
significantly dysregulated upon cerebral ischemia. Among them, miR-17 and -
20a have been reported to directly regulate HIF-1α in lung cancer cells [251]. 
Among the other novel miRNAs, miR-335 that has two binding sites on the 
3'UTR of Hif-1a was found to be the most promising regulator of Hif-1a 
(Figure 4.8). Moreover, the modulation of miR-335 expression has been found 
to affect cell viability in an in vitro ischemic condition via regulation of Hif-1a 
(Figure 4.10 and 4.11). Overexpression of miR-335 (via introducing miR-335 
mimic) in primary neuronal cells subjected to OGD significantly reduced Hif-
1a expression and subsequently improved cell viability (Figure 4.11B and C). 
The findings from this study are in agreement with a previous study which 
indicated that Hif-1a siRNA could increase neuronal cells viability during 





loss of HIF-1α function in neurons could increase neuronal susceptibility to 
hypoxia-induced death which suggested the neuroprotective effect of HIF-1α 
in neuronal cells. Increasing its intricacy as the master transcription factor of 
hypoxia, HIF-1α was reported to have dual functions in cell death and survival 
depending on the affected cells and the type of injury [31, 330].  
 
6.5.2 miR-335 regulates Hif-1a in cerebral ischemia 
Although HIF-1α has been implicated as an important player in cerebral 
ischemia [244], its function is still unclear. miRNAs as the gene regulators 
have demonstrated crucial role in ischemic stroke [188, 331]. Nonetheless, 
how miRNAs regulate Hif-1α upon the onset of the ischemic cascade is still 
elusive. In this study, Hif-1a mRNA expression was found to increase from 
ischemic stroke onset and demonstrated a biphasic expression pattern which 
peaked at 6 and 72hr (Figure 4.1B) as reported by Yeh et al [20] and Baranova 
et al [19]. Administration of pre miR-335 was observed to inhibit Hif-1a 
expression and consequently reduced the infarct volume by 60%, in rodent 
stroke model (Figure 4.12). On the contrary, pre miR-17 did not reduce the 
infarct volume, suggesting that modulation by miR-335 to be more crucial in 
an ischemic setting. Several other studies have reported that inhibition of Hif-
1α could bring beneficial effect in cerebral ischemia. For instance, using the 
neuron-specific Hif-1a knock-out mice, Helton et al [247] found that Hif-1a 
deficiency mice demonstrated reduced infarct volume upon 75min bilateral 
common carotid artery occlusion with concurrent downregulation of 
proapoptotic genes. Chen et al [332] found that Hif-1α specific siRNA 





about the reduction of infarct volume in transient ischemic stroke model. 2-
methoxyestradiol (2-ME), a HIF-1α protein inhibitor [333] and hyperbaric 
oxygen [334] treatment could also inhibit HIF-1α in the acute phase of 
ischemic stroke respectively and hence bringing about beneficial effects.                            
Nonetheless, Baranova et al [19] found that neuron-specific knockdown of 
Hif-1α increased tissue damage and reduced the survival rate of mice 
subjected to 30min focal middle cerebral artery occlusion (MCAo), indicating 
that HIF-1α is neuroprotective in acute phase of ischemic stroke. The 
discrepancy could be explained based on the different experimental settings 
used such as different animal models and different occlusion times. In this 
study, an embolus to occlude the MCA was used, which created a permanent 
MCAo model without reperfusion post occlusion whereas the model Baranova 
et al [19] used resulted from transient occlusion of MCA for 30min with 
reperfusion. Helton et al [247] used a global ischemic stroke model by 
occluding bilateral common carotid artery for 75min.  Although Cheng et al 
[332] used the same intraluminal suture model as that of Baranova etal [19], 
they occluded the middle cerebral artery for a longer duration of 2hr.   
Reduction of Hif-1a expression by the introduction of pre miR-335 was 
accompanied with the regulation of the downstream genes Bnip3, Mmp9 and 
Vegfa and Aqp4 (Figure 6.1). Since none of the genes has a binding site for 
miR-335 at the 3'UTR, the changes in their expression were mostly 
attributable to the regulation of Hif-1a via miR-335 and not a direct effect of 
miR-335. The dysregulated expression of these genes could also contribute in 
reducing the infarct volume. HIF-1α was confirmed to increase the 





At the same time, BNIP3 has also been reported to be upregulated in the early 
phase of cerebral ischemia which could possibly contribute to apoptosis [19]. 
Increased expression of Bnip3 has also been observed in this study. HIF-1α 
can also transactivate Mmp9 by binding its promoter and increase Mmp9 
mRNA transcription [335]. MMP9 has been widely studied in cerebral 
ischemia and indicated to be detrimental in the acute phase of cerebral 
ischemia. MMP9 as a matrix metalloproteinase aggravates blood brain barrier 
(BBB) disruption [336], which could lead to intracranial hemorrhage after 
ischemic stroke. Furthermore, MMP9 can be activated by endogenous or 
exogenous t-PA and aggravate t-PA induced side effects such as cerebral 
hemorrhage by neurovascular proteolysis [337]. Inhibition of HIF-1α was able  
to downregulate MMP9 and therefore reduced hemorrhagic transformation in 
ischemic stroke [249]. 
This study has also shown that miR-335 mimic could inhibit Hif-1α and hence 
its downstream gene Mmp9 transcription (Figure 4.13), which could reduce 
the Mmp9-induced detrimental effects. Although VEGF is well known to be 
an angiogenesis and neurogenesis regulator, which is favorable for ischemic 
stroke, it also increases cerebrovascular permeability in the early phase of 
ischemic stroke and leads to brain edema. Brain edema is a major and life-
threatening complication of a variety of brain injuries [338]. Increased 
cerebrovascular permeability is one of the most important factors for the 
development of brain edema. VEGFA antagonist was observed to reduce brain 
edema and infarct size in mouse stroke model [338]. Vegfa, a downstream 











Figure 6.1 Mechanism of the reduction of infarct volume by pre miR-335. Pre 
miR-335 could regulate downstream genes of Hif-1α, such as Bnip3, Mmp9, Vegfa 
and Aqp4 by modulating Hif-1α to result in beneficial outcome in cerebral ischemia. 
Left side of the figure presents that cerebral ischemia activated Hif-1α and its 
influences on its downstream genes which brought about a large infarct with severe 
brain edema. Right side of the figure demonstrates that pre miR-335 inhibits Hif-1α 
mRNA expression and hence could reverse the expression of Hif-1α downstream 












ischemia [19, 20]. In this study, miR-335 mimic was found to reduce Vegfa 
expression by inhibition of Hif-1α and hence may reduce cerebral edema and 
cell death as well.  HIF-1α was also indicated to be an upstream regulator of 
AQP4 [30, 247]. AQP4 belongs to the water-channel protein family, 
aquaporin family and facilitates water move in and out of brain. Although the 
early upregulation of AQP4 was associated with an increase in cerebral edema 
[340], increased Aqp4 expression at 24hr reperfusion time point after ischemic 
stroke correlated to a reduction of infarct volume [194]. Helton et al [247] also 
found that mice generated with a brain predominant deletion of Hif-1α 
demonstrated an increase in Aqp4 expression and subsequently showed a 
neuroprotective function in a global ischemic stroke model. In vivo study 
showed that inhibition of Hif-1a by miR-335 mimic increased the expression 
of Aqp4 at 24hr post occlusion with a reduction of infarct volume and 
implying that activation of Aqp4 expression via Hif-1α could play a beneficial 
role in cerebral ischemia. 
In this study, miR-335 was proved to directly modulate Hif-1α gene 
expression in both in vitro and in vivo conditions. Administration of miR-335 
mimic could bring about a reduction in infarct volume as well as a decrease in 
expression of Hif-1α in animal models of cerebral ischemia. By regulating Hif-
1α expression, miR-335 also indirectly affected the expression of the 
downstream genes that was crucial in the maintenance of cell viability and 
blood brain barrier.  
 





In this study, miR-335 and -93 were identified to direct target HIF-1α and 
miR-335 was a stronger modulator in comparison to miR-93 and hence was 
selected to test in in vivo ischemic stroke model. miR-17 has been validated to 
target Hif-1α and also seems to be a stronger regulator than miR-20a and miR-
93 despite sharing the same seed region. Hence miR-17 was used as a positive 
control in this in vivo setting.  
miR-17-92 cluster has been reported to target HIF-1α in lung cancer cells 
[153].  Subsequent study also indicated hif-1α could inhibit miR-17 and -20a 
[341] by repressing c-myc, which has been reported to induce miR-17-92 
cluster by directly target their promoter [342]. This make the interaction 
between miR-17 and HIF-1α become complicated. If pre miR-17 injection is 
supposed to reduce HIF-1α, however, HIF-1α also can inhibit miR-17. Hence, 
the extent to which pre miR-17 can inhibit hif-1α is determined by the pre 
miR-17 level in vivo, which needs to be further explored. Our results are also 
supported by another study, which showed miR-18a and -19 out of miR-17-92 
cluster instead of miR-17 significantly increased the proliferation and survival 
of neuronal progenitor cells [343]. Furthermore, miR-17 was found to be both 
pro-apoptotic and anti-apoptotic [344]. We need to investigate further to 
determine how these two functions are balanced in cerebral ischemia.   
 
6.6 Circulating miRNAs as novel biomarkers in diseases 
Ischemic stroke is a devastating condition characterized as a wide range of 
pathophysiological entities. Current common diagnosis of ischemic stroke 
relies on physician clinical examination and is further supplemented with 





in an acute setting to diagnose stroke, differentiate between stroke types, or 
even predict prognosis of stroke would be extremely valuable. Miscellaneous 
biomarkers have been studied for stroke diagnosis [345] in either individual 
biomarkers or multiple markers in a panel. However, there are no known 
individual or multiple biomarkers that can be targeted for routine use in acute 
ischemic stroke diagnosis, differentiation or risk prediction currently.  
MicroRNAs as the small regulatory RNA molecules have been found  in 
circulation in 2008 [188, 346]. miRNAs were shown to have considerable 
resistance to the enzymatic cleavage by RNase in blood and stable compared 
to large molecular weight RNAs under different harsh conditions including 
boiling, low/high pH, extended storage and freeze-thaw cycles. miRNA 
expression was found to be reproducible and consistent among individuals 
with cancer [346, 347]. By studying the expression of tissue specific miRNAs 
(miR-122, -133a and -124 specific for liver, muscle and brain respectively) in 
blood after tissue injury, Laterza et al [348] demonstrated that the expression 
of miRNA-122, -133a and -124 in the blood was closely correlated with that 
of the specific tissues; liver, muscle and brain injury respectively. Hence, it is 
possible that circulating miRNAs are used as the potential biomarkers for 
diagnosis and prognosis prediction of diseases. Subsequent study by Mitchell 
et al [347] found that miRNAs originating from human prostate cancer entered 
the circulation and could distinguish cancer patients from healthy controls 
with significant specificity and sensitivity. Similar findings were obtained in 
cardiovascular diseases as well, in which circulating miRNAs were shown as 
the potential biomarkers for heart failure and coronary artery diseases [348, 





brain tissue and blood of MCAo models [188]. The study on young ischemic 
stroke patients also indicated that miRNAs were differentially and stably 
expressed in circulation even after several months from the onset of cerebral 
ischemia [190].  
With the presence of miRNAs in circulation, the mechanisms of how miRNAs 
were released into blood from the injured tissue were also studied and some 
explanations were proposed. It was found that extracellular miRNAs may be 
packaged into secretory particles including exosomes as well as apoptotic 
bodies and transferred in the circulation. Exosomes are small intraluminal 
vesicles (50–100 nm in diameter) of multivesicular bodies released on 
exocytic fusion of multivesicular bodies with plasma membranes [351]. 
Apoptotic bodies (0.5-2 µm) are small membranous particles released during 
programmed cell death [352]. Accumulating evidence suggests that these 
secretory vesicles can function as intercellular transmitters to convey miRNAs 
[353]. Valadi et al [354] reported that exosomes released from human and 
murine mast cell lines contained mRNAs and miRNAs, which were 
transferred to other mast cells and functioned in the new location. Taylor et al 
[355] found that tumor-derived exosomes were present in the peripheral 
circulation and there was no significant difference between tumor-derived 
miRNA profiles and peripheral blood-derived exosomal miRNAs. Similarly, 
stem cells were also shown to affect the expression of genes in neighboring 
cells by transferring miRNAs in microvesicles [356]. Skog et al [357] studied 
glioblastoma cells and found that they can release exosomes containing 
mRNA, miRNA, and angiogenic proteins, which were taken up by brain 





addition, apoptotic bodies generated during atherosclerosis were found to 
carry miRNA-126 which triggered the production of chemokine CXC motif 
ligand 12 (CXCL12) in the recipient vascular cells [358]. The transfer of 
microparticles-derived miRNAs or mRNAs to recipient cells may be a new 
mechanism allowing gene-based communication between mammalian cells. 
The transferable miRNAs and mRNAs may be the potential biomarker to be 
used for diseases diagnosis. 
With what has been discovered so far, circulating miRNAs constitute a new 
approach for developing ideal biomarkers. Hence, miRNA expression analysis 
on whole blood of ischemic stroke patients was selected for the study.   
 
6.7 miRNA profiling in the blood of human stroke patients 
In this study, many miRNAs were found to be dysregulated in stroke patients 
when compared to healthy control. A total of 463 miRNAs was significantly 
dysregulated and they could be used to differentiate all ischemic stroke 
samples from the healthy control. Upon stroke progression, 432, 415 and 356 
miRNAs were found to be significantly expressed at baseline, month 3 and 
month 12 respectively. The observation that miRNAs can differentiate stroke 
patients and the control from acute phase up to one year from onset of stroke 
indicated miRNAs‘ importance in cerebral ischemia. 
miRNAs were also found to be differentially expressed in large artery and 
small vessel stroke subtypes. A total of 105 and 96 miRNAs was shown to be 
specific for large artery and small vessel stroke respectively. By further 
selection using the stringent criteria (fold change > 5 or < -5 or miRNAs 





specific for large artery stroke (Table 5.4) and 31 miRNAs specific for small 
vessel stroke (Table 5.5) were shortlisted. These miRNAs may be used as 
biomarkers to differentiate large artery and small vessel stroke subtypes at 
baseline. However, so far the functions of these miRNAs in cerebral ischemia 
were largely unknown. We could only understand their functions from the 
studies in other diseases, especially cancers. The major functions of these 
miRNAs were found to include immune response, proliferation and apoptosis, 
angiogenesis, hematopoietic regulation, inflammation, neuronal development 
and cell cycle (Table 6.1).  
It is well known that large artery and small vessel stroke are the popular stroke 
subtypes clinically. Large artery stroke is defined as; >50% stenosis or 
occlusion of a major brain artery or branch cortical artery due to 
atherosclerosis. Whereas small vessel stroke (lacunar stroke) is characterized 
by one of the traditional clinical lacunar syndromes without evidence of 
cerebral cortical dysfunction; MRI image indicating a largest infarct diameter 
< 15mm usually occurring in the region of penetrating arteries [401], such as 
basal ganglia, thalamus, internal capsule, corona radiata and pons; a history of 
diabetes or hypertension. However, it is sometimes hard to differentiate 
clinically the large artery and small vessel strokes. Lacunar syndromes can be 
caused by non-lacunar disease, such as cortical infarction and hemorrhagic 
stroke [402]. Large artery stroke can lead to the infarction in the regions of the 
penetrating arteries. In addition, the infarct diameter is less than 15mm in 
small vessel stroke. However, in patients with infarct diameter < 15mm 
combined a coincidental large arterial source, the etiology of stroke is still 





artery and small vessel stroke subtypes. Jickling et al [403] studied the gene 
expression in large artery stroke at ≤ 3hr, 5hr and 24hr and found that 554 
genes were specific for large artery stroke. Functional analysis of these genes 
demonstrated that they were involved into immune response related pathway 
(cytotoxic T lymphocyte target cell apoptosis, CCR5 (C-C chemokine receptor 
type 5) signaling in macrophages, T lymphocyte regulation and T lymphocyte  
differentiation); inflammation (inflammatory disorder); hematopoietic 
 
 
Table 6.1 The functions of miRNAs specific for large artery and small vessel 
stroke subtypes at baseline. The functions of miRNAs (fold change > 5 or < -5 or 
miRNAs shown opposite expression in large artery and small vessel stroke subtypes) 
were obtained from published data and summarized.    
 
Process/target miRNAs 
 Specific for 
large artery stroke 
Specific for 


















































































































































regulation (leukocyte development and morphology); and epithelium 
mesentrimal transformation (EMT) (invasion of cells). These functions were 
also found in those of miRNAs in this study. However, some miRNA 
functions found in this study such as angiogenesis, neuronal development and 
cell cycle were not included by the gene study of Jickling et al. It may because 
the samples of Jickling group were collected within 24hr whereas in this study, 
samples were collected from 2 – 10 days after stroke onset. The processes of 
angiogenesis, neuronal development and cell cycle may not strong enough 
within 24hr of stroke onset. In the study of Jickling et al, Nuclear factor-
kappaB (NF-κB) signaling and TGF-β signaling were found to be activated, 
which is also observed in this study. miR-520e demonstrated inhibition of 
hepatoma cells growth by directly targeting NF-κB-inducing kinase (NIK) and 
hence regulating NF-κB signaling pathway [374]. miR-601 was found to be 
anti-apoptotic by inhibiting NF-κB signaling pathway in lung cancer cells 
[372]. miR-29a was involved in TGF-β signaling pathway by which it regulate 
angiogenesis [362] and fibrosis [404]. By inducing TGF-β signaling to control 
the balance between cell specification and pluripotency, miR-302 played a 
role in maintaining the undifferentiated embryo stem cells (ESC) status [405]. 
In addition, it was found that ZEB1 gene presented in the study of Jickling et 
al as specific for large artery stroke was directly targeted by miR-200 family 
[379], selected as specific for large artery stroke in this study.    
Jickling et al [273] also reported that 90 genes were significantly different 
between lacunar and non-lacunar strokes and among them 41 genes can be 
used to discriminate lacunar stroke from other stroke subtypes with a more 





demonstrated that they were involved in immune response related pathways 
(innate and adaptive immune cell communication, TREM1 signaling, T helper 
cell differentiation, CCR5 signaling in macrophages, role of macrophages and 
fibroblasts and endothelial cells in rheumatoid arthritis); hematopoietic 
regulation (growth of myeloid cells & leukocytes, monocyte & leukocyte 
activation and recruitment); and angiogenesis (cardiovascular process of blood 
vessel, endothelial adhesion and angiogenesis of endothelial cells). These 
functions were also observed in this study demonstrated by miRNAs. In 
addition, TGF-β signaling presented in the study of Jickling et al was also 
observed in this study. miR-367 was indicated to maintain embryo stem cells 
in the undifferentiated state by inducing the TGF-β/Nodal/Activin pathway 
[405]. By comparing the genes reported by Jickling et al and miRNAs in this 
study specific for large artery or small vessel stroke subtypes, most of the 
functions of them can be found to be similar, which highly suggested that 
miRNAs may also be potentially used to differentiate stroke subtypes. 
Among these selected miRNAs specific for large artery and small vessel 
stroke subtypes respectively, members of miR-302/367 cluster and miR-
200/429 cluster were involved. Interestingly, although belonging to the same 
cluster, miRNA-302a-5p (miR-302a*) and -302b-5p (miR-302b*) were 
specific for large artery stroke at baseline whereas miR-367 was significantly 
expressed in only small vessel stroke samples at baseline. miR-302/367 cluster 
were known to be consist of nine different miRNAs: miR-302a, -302a*, -302b, 
-302b*, -302c, -302c*, -302d, -367 and -367* [406]. It was shown to be highly 
and specifically expressed in undifferentiated ESC [407]. The transcription 





determining region Y)-box 2 (Sox2) and Rex1 in ESC cells were shown to be 
upstream regulators of the miR-302/367 promoter [368, 397]. miR-302/367 
has been identified to post-transcriptionally regulate cyclin D1 and cyclin-
dependent kinase 4 (Cdk4), affecting cell cycle progression [397]. In addition 
to their role in self-renewal and proliferation, miR-302/367 may maintain cells 
in the undifferentiated state by inducing the TGFβ/Nodal/Activin pathway 
[405]. In this study, miRNA-302a-5p, -302b-5p and -367 were found to be 
significantly expressed in the blood samples of human stroke patients. Since 
the cluster‘s specific function is stem cells regulation, it is possible that miR-
302/367 cluster is also involved in regulating stem cells upon cerebral 
ischemia. However, miRNA-302a/b-5p and -367 demonstrate specificity for 
large artery and small vessel stroke respectively, which may also highlight 
their different function in altered stroke subtypes.  
Similarly, miR-429 and -200b-3p are the members of miR-200/429 cluster.  In 
this study, miR-429 was significantly expressed in large artery stroke whist 
miR-200b-3p (miR-200b) demonstrated significant dysregulation in small 
vessel stroke. miRNA-200 family includes five members; miR-200a, -200b, -
200c, -141 and -429, which are classified into miR-200a/b/429 and miR-
200c/141 clusters according to the different chromosome location. miR-200 
family was originally found to be associated with olfactory neurogenesis [376]. 
It was required for terminal differentiation of olfactory precursors but was 
dispensable for proper function of mature olfactory neurons. Recently, miR-
200 family was reported to be involved in EMT. During EMT, epithelial cells 
lose their cell polarity to enable cell–cell adhesion and gain migratory and 





migration and invasion as well as wound recovery. By directly targeting ZEB1 
and ZEB2 upon EMT, miR-200 family demonstrated the property of inhibiting 
cancer cell migration and invasion. In addition, miR-200 family was observed 
to be upregulated in ischemic preconditioning and miR-200b, -200c and -429 
were shown to be neuroprotective when transfected to neuronal cells subjected 
to OGD [378]. The function of miR-200 family in neurogenesis and EMT may 
hint that it could promote neurogenesis and contribute to neuronal stem cells 
migration upon cerebral ischemia. The specificity of miR-200b-3p and miR-
429 for large artery and small vessel stroke subtypes respectively suggests that 
neurogenesis and neuronal stem cells migration may be involved in both 
stroke subtypes in which miR-200b-3p and -429 play a role respectively.  
 
6.8 The possibility of translation from bench to bed side  
To understand the function of miRNAs in human ischemic stroke, pathway 
analysis was carried out by using the significantly expressed miRNAs upon 
cerebral ischemia. Nine pathways (Wnt signaling pathway, morphine 
addiction, basal cell carcinoma, focal adhesion, hedgehog signaling pathway, 
endocytosis, GABAergic synapse, axon guidance and glutamatergic synapse) 
were found to be common for both large artery and small vessel stroke 
subtypes at the observed time points. Interestingly, two pathways (hedgehog 
signaling pathway and GABAergic synapse) were also presented in the top ten 
pathways of both acute and recovery phases of ischemic stroke rat model 
(Figure 3.6). Furthermore, Wnt signaling pathway was found in the ischemic 
stroke model used in the study (Chapter 3, Table 3.4) as an important pathway 





involved in human stroke as well. This signifies that similar pathological 
processes are shared between rats and humans upon cerebral ischemia and 
hence it is possible to translate some of the results from ischemic stroke model 
for clinical use.   
miRNA expression were further observed in ischemic stroke animal models 
and human stroke patient samples in the corresponding time points. According 
to neuroimaging study [408], the duration of acute stroke in human patients is 
the first two days. Subsequently, subacute phase starts and lasts around 7–10 
days. The chronic/recovery phase can extend to several weeks or months in 
human stroke. In comparison to humans, the process of ischemic stroke in rats 
is much shorter. Studies [409, 410] indicated that 3 – 6hr is the acute phase of 
rat cerebral ischemia, 12 – 72hr denotes the subacute phase and chronic phase 
takes place after 96hr. However, the phases may vary according to the severity 
of ischemic stroke.     
It was found that miR-206 expression closely followed the infarct volume in 
ischemic stroke model. miR-206 expression in human stroke samples 
demonstrated decreased expression from baseline (subacute phase) to month 3 
(chronic or recovery phase), which was similar to that of ischemic stroke 
model. This similarity was also observed in another 17 miRNAs selected from 
ischemic stroke models (Table 5.6).  
Since eMCAo model mimics large artery stroke subtype in human, the 105 
miRNAs selected specific for large artery stroke at baseline (2 - 10 days) were 
investigated in ischemic stroke model. Among them, 15 miRNAs were found 
to be conserved in rat and human and demonstrated either similar or opposite 





miRNAs significantly expressed in both rat and human stroke may suggest 
that they play roles in both species upon cerebral ischemia and possible have 
the similar function. It was noticed that among these miRNAs, miR-9-5p is 
one of the miRNAs which were found to be enriched in the mammalian 
nervous system. miR-9-5p is highly conserved from flies to humans and is 
specifically expressed in neuronal precursor cells of the brain in rodents [411]. 
miR-9-5p was found to function in multiple stages of neuronal development 
such as early neurogenesis [377], neuronal progenitor cells proliferation [412], 
dendritic branching [413] and synaptic plasticity [414]. Furthermore, miR-9-
5p was downregulated in ischemic animal model [300]. The presence of miR-
9-5p in the blood of human patients upon acute cerebral ischemia was highly 
suggested that miR-9-5p was released from brain where it participated in 
neurogenesis or neuronal stem cells regulation. However, this observation 
need to be further investigated and confirmed. 
  
6.9 How to dissect the contributions of the various miRNAs in the 
pathogenesis of ischemic stroke, given the large number of miRNAs 
implicated? 
In this study, large amount of miRNAs were observed to be dysregulated in 
ischemic stroke model as well as human stroke patients. It is really hard to 
clarify the contributions of these miRNAs on the pathogenesis of cerebral 
ischemia. However, it was observed that significantly expressed miRNAs with 
distinct expression pattern usually play more important roles upon cerebral 
ischemia. These miRNAs could be first selected for further study and will 





individual miRNA has multiple targets, bioinformatics prediction will be used 
to narrow down the mRNA targets and luciferase reporter assay will help to 
confirm the direct interaction. Pull down assay may be used to identify which 
genes are involved in cerebral ischemia condition.  
The studied individual miRNA must be tested in vivo to validate its function. 
Because miRNAs are still new, a lot of information currently can only be 
predicted and the functions of miRNAs can be determined by pathway 
analysis. Realtime PCR and mRNA array analysis will suggest the expression 
of genes in different pathways and therefore provide the information on 
pathways interactions. 
 
6.10 The limitation of this study 
In human stroke study, healthy individuals were used as the control. There is a 
significant difference (p < 0.05) between the age of stroke patients and healthy 
controls. The age could be the factor which may influence the final results. 
However, it is difficult to find individuals with comparable age who are 
completely free of any risk factors of cerebrovascular or cardiovascular 
diseases. A large cohort of patients with or without stroke may be investigated 
to find suitable controls. 
      
6.11 Conclusions and future prospects of the study 
In this study, embolic stroke model was created to mimic a clinical cerebral 
ischemic condition seen in most of ischemic stroke patients. miRNA profiling 
from acute to recovery phases of cerebral ischemia was carried out to provide 





functional study was performed to understand the modulation of hypoxia-
inducible factor-1α gene in in vitro ischemic condition as well as in in vivo 
stroke models. It implied that miRNAs could be used as the potential 
therapeutic targets upon cerebral ischemia. For the sake of translation from 
bench to bed side, miRNA expression profile was studied in blood of human 
patients with different subtypes of stroke. Commonly expressed miRNAs in 
both animal models and human patients were investigated.   
miRNA profiling based on eMCAo model was carried out in acute and 
recovery phases of cerebral ischemia in this study. Considerable miRNAs 
were found to be significantly expressed upon cerebral ischemia progression, 
which hinted the indispensable roles of miRNAs during this process. miRNAs 
demonstrated consistent increase, decrease and expression reflecting infarct 
volume were selected, which may be the biomarkers to predict the progression 
of ischemic stroke. By using the validated miRNA-mRNA pairs, miRNAs‘ 
crucial roles in neuronal repair were also displayed. Further examination and 
validation of function of individual miRNA selected in this study should be 
carried out in the future. It is also important to understand the mechanism of 
action of miRNAs in cerebral ischemia before considering miRNAs in stroke 
therapy.  
As the master transcription factor in hypoxia condition, Hif-1α was indicated 
to be involved into ischemic cascade as an important regulator. In this study, 
miRNA-335 and miR-93 were identified as the direct regulators of Hif-1α by 
directly targeting its 3‘UTR. miRNA-335 was further demonstrated to regulate 
Hif-1α in in vitro neuronal culture OGD and could bring about neuroprotective 





phase of stroke significantly reduced Hif-1α expression and the infarct volume. 
These findings highlight the applicability and potential of miRNA based 
therapeutics in stroke. In extended study, pre miR-335 needs to be tested in a 
large cohort of animals in the near future. As it is widely known that one 
miRNA can have multiple mRNA targets, to gain a further understanding on 
the overall mechanisms modulated by miR-335, Pull-down assay will be 
carried out to understand the targets of miR-335 upon cerebral ischemia. It 
will be helpful to regulate the miR-335 in a good way to bring about favorable 
outcomes in ischemic stroke. 
So far, miRNA expression in human stoke patients was largely unknown. In 
this study, miRNA profiling was carried out in the blood of human stroke 
patients. The significantly expressed miRNAs upon cerebral ischemia were 
found to be able to differentiate ischemia stroke samples from healthy control 
at baseline (2 – 10 days), three month and twelve month. miRNAs specific for 
large artery and small vessel stroke subtypes were identified. These miRNAs 
could be the potential biomarkers to differentiate large artery and small vessel 
stroke subtypes. However, the expression of these miRNAs needs to be 
validated in the blood of human stroke patients in the near future. Thereafter, 
it will be good to test these miRNAs in another cohort to verify the efficiency 
of differentiating large artery and small vessel stroke subtypes.  
Because of the difficulty in obtaining human brain tissues from stroke patients, 
rats become the most popularly used animals for ischemic stroke model. In 
this study, by comparing the miRNA profiling in ischemic stroke rat models 
and human stroke patients, some miRNAs were found to be commonly 





miRNAs have higher chances to be brought to clinical study in the future. 
Especially, miRNA-206 expression was found to follow infarct volume in 
ischemic stroke models, which was validated by another cohort in this study. 
Anti miR-206 demonstrated neuroprotection upon neuronal cells subjected to 
OGD and administration of anti miR-206 showed significantly reduced infarct 
damage in ischemic stroke animal models. The expression of miRNA-206 in 
human stroke samples decreased from baseline to month 3, which was similar 
to that of ischemic stroke model in this study. miR-206 expression will be 
validated by realtime PCR in human stroke patients‘ blood samples in the 
future. Pull-down assay needs to be carried out to understand the mechanism 
of action of miR-206 in reducing infarct volume. Clinical trials may be 
considered in future if miR-206 does not show any toxicity and off-target 
effects on animal models of stroke. In addition, the miRNAs commonly 
expressed in both ischemic rat models and human stroke patients will be 
validated in both samples and the important miRNAs will be selected for 
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